<!DOCTYPE html>
<html lang="en">

  <head>
    <title>CancerFeed</title>
    <meta charset="utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <meta name="robots" content="noindex, nofollow" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <link rel="shortcut icon" type="image/x-icon" href="favicon.ico" />
    <link rel="alternate" type="application/rss+xml" title="CancerFeed" href="feed.atom" />
    <link href="index.css?v1.14.4" rel="stylesheet" />
    <style>
  :root {
    /**
     * Solarized Light
     * Ethan Schoonover (modified by aramisgithub)
     */
    --base00: #fdf6e3;
    --base01: #eee8d5;
    --base02: #93a1a1;
    --base03: #839496;
    --base04: #657b83;
    --base05: #586e75;
    --base06: #073642;
    --base07: #002b36;
    --base08: #dc322f;
    --base09: #cb4b16;
    --base0A: #b58900;
    --base0B: #859900;
    --base0C: #2aa198;
    --base0D: #268bd2;
    --base0E: #6c71c4;
    --base0F: #d33682;

    /**
    * Components
    */
    --source-name-color: var(--base0C);
    /**
   * Typograph
   */
    --font-family-default: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Oxygen-Sans, Ubuntu, Cantarell,
      "Helvetica Neue", sans-serif;
    --font-size-L: 3.6rem;
    --font-size-m: 2.2rem;
    --font-size-s: 1.8rem;
    --font-size-scaler: 52.5%; /* 1rem = 10px */
    --line-height-body: 1.4;
    --line-height-heading: 1.2;

  }
</style>

  </head>

  <body>
    <!-- %after-body-begin.html% -->
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-05-19 datetime="2023-05-19T10:00:00.000Z">2023-05-19</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-05-19 datetime="2023-05-19T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37205910"
                        open
                      >
                        <summary class="article-expander__title">Applying single cell multi-omic analyses to understand treatment resistance in pediatric high grade glioma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37205910/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Despite improvements in cancer patient outcomes seen in the past decade, tumor resistance to therapy remains a major impediment to achieving durable clinical responses. Intratumoral heterogeneity related to genetic, epigenetic, transcriptomic, proteomic, and metabolic differences between individual cancer cells has emerged as a driver of therapeutic resistance. This cell to cell heterogeneity can be assessed using single cell profiling technologies that enable the identification of tumor cell...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-05-17 datetime="2023-05-17T10:00:00.000Z">2023-05-17</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-05-17 datetime="2023-05-17T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37197843"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37195777"
                        open
                      >
                        <summary class="article-expander__title">Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37195768"
                        open
                      >
                        <summary class="article-expander__title">Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37195766"
                        open
                      >
                        <summary class="article-expander__title">Epidemiology and Pathogenesis of Myelodysplastic Syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37197843"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis of Indeterminate Potential Predicts Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37197843/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: CHIP is independently associated with adverse outcomes in individuals with established ASCVD, with especially high risks observed in TET2 and SF3B1/SRSF2/U2AF1 CHIP.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37195777"
                        open
                      >
                        <summary class="article-expander__title">Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37195768"
                        open
                      >
                        <summary class="article-expander__title">Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37195766"
                        open
                      >
                        <summary class="article-expander__title">Epidemiology and Pathogenesis of Myelodysplastic Syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37195777"
                        open
                      >
                        <summary class="article-expander__title">Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37195768"
                        open
                      >
                        <summary class="article-expander__title">Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37195766"
                        open
                      >
                        <summary class="article-expander__title">Epidemiology and Pathogenesis of Myelodysplastic Syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37196833"
                        open
                      >
                        <summary class="article-expander__title">Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37195777"
                        open
                      >
                        <summary class="article-expander__title">Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37195768"
                        open
                      >
                        <summary class="article-expander__title">Spectrum From Clonal Hematopoiesis to Myelodysplastic Neoplasm/Syndromes and Other Myeloid Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37195768/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis (CH) confers a high risk of aging-related diseases and hematologic malignancy. There are still significant knowledge gaps in identifying high-risk patients with CH and managing such patients. In this review, we focus on 3 areas: (1) the natural history of CH; (2) the risks of progression of CH, including CH of indeterminate potential, clonal cytopenia of undetermined significance, and therapy-related CH, to myeloid malignancy; and (3) the challenges and unmet needs of CH...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37195766"
                        open
                      >
                        <summary class="article-expander__title">Epidemiology and Pathogenesis of Myelodysplastic Syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37195766/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective hematopoiesis and variable cytopenias with a considerable risk of progression to acute myeloid leukemia. Epidemiological assessment of MDS remains challenging because of evolving classification systems, but the overall incidence in the United States is estimated to be approximately 4 per 100,000 and increases with age. The sequential accumulation of mutations drives disease evolution from asymptomatic clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37194418"
                        open
                      >
                        <summary class="article-expander__title">Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37196833"
                        open
                      >
                        <summary class="article-expander__title">Dissecting sources of variability in patient response to targeted therapy: anti-HER2 therapies as a case study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37196833/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION AND IMPLICATIONS: The platform can dissect sources of variability in response to target therapy, which may facilitate decision-making during drug development.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37195777"
                        open
                      >
                        <summary class="article-expander__title">Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37194418"
                        open
                      >
                        <summary class="article-expander__title">Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37195777"
                        open
                      >
                        <summary class="article-expander__title">Evolution of Therapeutic Benefit Measurement Criteria in Myelodysplastic Syndromes/Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37195777/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes/neoplasms (MDS) are heterogeneous, clonal myeloid neoplasms characterized by ineffective hematopoiesis, progressive cytopenias, and an increased risk of progression to acute myeloid leukemia. The diversity in disease severity, morphology, and genetic landscape challenges not only novel drug development but also therapeutic response assessment. The MDS International Working Group (IWG) response criteria were first published in the year 2000 focusing on measures of blast...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37194418"
                        open
                      >
                        <summary class="article-expander__title">Mutational evolution after chemotherapy-progression in metastatic colorectal cancer revealed by circulating tumor DNA analysis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37194418/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Emerging new mutations after treatment can provide clues to acquired resistant mechanisms. Circulating tumor DNA (ctDNA) sequencing has enabled noninvasive repeated tumor mutational profiling. We aimed to investigate newly emerging mutations in ctDNA after disease progression in metastatic colorectal cancer (mCRC). Blood samples were prospectively collected from mCRC patients receiving palliative chemotherapy before treatment and at radiological evaluations. ctDNA from pretreatment and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-05-16 datetime="2023-05-16T10:00:00.000Z">2023-05-16</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-05-16 datetime="2023-05-16T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37191835"
                        open
                      >
                        <summary class="article-expander__title">Stem cell regulation and dynamics in myeloid malignancies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37191835"
                        open
                      >
                        <summary class="article-expander__title">Stem cell regulation and dynamics in myeloid malignancies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37191835"
                        open
                      >
                        <summary class="article-expander__title">Stem cell regulation and dynamics in myeloid malignancies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37191835"
                        open
                      >
                        <summary class="article-expander__title">Stem cell regulation and dynamics in myeloid malignancies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37191835/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In this issue of PIH, we asked four researchers to write about basic research on the molecular mechanisms of the development of myeloid malignancies, in particular two epigenetic regulation and two space- and time-dependent factors. Regarding epigenomic regulation, Dr. Yang reviewed ASXL1, a polycomb modifier gene that is often mutated in myeloid malignancies, but also in clonal hematopoiesis in healthy elderly people, and Dr. Vu reviewed RNA modifications, which are critical for development and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37192968"
                        open
                      >
                        <summary class="article-expander__title">Toward a systems-level probing of tumor clonality</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37192000"
                        open
                      >
                        <summary class="article-expander__title">Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37192000/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterizes most cancer types, linked with disease outcomes. However, the underlying processes are incompletely understood. We show that elevated transcription of HERVH proviruses predicts survival of lung squamous cell carcinoma (LUSC) and identify an isoform of CALB1, encoding Calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37192968"
                        open
                      >
                        <summary class="article-expander__title">Toward a systems-level probing of tumor clonality</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37192000"
                        open
                      >
                        <summary class="article-expander__title">Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37192000/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterizes most cancer types, linked with disease outcomes. However, the underlying processes are incompletely understood. We show that elevated transcription of HERVH proviruses predicts survival of lung squamous cell carcinoma (LUSC) and identify an isoform of CALB1, encoding Calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37192968"
                        open
                      >
                        <summary class="article-expander__title">Toward a systems-level probing of tumor clonality</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37192968/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancer has been described as a genetic disease that clonally evolves in the face of selective pressures imposed by cell-intrinsic and extrinsic factors. Although classical models based on genetic data predominantly propose Darwinian mechanisms of cancer evolution, recent single-cell profiling of cancers has described unprecedented heterogeneity in tumors providing support for alternative models of branched and neutral evolution through both genetic and non-genetic mechanisms. Emerging evidence...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37192000"
                        open
                      >
                        <summary class="article-expander__title">Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37192000/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterizes most cancer types, linked with disease outcomes. However, the underlying processes are incompletely understood. We show that elevated transcription of HERVH proviruses predicts survival of lung squamous cell carcinoma (LUSC) and identify an isoform of CALB1, encoding Calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37192000"
                        open
                      >
                        <summary class="article-expander__title">Human endogenous retrovirus onco-exaptation counters cancer cell senescence through Calbindin</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37192000/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Increased levels and diversity of human endogenous retrovirus (HERV) transcription characterizes most cancer types, linked with disease outcomes. However, the underlying processes are incompletely understood. We show that elevated transcription of HERVH proviruses predicts survival of lung squamous cell carcinoma (LUSC) and identify an isoform of CALB1, encoding Calbindin, ectopically driven by an upstream HERVH provirus under the control of KLF5, as the mediator of this effect. HERVH-CALB1...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-05-15 datetime="2023-05-15T10:00:00.000Z">2023-05-15</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-05-15 datetime="2023-05-15T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37186988"
                        open
                      >
                        <summary class="article-expander__title">Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37186988"
                        open
                      >
                        <summary class="article-expander__title">Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37186988"
                        open
                      >
                        <summary class="article-expander__title">Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37186988"
                        open
                      >
                        <summary class="article-expander__title">Review of clonal hematopoiesis, subtypes and its role in neoplasia and different morbidities</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37186988/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis (CH) is the development of a certain cell lineage which is the cornerstone of hematologic malignancy especially myeloid neoplasms, however, can also be found in old age (6th-7th decade). CH is caused by many different somatic mutations most commonly in DNMT3A, TET2, ASXL1, SF3B1 and TP53. It is detected by different sequencing methods, the most commonly used ones are next generation sequencing (NGS) which can be whole exome, whole genome sequencing or a panel for certain...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-05-13 datetime="2023-05-13T10:00:00.000Z">2023-05-13</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-05-13 datetime="2023-05-13T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37175518"
                        open
                      >
                        <summary class="article-expander__title">The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37173944"
                        open
                      >
                        <summary class="article-expander__title">Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37175518"
                        open
                      >
                        <summary class="article-expander__title">The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37173944"
                        open
                      >
                        <summary class="article-expander__title">Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37175518"
                        open
                      >
                        <summary class="article-expander__title">The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37173944"
                        open
                      >
                        <summary class="article-expander__title">Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37175518"
                        open
                      >
                        <summary class="article-expander__title">The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37173944"
                        open
                      >
                        <summary class="article-expander__title">Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37175518"
                        open
                      >
                        <summary class="article-expander__title">The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230515205819&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37173944"
                        open
                      >
                        <summary class="article-expander__title">Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230515205819&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37175518"
                        open
                      >
                        <summary class="article-expander__title">The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37173944"
                        open
                      >
                        <summary class="article-expander__title">Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37175518"
                        open
                      >
                        <summary class="article-expander__title">The Potential of Liquid Biopsy in Detection of Endometrial Cancer Biomarkers: A Pilot Study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37175518/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Endometrial cancer belongs to the most common gynecologic cancer types globally, with increasing incidence. There are numerous ways of classifying different cases. The most recent decade has brought advances in molecular classification, which show more accurate prognostic factors and the possibility of personalised adjuvant treatment. In addition, diagnostic approaches lag behind these advances, with methods causing patients discomfort while lacking the reproducibility of tissue sampling for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37173944"
                        open
                      >
                        <summary class="article-expander__title">Single-Cell Next-Generation Sequencing to Monitor Hematopoietic Stem-Cell Transplantation: Current Applications and Future Perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37173944/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are genetically complex and diverse diseases. Such complexity makes challenging the monitoring of response to treatment. Measurable residual disease (MRD) assessment is a powerful tool for monitoring response and guiding therapeutic interventions. This is accomplished through targeted next-generation sequencing (NGS), as well as polymerase chain reaction and multiparameter flow cytometry, to detect genomic aberrations at a...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37178708"
                        open
                      >
                        <summary class="article-expander__title">Utility of polygenic risk scores in UK cancer screening: a modelling analysis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37176124"
                        open
                      >
                        <summary class="article-expander__title">Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37178708"
                        open
                      >
                        <summary class="article-expander__title">Utility of polygenic risk scores in UK cancer screening: a modelling analysis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37176124"
                        open
                      >
                        <summary class="article-expander__title">Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37178708"
                        open
                      >
                        <summary class="article-expander__title">Utility of polygenic risk scores in UK cancer screening: a modelling analysis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37176124"
                        open
                      >
                        <summary class="article-expander__title">Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37178708"
                        open
                      >
                        <summary class="article-expander__title">Utility of polygenic risk scores in UK cancer screening: a modelling analysis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37176124"
                        open
                      >
                        <summary class="article-expander__title">Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37178708"
                        open
                      >
                        <summary class="article-expander__title">Utility of polygenic risk scores in UK cancer screening: a modelling analysis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230515205818&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37176124"
                        open
                      >
                        <summary class="article-expander__title">Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230515205818&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37178708"
                        open
                      >
                        <summary class="article-expander__title">Utility of polygenic risk scores in UK cancer screening: a modelling analysis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37178708/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>BACKGROUND: It is proposed that, through restriction to individuals delineated as high risk, polygenic risk scores (PRSs) might enable more efficient targeting of existing cancer screening programmes and enable extension into new age ranges and disease types. To address this proposition, we present an overview of the performance of PRS tools (ie, models and sets of single nucleotide polymorphisms) alongside harms and benefits of PRS-stratified cancer screening for eight example cancers (breast,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37176124"
                        open
                      >
                        <summary class="article-expander__title">Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37176124"
                        open
                      >
                        <summary class="article-expander__title">Longitudinal Analyses of Mutational Subclonal Architecture and Tumor Subtypes in Recurrent Bladder Cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37176124/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Longitudinal tumor sequencing of recurrent bladder cancer (BC) can facilitate the investigation of BC progression-associated genomic and transcriptomic alterations. In this study, we analyzed 18 tumor specimens including distant and locoregional metastases obtained during tumor progression for five BC patients using whole-exome and transcriptome sequencing. Along with the substantial level of intratumoral mutational heterogeneity across the cases, we observed that clonal mutations were enriched...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-05-12 datetime="2023-05-12T10:00:00.000Z">2023-05-12</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-05-12 datetime="2023-05-12T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37172086"
                        open
                      >
                        <summary class="article-expander__title">Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37172086"
                        open
                      >
                        <summary class="article-expander__title">Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37172086"
                        open
                      >
                        <summary class="article-expander__title">Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37172086"
                        open
                      >
                        <summary class="article-expander__title">Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37172086"
                        open
                      >
                        <summary class="article-expander__title">Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230515205818&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37172086"
                        open
                      >
                        <summary class="article-expander__title">Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37172086"
                        open
                      >
                        <summary class="article-expander__title">Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37172086"
                        open
                      >
                        <summary class="article-expander__title">Efficient cancer modeling through CRISPR-Cas9/HDR-based somatic precision gene editing in mice</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37172086/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CRISPR-Cas9 has been used successfully to introduce indels in somatic cells of rodents; however, precise editing of single nucleotides has been hampered by limitations of flexibility and efficiency. Here, we report technological modifications to the CRISPR-Cas9 vector system that now allows homology-directed repair-mediated precise editing of any proto-oncogene in murine somatic tissues to generate tumor models with high flexibility and efficiency. Somatic editing of either Kras or Pik3ca in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-05-11 datetime="2023-05-11T10:00:00.000Z">2023-05-11</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-05-11 datetime="2023-05-11T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37167533"
                        open
                      >
                        <summary class="article-expander__title">Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37167533"
                        open
                      >
                        <summary class="article-expander__title">Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37167533"
                        open
                      >
                        <summary class="article-expander__title">Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37167533"
                        open
                      >
                        <summary class="article-expander__title">Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37167533"
                        open
                      >
                        <summary class="article-expander__title">Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230515205819&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37167533"
                        open
                      >
                        <summary class="article-expander__title">Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37167533"
                        open
                      >
                        <summary class="article-expander__title">Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37167533"
                        open
                      >
                        <summary class="article-expander__title">Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37167533"
                        open
                      >
                        <summary class="article-expander__title">Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37170152"
                        open
                      >
                        <summary class="article-expander__title">Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;13
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37168490"
                        open
                      >
                        <summary class="article-expander__title">Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37167533"
                        open
                      >
                        <summary class="article-expander__title">Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37170152"
                        open
                      >
                        <summary class="article-expander__title">Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;13
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37168490"
                        open
                      >
                        <summary class="article-expander__title">Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37167533"
                        open
                      >
                        <summary class="article-expander__title">Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37170152"
                        open
                      >
                        <summary class="article-expander__title">Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;13
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37168490"
                        open
                      >
                        <summary class="article-expander__title">Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37167533"
                        open
                      >
                        <summary class="article-expander__title">Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37170152"
                        open
                      >
                        <summary class="article-expander__title">Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;13
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37168490"
                        open
                      >
                        <summary class="article-expander__title">Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37167533"
                        open
                      >
                        <summary class="article-expander__title">Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37170152"
                        open
                      >
                        <summary class="article-expander__title">Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230515205818&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;13
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37168490"
                        open
                      >
                        <summary class="article-expander__title">Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230515205818&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37167533"
                        open
                      >
                        <summary class="article-expander__title">Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230515205818&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37170152"
                        open
                      >
                        <summary class="article-expander__title">Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;13
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37168490"
                        open
                      >
                        <summary class="article-expander__title">Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37167533"
                        open
                      >
                        <summary class="article-expander__title">Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37170152"
                        open
                      >
                        <summary class="article-expander__title">Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37168490"
                        open
                      >
                        <summary class="article-expander__title">Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37167533"
                        open
                      >
                        <summary class="article-expander__title">Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37170152"
                        open
                      >
                        <summary class="article-expander__title">Exploring circular MET RNA as a potential biomarker in tumors exhibiting high MET activity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37170152/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: We found that measurement of circMET levels allows identification and tracking of patients characterized by high MET activity. Circulating circMET (ccMET) detection and analysis could be a simple, cost-effective, non-invasive approach to better implement patient stratification based on MET expression, as well as to dynamically monitor over time both therapy response and clonal evolution during treatment.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37168490"
                        open
                      >
                        <summary class="article-expander__title">Refining the Treatment of Pancreatic Cancer From Big Data to Improved Individual Survival</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37168490/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Pancreatic cancer is one of the most lethal cancers worldwide, most notably in Europe and North America. Great strides have been made in combining the most effective conventional therapies to improve survival at least in the short and medium term. The start of treatment can only be made once a diagnosis is made, which at this point, the tumor volume is already very high in the primary cancer and systemically. If caught at the earliest opportunity (in circa 20% patients) surgical resection of the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37167533"
                        open
                      >
                        <summary class="article-expander__title">Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37167533"
                        open
                      >
                        <summary class="article-expander__title">Transdifferentiation, phenotypic infidelity, progression, and transformation in T/NK-cell neoplasms: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37167533/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This cohort of cases allowed us to illustrate, discuss, and review current concepts of transdifferentiation, aberrant antigen expression, and progression in various T/NK-cell neoplasms.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-05-09 datetime="2023-05-09T10:00:00.000Z">2023-05-09</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-05-09 datetime="2023-05-09T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37160316"
                        open
                      >
                        <summary class="article-expander__title">Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37159554"
                        open
                      >
                        <summary class="article-expander__title">Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37160316"
                        open
                      >
                        <summary class="article-expander__title">Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37159554"
                        open
                      >
                        <summary class="article-expander__title">Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37160316"
                        open
                      >
                        <summary class="article-expander__title">Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37159554"
                        open
                      >
                        <summary class="article-expander__title">Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37160316"
                        open
                      >
                        <summary class="article-expander__title">Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37159554"
                        open
                      >
                        <summary class="article-expander__title">Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37160316"
                        open
                      >
                        <summary class="article-expander__title">Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230515205819&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37159554"
                        open
                      >
                        <summary class="article-expander__title">Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230515205819&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37160316"
                        open
                      >
                        <summary class="article-expander__title">Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37159554"
                        open
                      >
                        <summary class="article-expander__title">Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37160316"
                        open
                      >
                        <summary class="article-expander__title">Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37159554"
                        open
                      >
                        <summary class="article-expander__title">Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37160316"
                        open
                      >
                        <summary class="article-expander__title">Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37159554"
                        open
                      >
                        <summary class="article-expander__title">Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37160316"
                        open
                      >
                        <summary class="article-expander__title">Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37159554"
                        open
                      >
                        <summary class="article-expander__title">Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37159554"
                        open
                      >
                        <summary class="article-expander__title">Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37159554"
                        open
                      >
                        <summary class="article-expander__title">Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37159554/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: Considering the low TP53 variant allele fraction in blood, absence of variant detection in oral swab and saliva samples, the lack of LFS clinical criteria, and history of exposure to environmental risk factors for cancer, the main hypothesis for this case was aberrant clonal expansion due to clonal hematopoiesis. Oncologists should interpret TP53 findings during germline testing with caution.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37160316"
                        open
                      >
                        <summary class="article-expander__title">Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37160316"
                        open
                      >
                        <summary class="article-expander__title">Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37157910"
                        open
                      >
                        <summary class="article-expander__title">Reuniting philosophy and science to advance cancer research</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37160316"
                        open
                      >
                        <summary class="article-expander__title">Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37157910"
                        open
                      >
                        <summary class="article-expander__title">Reuniting philosophy and science to advance cancer research</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37160316"
                        open
                      >
                        <summary class="article-expander__title">Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37157910"
                        open
                      >
                        <summary class="article-expander__title">Reuniting philosophy and science to advance cancer research</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37160316"
                        open
                      >
                        <summary class="article-expander__title">Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230515205818&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37157910"
                        open
                      >
                        <summary class="article-expander__title">Reuniting philosophy and science to advance cancer research</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230515205818&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37160316"
                        open
                      >
                        <summary class="article-expander__title">Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37157910"
                        open
                      >
                        <summary class="article-expander__title">Reuniting philosophy and science to advance cancer research</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37160316"
                        open
                      >
                        <summary class="article-expander__title">Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37157910"
                        open
                      >
                        <summary class="article-expander__title">Reuniting philosophy and science to advance cancer research</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37160316"
                        open
                      >
                        <summary class="article-expander__title">Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37157910"
                        open
                      >
                        <summary class="article-expander__title">Reuniting philosophy and science to advance cancer research</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37160316"
                        open
                      >
                        <summary class="article-expander__title">Clonal cytopenia of undetermined significance (CCUS)-associated reversion of donor-derived, transient αβ T-cell large granular clonal lymphocytosis, emerging post-transplant in a patient with a history of γδ T-cell large granular lymphocytic leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37160316/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) has revolutionized the therapy of hematolymphoid malignancies. Yet, how to best detect or predict the emergence of HSCT-related complications remain unresolved. Here, we describe a case of donor-derived, transient Alpha Beta (αβ) T-cell large granular clonal lymphocytosis and cytopenia that emerged post-HSCT in a patient with a history of gamma delta (γδ) T-cell large granular lymphocytic leukemia (T-LGLL). Clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37157910"
                        open
                      >
                        <summary class="article-expander__title">Reuniting philosophy and science to advance cancer research</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37157910"
                        open
                      >
                        <summary class="article-expander__title">Reuniting philosophy and science to advance cancer research</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37157910"
                        open
                      >
                        <summary class="article-expander__title">Reuniting philosophy and science to advance cancer research</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37157910/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancers rely on multiple, heterogeneous processes at different scales, pertaining to many biomedical fields. Therefore, understanding cancer is necessarily an interdisciplinary task that requires placing specialised experimental and clinical research into a broader conceptual, theoretical, and methodological framework. Without such a framework, oncology will collect piecemeal results, with scant dialogue between the different scientific communities studying cancer. We argue that one important...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-05-08 datetime="2023-05-08T10:00:00.000Z">2023-05-08</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-05-08 datetime="2023-05-08T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37156299"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37156299"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37156299"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37156299"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37156299"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230515205819&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230515205819&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37156299"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37156299"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37156299"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37156299"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37156299"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37156299"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of indeterminate potential and outcomes after heart transplantation: A multi-center study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37156299/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cardiac allograft vasculopathy (CAV) is a leading cause of late graft failure and mortality after heart transplantation (HT). Sharing some features with atherosclerosis, CAV results in diffuse narrowing of the epicardial coronaries and microvasculature with consequent graft ischemia. Recently, clonal hematopoiesis of indeterminate potential (CHIP) has emerged as a risk factor for cardiovascular disease and mortality. We aimed to investigate the relationship between CHIP and post-transplant...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37155154"
                        open
                      >
                        <summary class="article-expander__title">FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancers originate from a single cell according to Nowell&#x27;s theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37155154"
                        open
                      >
                        <summary class="article-expander__title">FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancers originate from a single cell according to Nowell&#x27;s theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37155154"
                        open
                      >
                        <summary class="article-expander__title">FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancers originate from a single cell according to Nowell&#x27;s theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37155154"
                        open
                      >
                        <summary class="article-expander__title">FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230515205818&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancers originate from a single cell according to Nowell&#x27;s theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230515205818&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37155154"
                        open
                      >
                        <summary class="article-expander__title">FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancers originate from a single cell according to Nowell&#x27;s theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37155154"
                        open
                      >
                        <summary class="article-expander__title">FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancers originate from a single cell according to Nowell&#x27;s theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37155154"
                        open
                      >
                        <summary class="article-expander__title">FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancers originate from a single cell according to Nowell&#x27;s theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37155154"
                        open
                      >
                        <summary class="article-expander__title">FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancers originate from a single cell according to Nowell&#x27;s theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37155154"
                        open
                      >
                        <summary class="article-expander__title">FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancers originate from a single cell according to Nowell&#x27;s theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37155154"
                        open
                      >
                        <summary class="article-expander__title">FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancers originate from a single cell according to Nowell&#x27;s theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37155154"
                        open
                      >
                        <summary class="article-expander__title">FAM46C-mediated tumor heterogeneity predicts extramedullary metastasis and poorer survival in multiple myeloma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37155154/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancers originate from a single cell according to Nowell&#x27;s theory of clonal evolution. The enrichment of the most aggressive clones has been developed and the heterogeneity arises for genomic instability and environmental selection. Multiple myeloma (MM) is a multiple relapse plasma cell cancer generated from bone marrow. Although there were accumulating researches in multiple myeloma pathogenesis, the heterogeneity remains poorly understood. The participants enrolled in this study were 4 EMP+...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37153874"
                        open
                      >
                        <summary class="article-expander__title">Impact of Clonal Architecture on Clinical Course and Prognosis in Patients With Myeloproliferative Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37153874/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPNs) are caused by a somatic gain-of-function mutation in 1 of the 3 disease driver genes JAK2, MPL, or CALR. About half of the MPNs patients also carry additional somatic mutations that modify the clinical course. The order of acquisition of these gene mutations has been proposed to influence the phenotype and evolution of the disease. We studied 50 JAK2-V617F-positive MPN patients who carried at least 1 additional somatic mutation and determined the clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-05-07 datetime="2023-05-07T10:00:00.000Z">2023-05-07</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-05-07 datetime="2023-05-07T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37150255"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37150255"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37150255"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37150255"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37150255"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230515205819&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37150255"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37150255"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37150255"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37150255"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37150255"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37150255"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37150255"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations is associated with increased lung cancer risk: insight from the INTEGRAL-ILCCO cohort analysis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37150255/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) detected in white blood cells represent a type of clonal hematopoiesis (CH) that is understudied compared to CH-related somatic mutations. A few recent studies indicated their potential link with non-hematological cancers, especially lung cancer. In this study, we investigated the association between mCAs and lung cancer using the high-density genotyping data from the OncoArray study of INTEGRAL-ILCCO, the largest single genetic study of lung cancer with...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37149862"
                        open
                      >
                        <summary class="article-expander__title">Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37149862"
                        open
                      >
                        <summary class="article-expander__title">Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37149862"
                        open
                      >
                        <summary class="article-expander__title">Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230515205818&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37149862"
                        open
                      >
                        <summary class="article-expander__title">Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37149862"
                        open
                      >
                        <summary class="article-expander__title">Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37149862"
                        open
                      >
                        <summary class="article-expander__title">Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37149862"
                        open
                      >
                        <summary class="article-expander__title">Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37149862"
                        open
                      >
                        <summary class="article-expander__title">Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37149862"
                        open
                      >
                        <summary class="article-expander__title">Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37149862"
                        open
                      >
                        <summary class="article-expander__title">Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37149862"
                        open
                      >
                        <summary class="article-expander__title">Glioblastoma cell fate is differentially regulated by the microenvironments of the tumor bulk and infiltrative margin</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37149862/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Glioblastoma (GBM) recurrence originates from invasive margin cells that escape surgical debulking, but to what extent these cells resemble their bulk counterparts remains unclear. Here, we generated three immunocompetent somatic GBM mouse models, driven by subtype-associated mutations, to compare matched bulk and margin cells. We find that, regardless of mutations, tumors converge on common sets of neural-like cellular states. However, bulk and margin have distinct biology. Injury-like programs...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-05-05 datetime="2023-05-05T10:00:00.000Z">2023-05-05</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-05-05 datetime="2023-05-05T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146604"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146604"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230518205810&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146604"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146604"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146604"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230515205819&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146604"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146604"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146604"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146604"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146604"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146604"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146604"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146604"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146604"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146604/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Knowledge about evolution of clonal hematopoiesis, which may drive malignant progression, is crucial for clinical decision-making. We investigated the landscape of clonal evolution by error-corrected sequencing on 7,045 sequential samples from 3,359 individuals in the prospective population-based Lifelines cohort, with a special focus on cytosis and cytopenia. Spliceosome (SRSF2/U2AF1/SF3B1) and JAK2 mutated clones show highest growth rates over a median 3.6-year period, while clone sizes for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146586"
                        open
                      >
                        <summary class="article-expander__title">GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146250"
                        open
                      >
                        <summary class="article-expander__title">Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37143651"
                        open
                      >
                        <summary class="article-expander__title">Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146586"
                        open
                      >
                        <summary class="article-expander__title">GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230515205818&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146250"
                        open
                      >
                        <summary class="article-expander__title">Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230515205818&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37143651"
                        open
                      >
                        <summary class="article-expander__title">Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230515205818&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146586"
                        open
                      >
                        <summary class="article-expander__title">GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146250"
                        open
                      >
                        <summary class="article-expander__title">Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37143651"
                        open
                      >
                        <summary class="article-expander__title">Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146586"
                        open
                      >
                        <summary class="article-expander__title">GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146250"
                        open
                      >
                        <summary class="article-expander__title">Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37143651"
                        open
                      >
                        <summary class="article-expander__title">Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146586"
                        open
                      >
                        <summary class="article-expander__title">GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146250"
                        open
                      >
                        <summary class="article-expander__title">Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37143651"
                        open
                      >
                        <summary class="article-expander__title">Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146586"
                        open
                      >
                        <summary class="article-expander__title">GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146250"
                        open
                      >
                        <summary class="article-expander__title">Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37143651"
                        open
                      >
                        <summary class="article-expander__title">Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146586"
                        open
                      >
                        <summary class="article-expander__title">GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146250"
                        open
                      >
                        <summary class="article-expander__title">Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37143651"
                        open
                      >
                        <summary class="article-expander__title">Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146586"
                        open
                      >
                        <summary class="article-expander__title">GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146250"
                        open
                      >
                        <summary class="article-expander__title">Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37143651"
                        open
                      >
                        <summary class="article-expander__title">Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146586"
                        open
                      >
                        <summary class="article-expander__title">GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146250"
                        open
                      >
                        <summary class="article-expander__title">Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37143651"
                        open
                      >
                        <summary class="article-expander__title">Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146586"
                        open
                      >
                        <summary class="article-expander__title">GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146250"
                        open
                      >
                        <summary class="article-expander__title">Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37143651"
                        open
                      >
                        <summary class="article-expander__title">Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146586"
                        open
                      >
                        <summary class="article-expander__title">GTAC enables parallel genotyping of multiple genomic loci with chromatin accessibility profiling in single cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146586/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Understanding clonal evolution and cancer development requires experimental approaches for characterizing the consequences of somatic mutations on gene regulation. However, no methods currently exist that efficiently link high-content chromatin accessibility with high-confidence genotyping in single cells. To address this, we developed Genotyping with the Assay for Transposase-Accessible Chromatin (GTAC), enabling accurate mutation detection at multiple amplified loci, coupled with robust...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146250"
                        open
                      >
                        <summary class="article-expander__title">Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37143651"
                        open
                      >
                        <summary class="article-expander__title">Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37146250"
                        open
                      >
                        <summary class="article-expander__title">Genetic events associated with venetoclax resistance in CLL identified by whole exome sequencing of patient samples</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37146250/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Although BCL2 mutations are reported as later occurring events leading to venetoclax resistance, many other mechanisms of progression have been reported but remain poorly understood. Here we analyze longitudinal tumor samples from eleven patients with disease progression on venetoclax to characterize the clonal evolution of resistance. All patients tested showed increased in vitro resistance to venetoclax at their post-treatment timepoint. We found the previously described acquired BCL2-G101V...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37143651"
                        open
                      >
                        <summary class="article-expander__title">Insights into IGH clonal evolution in BCP-ALL: frequency, mechanisms, associations, and diagnostic implications</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37143651/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The malignant transformation leading to a maturation arrest in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) occurs early in B-cell development, in a pro-B or pre-B cell, when somatic recombination of variable (V), diversity (D), and joining (J) segment immunoglobulin (IG) genes and the B-cell rescue mechanism of V(H) replacement might be ongoing or fully active, driving clonal evolution. In this study of newly diagnosed BCP-ALL, we sought to understand the mechanistic...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-05-04 datetime="2023-05-04T10:00:00.000Z">2023-05-04</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-05-04 datetime="2023-05-04T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140166"
                        open
                      >
                        <summary class="article-expander__title">Familial Clonal Hematopoiesis in a Long Telomere Syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230517205652&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140166"
                        open
                      >
                        <summary class="article-expander__title">Familial Clonal Hematopoiesis in a Long Telomere Syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140166"
                        open
                      >
                        <summary class="article-expander__title">Familial Clonal Hematopoiesis in a Long Telomere Syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230515205819&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140166"
                        open
                      >
                        <summary class="article-expander__title">Familial Clonal Hematopoiesis in a Long Telomere Syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140166"
                        open
                      >
                        <summary class="article-expander__title">Familial Clonal Hematopoiesis in a Long Telomere Syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140166"
                        open
                      >
                        <summary class="article-expander__title">Familial Clonal Hematopoiesis in a Long Telomere Syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140166"
                        open
                      >
                        <summary class="article-expander__title">Familial Clonal Hematopoiesis in a Long Telomere Syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140166"
                        open
                      >
                        <summary class="article-expander__title">Familial Clonal Hematopoiesis in a Long Telomere Syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140166"
                        open
                      >
                        <summary class="article-expander__title">Familial Clonal Hematopoiesis in a Long Telomere Syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140166"
                        open
                      >
                        <summary class="article-expander__title">Familial Clonal Hematopoiesis in a Long Telomere Syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140166"
                        open
                      >
                        <summary class="article-expander__title">Familial Clonal Hematopoiesis in a Long Telomere Syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140166"
                        open
                      >
                        <summary class="article-expander__title">Familial Clonal Hematopoiesis in a Long Telomere Syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140166"
                        open
                      >
                        <summary class="article-expander__title">Familial Clonal Hematopoiesis in a Long Telomere Syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140166"
                        open
                      >
                        <summary class="article-expander__title">Familial Clonal Hematopoiesis in a Long Telomere Syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140166/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: POT1 mutations associated with long telomere length conferred a predisposition to a familial clonal hematopoiesis syndrome that was associated with a range of benign and malignant solid neoplasms. The risk of these phenotypes was mediated by extended cellular longevity and by the capacity to maintain telomeres over time. (Funded by the National Institutes of Health and others.).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140929"
                        open
                      >
                        <summary class="article-expander__title">Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230515205818&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140929"
                        open
                      >
                        <summary class="article-expander__title">Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140929"
                        open
                      >
                        <summary class="article-expander__title">Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37139709"
                        open
                      >
                        <summary class="article-expander__title">Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140929"
                        open
                      >
                        <summary class="article-expander__title">Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37139709"
                        open
                      >
                        <summary class="article-expander__title">Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140929"
                        open
                      >
                        <summary class="article-expander__title">Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37139709"
                        open
                      >
                        <summary class="article-expander__title">Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140929"
                        open
                      >
                        <summary class="article-expander__title">Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37139709"
                        open
                      >
                        <summary class="article-expander__title">Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140929"
                        open
                      >
                        <summary class="article-expander__title">Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37139709"
                        open
                      >
                        <summary class="article-expander__title">Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140929"
                        open
                      >
                        <summary class="article-expander__title">Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37139709"
                        open
                      >
                        <summary class="article-expander__title">Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140929"
                        open
                      >
                        <summary class="article-expander__title">Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37139709"
                        open
                      >
                        <summary class="article-expander__title">Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140929"
                        open
                      >
                        <summary class="article-expander__title">Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37139709"
                        open
                      >
                        <summary class="article-expander__title">Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140929"
                        open
                      >
                        <summary class="article-expander__title">Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37139709"
                        open
                      >
                        <summary class="article-expander__title">Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37140929"
                        open
                      >
                        <summary class="article-expander__title">Resolving the pathogenesis of anaplastic Wilms tumors through spatial mapping of cancer cell evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37140929/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: WTs with DA display significantly more complex phylogenies compared to non-DA WTs, including features of saltatory and parallel evolution. The subclonal landscape of individual tumors was constrained by anatomic compartments, which should be considered when sampling tissue for precision diagnostics.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37139709"
                        open
                      >
                        <summary class="article-expander__title">Molecular-defined clonal evolution in patients with classical myeloproliferative neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37139709/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Classical myeloproliferative neoplasms (MPNs) are characterized by distinct clinical phenotypes. The discovery of driver mutations in JAK2, CALR and MPL genes provided new insights into their pathogenesis. Next-generation sequencing (NGS) identified additional somatic mutations, most frequently in epigenetic modulator genes. In this study, a cohort of 95 MPN patients was genetically characterized using targeted NGS. Clonal hierarchies of detected mutations were subsequently analysed using colony...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-05-03 datetime="2023-05-03T10:00:00.000Z">2023-05-03</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-05-03 datetime="2023-05-03T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37133448"
                        open
                      >
                        <summary class="article-expander__title">A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37133448"
                        open
                      >
                        <summary class="article-expander__title">A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37133448"
                        open
                      >
                        <summary class="article-expander__title">A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37133448"
                        open
                      >
                        <summary class="article-expander__title">A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37133448"
                        open
                      >
                        <summary class="article-expander__title">A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37133448"
                        open
                      >
                        <summary class="article-expander__title">A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37133448"
                        open
                      >
                        <summary class="article-expander__title">A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37133448"
                        open
                      >
                        <summary class="article-expander__title">A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37133448"
                        open
                      >
                        <summary class="article-expander__title">A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37133448"
                        open
                      >
                        <summary class="article-expander__title">A rare subset of primary tumor cells with concomitant hyper-activation of extracellular matrix remodeling and dsRNA-IFN1 signaling metastasizes in breast cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37133448/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Metastatic breast cancer (BC) has a poor prognosis and is largely considered incurable. A better understanding of the molecular determinants of BC metastasis could facilitate development of improved prevention and treatment strategies. We used lentiviral barcoding coupled to single-cell RNA sequencing to trace clonal and transcriptional evolution during BC metastasis and showed that metastases derive from rare pro-metastatic clones that are under-represented in primary tumors. Both low clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-05-02 datetime="2023-05-02T10:00:00.000Z">2023-05-02</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-05-02 datetime="2023-05-02T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37131267"
                        open
                      >
                        <summary class="article-expander__title">Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37131267"
                        open
                      >
                        <summary class="article-expander__title">Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37131267"
                        open
                      >
                        <summary class="article-expander__title">Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37131267"
                        open
                      >
                        <summary class="article-expander__title">Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37131267"
                        open
                      >
                        <summary class="article-expander__title">Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37131267"
                        open
                      >
                        <summary class="article-expander__title">Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37131267"
                        open
                      >
                        <summary class="article-expander__title">Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37131267"
                        open
                      >
                        <summary class="article-expander__title">Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37131267"
                        open
                      >
                        <summary class="article-expander__title">Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37131267/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Overall, our study demonstrated the genomic, epigenomic, and transcriptomic features of metastatic lesions in FH-RCC and revealed their early evolutionary trajectory. These results provided multi-omics evidence portraying the progression of FH-RCC.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-05-01 datetime="2023-05-01T10:00:00.000Z">2023-05-01</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-05-01 datetime="2023-05-01T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37126548"
                        open
                      >
                        <summary class="article-expander__title">The genetic determinants of recurrent somatic mutations in 43,693 blood genomes</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;18
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37126548"
                        open
                      >
                        <summary class="article-expander__title">The genetic determinants of recurrent somatic mutations in 43,693 blood genomes</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230515205819&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;18
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37126548"
                        open
                      >
                        <summary class="article-expander__title">The genetic determinants of recurrent somatic mutations in 43,693 blood genomes</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;18
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37126548"
                        open
                      >
                        <summary class="article-expander__title">The genetic determinants of recurrent somatic mutations in 43,693 blood genomes</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;18
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37126548"
                        open
                      >
                        <summary class="article-expander__title">The genetic determinants of recurrent somatic mutations in 43,693 blood genomes</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;18
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37126548"
                        open
                      >
                        <summary class="article-expander__title">The genetic determinants of recurrent somatic mutations in 43,693 blood genomes</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;18
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37126548"
                        open
                      >
                        <summary class="article-expander__title">The genetic determinants of recurrent somatic mutations in 43,693 blood genomes</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;18
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37126548"
                        open
                      >
                        <summary class="article-expander__title">The genetic determinants of recurrent somatic mutations in 43,693 blood genomes</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;18
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37126548"
                        open
                      >
                        <summary class="article-expander__title">The genetic determinants of recurrent somatic mutations in 43,693 blood genomes</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;18
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37126548"
                        open
                      >
                        <summary class="article-expander__title">The genetic determinants of recurrent somatic mutations in 43,693 blood genomes</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;18
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37126548"
                        open
                      >
                        <summary class="article-expander__title">The genetic determinants of recurrent somatic mutations in 43,693 blood genomes</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;18
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37126548"
                        open
                      >
                        <summary class="article-expander__title">The genetic determinants of recurrent somatic mutations in 43,693 blood genomes</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;18
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37126548"
                        open
                      >
                        <summary class="article-expander__title">The genetic determinants of recurrent somatic mutations in 43,693 blood genomes</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;18
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37126548"
                        open
                      >
                        <summary class="article-expander__title">The genetic determinants of recurrent somatic mutations in 43,693 blood genomes</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;18
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37126548"
                        open
                      >
                        <summary class="article-expander__title">The genetic determinants of recurrent somatic mutations in 43,693 blood genomes</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;16
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37126548"
                        open
                      >
                        <summary class="article-expander__title">The genetic determinants of recurrent somatic mutations in 43,693 blood genomes</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37126548/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Nononcogenic somatic mutations are thought to be uncommon and inconsequential. To test this, we analyzed 43,693 National Heart, Lung and Blood Institute Trans-Omics for Precision Medicine blood whole genomes from 37 cohorts and identified 7131 non-missense somatic mutations that are recurrently mutated in at least 50 individuals. These recurrent non-missense somatic mutations (RNMSMs) are not clearly explained by other clonal phenomena such as clonal hematopoiesis. RNMSM prevalence increased...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;13
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-30 datetime="2023-04-30T10:00:00.000Z">2023-04-30</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-30 datetime="2023-04-30T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37121869"
                        open
                      >
                        <summary class="article-expander__title">Mitigating age-related somatic mutation burden</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37121869"
                        open
                      >
                        <summary class="article-expander__title">Mitigating age-related somatic mutation burden</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230515205819&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37121869"
                        open
                      >
                        <summary class="article-expander__title">Mitigating age-related somatic mutation burden</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37121869"
                        open
                      >
                        <summary class="article-expander__title">Mitigating age-related somatic mutation burden</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37121869"
                        open
                      >
                        <summary class="article-expander__title">Mitigating age-related somatic mutation burden</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37121869"
                        open
                      >
                        <summary class="article-expander__title">Mitigating age-related somatic mutation burden</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37121869"
                        open
                      >
                        <summary class="article-expander__title">Mitigating age-related somatic mutation burden</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37121869"
                        open
                      >
                        <summary class="article-expander__title">Mitigating age-related somatic mutation burden</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37121869"
                        open
                      >
                        <summary class="article-expander__title">Mitigating age-related somatic mutation burden</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37121869"
                        open
                      >
                        <summary class="article-expander__title">Mitigating age-related somatic mutation burden</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37121869"
                        open
                      >
                        <summary class="article-expander__title">Mitigating age-related somatic mutation burden</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37121869"
                        open
                      >
                        <summary class="article-expander__title">Mitigating age-related somatic mutation burden</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37121869"
                        open
                      >
                        <summary class="article-expander__title">Mitigating age-related somatic mutation burden</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37121869"
                        open
                      >
                        <summary class="article-expander__title">Mitigating age-related somatic mutation burden</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37121869"
                        open
                      >
                        <summary class="article-expander__title">Mitigating age-related somatic mutation burden</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37121869"
                        open
                      >
                        <summary class="article-expander__title">Mitigating age-related somatic mutation burden</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37121869/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomes are inherently unstable and require constant DNA repair to maintain their genetic information. However, selective pressure has optimized repair mechanisms in somatic cells only to allow transmitting genetic information to the next generation, not to maximize sequence integrity long beyond the reproductive age. Recent studies have confirmed that somatic mutations, due to errors during genome repair and replication, accumulate in tissues and organs of humans and model organisms. Here, we...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-29 datetime="2023-04-29T10:00:00.000Z">2023-04-29</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-29 datetime="2023-04-29T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37119011"
                        open
                      >
                        <summary class="article-expander__title">VEXAS: is it time to reshape the nosology of clonal hematopoiesis?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230516205931&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37119011"
                        open
                      >
                        <summary class="article-expander__title">VEXAS: is it time to reshape the nosology of clonal hematopoiesis?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230515205819&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37119011"
                        open
                      >
                        <summary class="article-expander__title">VEXAS: is it time to reshape the nosology of clonal hematopoiesis?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37119011"
                        open
                      >
                        <summary class="article-expander__title">VEXAS: is it time to reshape the nosology of clonal hematopoiesis?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37119011"
                        open
                      >
                        <summary class="article-expander__title">VEXAS: is it time to reshape the nosology of clonal hematopoiesis?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37119011"
                        open
                      >
                        <summary class="article-expander__title">VEXAS: is it time to reshape the nosology of clonal hematopoiesis?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37119011"
                        open
                      >
                        <summary class="article-expander__title">VEXAS: is it time to reshape the nosology of clonal hematopoiesis?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37119011"
                        open
                      >
                        <summary class="article-expander__title">VEXAS: is it time to reshape the nosology of clonal hematopoiesis?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37119011"
                        open
                      >
                        <summary class="article-expander__title">VEXAS: is it time to reshape the nosology of clonal hematopoiesis?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37119011"
                        open
                      >
                        <summary class="article-expander__title">VEXAS: is it time to reshape the nosology of clonal hematopoiesis?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37119011"
                        open
                      >
                        <summary class="article-expander__title">VEXAS: is it time to reshape the nosology of clonal hematopoiesis?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37119011"
                        open
                      >
                        <summary class="article-expander__title">VEXAS: is it time to reshape the nosology of clonal hematopoiesis?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37119011"
                        open
                      >
                        <summary class="article-expander__title">VEXAS: is it time to reshape the nosology of clonal hematopoiesis?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The recent description of VEXAS (for vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) challenges the nosological framework of myelodysplastic syndromes.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37119011"
                        open
                      >
                        <summary class="article-expander__title">VEXAS: is it time to reshape the nosology of clonal hematopoiesis?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The recent description of VEXAS (for Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) challenges the nosological framework of myelodysplastic syndromes.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37119011"
                        open
                      >
                        <summary class="article-expander__title">VEXAS: is it time to reshape the nosology of clonal hematopoiesis?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The recent description of VEXAS (for Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) challenges the nosological framework of myelodysplastic syndromes.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37119011"
                        open
                      >
                        <summary class="article-expander__title">VEXAS: is it time to reshape the nosology of clonal hematopoiesis?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The recent description of VEXAS (for Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) challenges the nosological framework of myelodysplastic syndromes.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37119011"
                        open
                      >
                        <summary class="article-expander__title">VEXAS: is it time to reshape the nosology of clonal hematopoiesis?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The recent description of VEXAS (for Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) challenges the nosological framework of myelodysplastic syndromes.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37119011"
                        open
                      >
                        <summary class="article-expander__title">VEXAS: is it time to reshape the nosology of clonal hematopoiesis?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37119011/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The recent description of VEXAS (for Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) challenges the nosological framework of myelodysplastic syndromes.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-28 datetime="2023-04-28T10:00:00.000Z">2023-04-28</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-28 datetime="2023-04-28T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37118760"
                        open
                      >
                        <summary class="article-expander__title">New approaches to idiopathic neutropenia in the era of clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230515205819&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37117740"
                        open
                      >
                        <summary class="article-expander__title">The burden of rare protein-truncating genetic variants on human lifespan</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230515205819&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37118760"
                        open
                      >
                        <summary class="article-expander__title">New approaches to idiopathic neutropenia in the era of clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37117740"
                        open
                      >
                        <summary class="article-expander__title">The burden of rare protein-truncating genetic variants on human lifespan</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230514205932&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37118760"
                        open
                      >
                        <summary class="article-expander__title">New approaches to idiopathic neutropenia in the era of clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37117740"
                        open
                      >
                        <summary class="article-expander__title">The burden of rare protein-truncating genetic variants on human lifespan</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230513210018&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37118760"
                        open
                      >
                        <summary class="article-expander__title">New approaches to idiopathic neutropenia in the era of clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37117740"
                        open
                      >
                        <summary class="article-expander__title">The burden of rare protein-truncating genetic variants on human lifespan</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37115512"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Young Women Treated for Breast Cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37118760"
                        open
                      >
                        <summary class="article-expander__title">New approaches to idiopathic neutropenia in the era of clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37117740"
                        open
                      >
                        <summary class="article-expander__title">The burden of rare protein-truncating genetic variants on human lifespan</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37115512"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Young Women Treated for Breast Cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37118760"
                        open
                      >
                        <summary class="article-expander__title">New approaches to idiopathic neutropenia in the era of clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37117740"
                        open
                      >
                        <summary class="article-expander__title">The burden of rare protein-truncating genetic variants on human lifespan</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37115512"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Young Women Treated for Breast Cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37118760"
                        open
                      >
                        <summary class="article-expander__title">New approaches to idiopathic neutropenia in the era of clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37117740"
                        open
                      >
                        <summary class="article-expander__title">The burden of rare protein-truncating genetic variants on human lifespan</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37115512"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Young Women Treated for Breast Cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37118760"
                        open
                      >
                        <summary class="article-expander__title">New approaches to idiopathic neutropenia in the era of clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37117740"
                        open
                      >
                        <summary class="article-expander__title">The burden of rare protein-truncating genetic variants on human lifespan</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37115512"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Young Women Treated for Breast Cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37118760"
                        open
                      >
                        <summary class="article-expander__title">New approaches to idiopathic neutropenia in the era of clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37117740"
                        open
                      >
                        <summary class="article-expander__title">The burden of rare protein-truncating genetic variants on human lifespan</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37115512"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Young Women Treated for Breast Cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37118760"
                        open
                      >
                        <summary class="article-expander__title">New approaches to idiopathic neutropenia in the era of clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37117740"
                        open
                      >
                        <summary class="article-expander__title">The burden of rare protein-truncating genetic variants on human lifespan</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37115512"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Young Women Treated for Breast Cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37118760"
                        open
                      >
                        <summary class="article-expander__title">New approaches to idiopathic neutropenia in the era of clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37117740"
                        open
                      >
                        <summary class="article-expander__title">The burden of rare protein-truncating genetic variants on human lifespan</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37115512"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Young Women Treated for Breast Cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37118760"
                        open
                      >
                        <summary class="article-expander__title">New approaches to idiopathic neutropenia in the era of clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37117740"
                        open
                      >
                        <summary class="article-expander__title">The burden of rare protein-truncating genetic variants on human lifespan</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37115512"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Young Women Treated for Breast Cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37118760"
                        open
                      >
                        <summary class="article-expander__title">New approaches to idiopathic neutropenia in the era of clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37117740"
                        open
                      >
                        <summary class="article-expander__title">The burden of rare protein-truncating genetic variants on human lifespan</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37115512"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Young Women Treated for Breast Cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37118760"
                        open
                      >
                        <summary class="article-expander__title">New approaches to idiopathic neutropenia in the era of clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37117740"
                        open
                      >
                        <summary class="article-expander__title">The burden of rare protein-truncating genetic variants on human lifespan</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37115512"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Young Women Treated for Breast Cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37118760"
                        open
                      >
                        <summary class="article-expander__title">New approaches to idiopathic neutropenia in the era of clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37117740"
                        open
                      >
                        <summary class="article-expander__title">The burden of rare protein-truncating genetic variants on human lifespan</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37115512"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Young Women Treated for Breast Cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37118760"
                        open
                      >
                        <summary class="article-expander__title">New approaches to idiopathic neutropenia in the era of clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37117740"
                        open
                      >
                        <summary class="article-expander__title">The burden of rare protein-truncating genetic variants on human lifespan</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37115512"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Young Women Treated for Breast Cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37118760"
                        open
                      >
                        <summary class="article-expander__title">New approaches to idiopathic neutropenia in the era of clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37118760/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Isolated chronic idiopathic neutropenia (CIN) is a rare disease with multiple contributing etiologies that must be ruled out before establishing a diagnosis. We studied clinical and molecular data of 238 consecutive adult patients with CIN. Autoimmune neutropenia was present in 28% of our cohort. In contrast, T cell-mediated neutropenia was the main underlying pathological mechanism among patients with T cell expansions, such as T-cell large granular lymphocytic leukemia (T-LGL) and T cell...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37117740"
                        open
                      >
                        <summary class="article-expander__title">The burden of rare protein-truncating genetic variants on human lifespan</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37117740/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genetic predisposition has been shown to contribute substantially to the age at which we die. Genome-wide association studies (GWASs) have linked more than 20 loci to phenotypes related to human lifespan¹. However, little is known about how lifespan is impacted by gene loss of function. Through whole-exome sequencing of 352,338 UK Biobank participants of European ancestry, we assessed the relevance of protein-truncating variant (PTV) gene burden on individual and parental survival. We identified...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37115512"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Young Women Treated for Breast Cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37115512"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Young Women Treated for Breast Cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37115512/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230428205526&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data show that for young women with early-stage breast cancer, CHIP is uncommon after cytotoxic exposure, is unlikely to contribute to adverse outcomes over the decade-long follow up and may not require additional monitoring if discovered incidentally.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-27 datetime="2023-04-27T10:00:00.000Z">2023-04-27</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-27 datetime="2023-04-27T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37106072"
                        open
                      >
                        <summary class="article-expander__title">Single duplex DNA sequencing with CODEC detects mutations with high sensitivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230512205523&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules (&#x27;single duplexes&#x27;) to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37106072"
                        open
                      >
                        <summary class="article-expander__title">Single duplex DNA sequencing with CODEC detects mutations with high sensitivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules (&#x27;single duplexes&#x27;) to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37106072"
                        open
                      >
                        <summary class="article-expander__title">Single duplex DNA sequencing with CODEC detects mutations with high sensitivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules (&#x27;single duplexes&#x27;) to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37106072"
                        open
                      >
                        <summary class="article-expander__title">Single duplex DNA sequencing with CODEC detects mutations with high sensitivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules (&#x27;single duplexes&#x27;) to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37106072"
                        open
                      >
                        <summary class="article-expander__title">Single duplex DNA sequencing with CODEC detects mutations with high sensitivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules (&#x27;single duplexes&#x27;) to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37106072"
                        open
                      >
                        <summary class="article-expander__title">Single duplex DNA sequencing with CODEC detects mutations with high sensitivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules (&#x27;single duplexes&#x27;) to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37106072"
                        open
                      >
                        <summary class="article-expander__title">Single duplex DNA sequencing with CODEC detects mutations with high sensitivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules (&#x27;single duplexes&#x27;) to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37106072"
                        open
                      >
                        <summary class="article-expander__title">Single duplex DNA sequencing with CODEC detects mutations with high sensitivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules (&#x27;single duplexes&#x27;) to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37106072"
                        open
                      >
                        <summary class="article-expander__title">Single duplex DNA sequencing with CODEC detects mutations with high sensitivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules (&#x27;single duplexes&#x27;) to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37106072"
                        open
                      >
                        <summary class="article-expander__title">Single duplex DNA sequencing with CODEC detects mutations with high sensitivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules (&#x27;single duplexes&#x27;) to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37106072"
                        open
                      >
                        <summary class="article-expander__title">Single duplex DNA sequencing with CODEC detects mutations with high sensitivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules (&#x27;single duplexes&#x27;) to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37106072"
                        open
                      >
                        <summary class="article-expander__title">Single duplex DNA sequencing with CODEC detects mutations with high sensitivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules (&#x27;single duplexes&#x27;) to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37106072"
                        open
                      >
                        <summary class="article-expander__title">Single duplex DNA sequencing with CODEC detects mutations with high sensitivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules (&#x27;single duplexes&#x27;) to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37106072"
                        open
                      >
                        <summary class="article-expander__title">Single duplex DNA sequencing with CODEC detects mutations with high sensitivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules (&#x27;single duplexes&#x27;) to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37106072"
                        open
                      >
                        <summary class="article-expander__title">Single duplex DNA sequencing with CODEC detects mutations with high sensitivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37106072/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230428205526&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Detecting mutations from single DNA molecules is crucial in many fields but challenging. Next-generation sequencing (NGS) affords tremendous throughput but cannot directly sequence double-stranded DNA molecules (&#x27;single duplexes&#x27;) to discern the true mutations on both strands. Here we present Concatenating Original Duplex for Error Correction (CODEC), which confers single duplex resolution to NGS. CODEC affords 1,000-fold higher accuracy than NGS, using up to 100-fold fewer reads than duplex...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105856"
                        open
                      >
                        <summary class="article-expander__title">Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105769"
                        open
                      >
                        <summary class="article-expander__title">Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230511205726&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>A tumor&#x27;s heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell&#x27;s mutation and identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105856"
                        open
                      >
                        <summary class="article-expander__title">Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105769"
                        open
                      >
                        <summary class="article-expander__title">Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>A tumor&#x27;s heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell&#x27;s mutation and identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105856"
                        open
                      >
                        <summary class="article-expander__title">Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105769"
                        open
                      >
                        <summary class="article-expander__title">Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>A tumor&#x27;s heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell&#x27;s mutation and identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105856"
                        open
                      >
                        <summary class="article-expander__title">Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105769"
                        open
                      >
                        <summary class="article-expander__title">Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>A tumor&#x27;s heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell&#x27;s mutation and identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105856"
                        open
                      >
                        <summary class="article-expander__title">Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105769"
                        open
                      >
                        <summary class="article-expander__title">Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>A tumor&#x27;s heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell&#x27;s mutation and identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105856"
                        open
                      >
                        <summary class="article-expander__title">Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105769"
                        open
                      >
                        <summary class="article-expander__title">Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>A tumor&#x27;s heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell&#x27;s mutation and identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105856"
                        open
                      >
                        <summary class="article-expander__title">Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105769"
                        open
                      >
                        <summary class="article-expander__title">Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>A tumor&#x27;s heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell&#x27;s mutation and identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105856"
                        open
                      >
                        <summary class="article-expander__title">Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105769"
                        open
                      >
                        <summary class="article-expander__title">Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>A tumor&#x27;s heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell&#x27;s mutation and identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105856"
                        open
                      >
                        <summary class="article-expander__title">Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105769"
                        open
                      >
                        <summary class="article-expander__title">Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>A tumor&#x27;s heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell&#x27;s mutation and identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105856"
                        open
                      >
                        <summary class="article-expander__title">Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105769"
                        open
                      >
                        <summary class="article-expander__title">Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>A tumor&#x27;s heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell&#x27;s mutation and identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105856"
                        open
                      >
                        <summary class="article-expander__title">Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105769"
                        open
                      >
                        <summary class="article-expander__title">Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>A tumor&#x27;s heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell&#x27;s mutation and identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105856"
                        open
                      >
                        <summary class="article-expander__title">Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105769"
                        open
                      >
                        <summary class="article-expander__title">Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>A tumor&#x27;s heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell&#x27;s mutation and identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105856"
                        open
                      >
                        <summary class="article-expander__title">Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105769"
                        open
                      >
                        <summary class="article-expander__title">Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>A tumor&#x27;s heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell&#x27;s mutation and identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105856"
                        open
                      >
                        <summary class="article-expander__title">Cellular barcoding tracks heterogeneous clones through selective pressures and phenotypic transitions</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105856/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230428205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Genomic DNA barcoding has emerged as a sensitive and flexible tool to measure the fates of clonal subpopulations within a heterogeneous cancer cell population. Coupling cellular barcoding with single-cell transcriptomics permits the longitudinal analysis of molecular mechanisms with detailed clone-level resolution. Numerous recent studies have employed these tools to track clonal cell states in cancer progression and treatment response. With these new technologies comes the opportunity to...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37105769"
                        open
                      >
                        <summary class="article-expander__title">Deciphering cell-cell interactions and communication in the tumor microenvironment and unraveling intratumoral genetic heterogeneity via single-cell genomic sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37105769/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230428205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>A tumor&#x27;s heterogeneity has important implications in terms of its clonal origin, progression, stemness, and drug resistance. Therefore, because of its significance in treatment, it is important to understand the gene expression pattern of a single cell, track gene expression or mutation in heterogeneous cells, evaluate the clonal origin of cancer cells, and determine the selective evolution of different subpopulations of cancer cells. Researchers are able to trace a cell&#x27;s mutation and identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-26 datetime="2023-04-26T10:00:00.000Z">2023-04-26</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-26 datetime="2023-04-26T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37100116"
                        open
                      >
                        <summary class="article-expander__title">Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37100116"
                        open
                      >
                        <summary class="article-expander__title">Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37100116"
                        open
                      >
                        <summary class="article-expander__title">Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37100116"
                        open
                      >
                        <summary class="article-expander__title">Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37100116"
                        open
                      >
                        <summary class="article-expander__title">Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37100116"
                        open
                      >
                        <summary class="article-expander__title">Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37100116"
                        open
                      >
                        <summary class="article-expander__title">Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37100116"
                        open
                      >
                        <summary class="article-expander__title">Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37100116"
                        open
                      >
                        <summary class="article-expander__title">Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37100116"
                        open
                      >
                        <summary class="article-expander__title">Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37100116"
                        open
                      >
                        <summary class="article-expander__title">Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37100116"
                        open
                      >
                        <summary class="article-expander__title">Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37100116"
                        open
                      >
                        <summary class="article-expander__title">Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230428205526&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37100116"
                        open
                      >
                        <summary class="article-expander__title">Recent advances in understanding the impact of infection and inflammation on hematopoietic stem and progenitor cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37100116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Just over one decade ago, it was discovered that hematopoietic stem cells (HSCs) could directly respond to inflammatory cytokines by mounting a proliferative response thought to mediate the emergency production of mature blood cells. In the intervening years, we have gained mechanistic insight into this so-called activation process and have started to learn such a response may come at a cost in terms of ultimately resulting in HSC exhaustion and hematologic dysfunction. In this review article,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-24 datetime="2023-04-24T10:00:00.000Z">2023-04-24</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-24 datetime="2023-04-24T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37088956"
                        open
                      >
                        <summary class="article-expander__title">Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37088956"
                        open
                      >
                        <summary class="article-expander__title">Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37088956"
                        open
                      >
                        <summary class="article-expander__title">Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37088956"
                        open
                      >
                        <summary class="article-expander__title">Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37088956"
                        open
                      >
                        <summary class="article-expander__title">Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37088956"
                        open
                      >
                        <summary class="article-expander__title">Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37088956"
                        open
                      >
                        <summary class="article-expander__title">Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37088956"
                        open
                      >
                        <summary class="article-expander__title">Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37088956"
                        open
                      >
                        <summary class="article-expander__title">Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37088956"
                        open
                      >
                        <summary class="article-expander__title">Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37088956"
                        open
                      >
                        <summary class="article-expander__title">Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37088956"
                        open
                      >
                        <summary class="article-expander__title">Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37088956"
                        open
                      >
                        <summary class="article-expander__title">Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230428205526&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37088956"
                        open
                      >
                        <summary class="article-expander__title">Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37088956"
                        open
                      >
                        <summary class="article-expander__title">Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37088956"
                        open
                      >
                        <summary class="article-expander__title">Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37092904"
                        open
                      >
                        <summary class="article-expander__title">The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37090647"
                        open
                      >
                        <summary class="article-expander__title">Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230510205718&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37092904"
                        open
                      >
                        <summary class="article-expander__title">The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37090647"
                        open
                      >
                        <summary class="article-expander__title">Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230509205648&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37092904"
                        open
                      >
                        <summary class="article-expander__title">The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37090647"
                        open
                      >
                        <summary class="article-expander__title">Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37092904"
                        open
                      >
                        <summary class="article-expander__title">The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37090647"
                        open
                      >
                        <summary class="article-expander__title">Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37092904"
                        open
                      >
                        <summary class="article-expander__title">The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37090647"
                        open
                      >
                        <summary class="article-expander__title">Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37092904"
                        open
                      >
                        <summary class="article-expander__title">The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37090647"
                        open
                      >
                        <summary class="article-expander__title">Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37092904"
                        open
                      >
                        <summary class="article-expander__title">The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37090647"
                        open
                      >
                        <summary class="article-expander__title">Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37092904"
                        open
                      >
                        <summary class="article-expander__title">The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37090647"
                        open
                      >
                        <summary class="article-expander__title">Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37092904"
                        open
                      >
                        <summary class="article-expander__title">The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37090647"
                        open
                      >
                        <summary class="article-expander__title">Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37092904"
                        open
                      >
                        <summary class="article-expander__title">The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37090647"
                        open
                      >
                        <summary class="article-expander__title">Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37092904"
                        open
                      >
                        <summary class="article-expander__title">The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37090647"
                        open
                      >
                        <summary class="article-expander__title">Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37092904"
                        open
                      >
                        <summary class="article-expander__title">The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37090647"
                        open
                      >
                        <summary class="article-expander__title">Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37092904"
                        open
                      >
                        <summary class="article-expander__title">The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230428205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37090647"
                        open
                      >
                        <summary class="article-expander__title">Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230428205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37092904"
                        open
                      >
                        <summary class="article-expander__title">The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37090647"
                        open
                      >
                        <summary class="article-expander__title">Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37092904"
                        open
                      >
                        <summary class="article-expander__title">The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37090647"
                        open
                      >
                        <summary class="article-expander__title">Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37092904"
                        open
                      >
                        <summary class="article-expander__title">The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37090647"
                        open
                      >
                        <summary class="article-expander__title">Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37092904"
                        open
                      >
                        <summary class="article-expander__title">The emerging role of circulating tumor DNA in non-colorectal gastrointestinal cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37092904/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Assays to detect circulating tumor DNA (ctDNA) have multiple clinically important applications in management of multiple types of gastrointestinal cancers. Different methodologies of ctDNA detection have varying sensitivities and potential applications in different contexts. For patients with localized cancers treated for curative intent, ctDNA detection is associated with prognosis in multiple cancer types, and persistent detection of ctDNA after surgical resection is highly concerning for...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-23 datetime="2023-04-23T10:00:00.000Z">2023-04-23</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-23 datetime="2023-04-23T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37088956"
                        open
                      >
                        <summary class="article-expander__title">Effects of radioactive iodine on clonal hematopoiesis in patients with thyroid cancer: A prospective study</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37088956/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: There was no increase in CH in patients treated with RAI over a 2-year follow-up period. Larger studies with longer follow-up periods are needed to investigate the association between RAI and clonal dynamics. The presence of CH is associated with worse structural progression in both BRAFV600E-mutant and wild-type thyroid cancers.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-22 datetime="2023-04-22T10:00:00.000Z">2023-04-22</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-22 datetime="2023-04-22T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086813"
                        open
                      >
                        <summary class="article-expander__title">Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions, including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors, including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor murine double minute X (MDMX) plays crucial roles, especially in leukemia initiation. MDMX is broadly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086813"
                        open
                      >
                        <summary class="article-expander__title">Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions, including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors, including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor murine double minute X (MDMX) plays crucial roles, especially in leukemia initiation. MDMX is broadly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086813"
                        open
                      >
                        <summary class="article-expander__title">Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions, including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors, including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor murine double minute X (MDMX) plays crucial roles, especially in leukemia initiation. MDMX is broadly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086813"
                        open
                      >
                        <summary class="article-expander__title">Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions, including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors, including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor murine double minute X (MDMX) plays crucial roles, especially in leukemia initiation. MDMX is broadly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086813"
                        open
                      >
                        <summary class="article-expander__title">Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions, including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors, including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor murine double minute X (MDMX) plays crucial roles, especially in leukemia initiation. MDMX is broadly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086813"
                        open
                      >
                        <summary class="article-expander__title">Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions, including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors, including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor murine double minute X (MDMX) plays crucial roles, especially in leukemia initiation. MDMX is broadly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086813"
                        open
                      >
                        <summary class="article-expander__title">Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions, including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors, including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor murine double minute X (MDMX) plays crucial roles, especially in leukemia initiation. MDMX is broadly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086813"
                        open
                      >
                        <summary class="article-expander__title">Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions, including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors, including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor murine double minute X (MDMX) plays crucial roles, especially in leukemia initiation. MDMX is broadly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086813"
                        open
                      >
                        <summary class="article-expander__title">Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions, including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors, including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor murine double minute X (MDMX) plays crucial roles, especially in leukemia initiation. MDMX is broadly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086813"
                        open
                      >
                        <summary class="article-expander__title">Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions, including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors, including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor murine double minute X (MDMX) plays crucial roles, especially in leukemia initiation. MDMX is broadly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086813"
                        open
                      >
                        <summary class="article-expander__title">Murine double minute X plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230428205526&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions, including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors, including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor murine double minute X (MDMX) plays crucial roles, especially in leukemia initiation. MDMX is broadly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086813"
                        open
                      >
                        <summary class="article-expander__title">Review: MDMX plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor Murine Double Minute X (MDMX) plays crucial roles especially in leukemia initiation. MDMX is broadly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086813"
                        open
                      >
                        <summary class="article-expander__title">Review: MDMX plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor Murine Double Minute X (MDMX) plays crucial roles especially in leukemia initiation. MDMX is broadly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086813"
                        open
                      >
                        <summary class="article-expander__title">Review: MDMX plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor Murine Double Minute X (MDMX) plays crucial roles especially in leukemia initiation. MDMX is broadly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086716"
                        open
                      >
                        <summary class="article-expander__title">Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086716"
                        open
                      >
                        <summary class="article-expander__title">Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086716"
                        open
                      >
                        <summary class="article-expander__title">Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086716"
                        open
                      >
                        <summary class="article-expander__title">Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086716"
                        open
                      >
                        <summary class="article-expander__title">Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086716"
                        open
                      >
                        <summary class="article-expander__title">Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086716"
                        open
                      >
                        <summary class="article-expander__title">Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086716"
                        open
                      >
                        <summary class="article-expander__title">Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086716"
                        open
                      >
                        <summary class="article-expander__title">Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086716"
                        open
                      >
                        <summary class="article-expander__title">Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086716"
                        open
                      >
                        <summary class="article-expander__title">Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230428205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086716"
                        open
                      >
                        <summary class="article-expander__title">Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086716"
                        open
                      >
                        <summary class="article-expander__title">Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086716"
                        open
                      >
                        <summary class="article-expander__title">Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-21 datetime="2023-04-21T10:00:00.000Z">2023-04-21</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-21 datetime="2023-04-21T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084382"
                        open
                      >
                        <summary class="article-expander__title">Spectrum of clonal hematopoiesis in VEXAS syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230508205817&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084382"
                        open
                      >
                        <summary class="article-expander__title">Spectrum of clonal hematopoiesis in VEXAS syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084069"
                        open
                      >
                        <summary class="article-expander__title">Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet&#x27;s disease harboring GATA2 mutation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet&#x27;s disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37083525"
                        open
                      >
                        <summary class="article-expander__title">Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by TET2, TP53, and CBL mutations</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084382"
                        open
                      >
                        <summary class="article-expander__title">Spectrum of clonal hematopoiesis in VEXAS syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084069"
                        open
                      >
                        <summary class="article-expander__title">Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet&#x27;s disease harboring GATA2 mutation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet&#x27;s disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37083525"
                        open
                      >
                        <summary class="article-expander__title">Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by TET2, TP53, and CBL mutations</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084382"
                        open
                      >
                        <summary class="article-expander__title">Spectrum of clonal hematopoiesis in VEXAS syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084069"
                        open
                      >
                        <summary class="article-expander__title">Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet&#x27;s disease harboring GATA2 mutation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet&#x27;s disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37083525"
                        open
                      >
                        <summary class="article-expander__title">Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by TET2, TP53, and CBL mutations</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084382"
                        open
                      >
                        <summary class="article-expander__title">Spectrum of clonal hematopoiesis in VEXAS syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084069"
                        open
                      >
                        <summary class="article-expander__title">Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet&#x27;s disease harboring GATA2 mutation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet&#x27;s disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37083525"
                        open
                      >
                        <summary class="article-expander__title">Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by TET2, TP53, and CBL mutations</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084382"
                        open
                      >
                        <summary class="article-expander__title">Spectrum of clonal hematopoiesis in VEXAS syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084069"
                        open
                      >
                        <summary class="article-expander__title">Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet&#x27;s disease harboring GATA2 mutation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet&#x27;s disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37083525"
                        open
                      >
                        <summary class="article-expander__title">Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by TET2, TP53, and CBL mutations</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084382"
                        open
                      >
                        <summary class="article-expander__title">Spectrum of clonal hematopoiesis in VEXAS syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084069"
                        open
                      >
                        <summary class="article-expander__title">Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet&#x27;s disease harboring GATA2 mutation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet&#x27;s disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37083525"
                        open
                      >
                        <summary class="article-expander__title">Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by TET2, TP53, and CBL mutations</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084382"
                        open
                      >
                        <summary class="article-expander__title">Spectrum of clonal hematopoiesis in VEXAS syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084069"
                        open
                      >
                        <summary class="article-expander__title">Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet&#x27;s disease harboring GATA2 mutation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet&#x27;s disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37083525"
                        open
                      >
                        <summary class="article-expander__title">Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by TET2, TP53, and CBL mutations</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084382"
                        open
                      >
                        <summary class="article-expander__title">Spectrum of clonal hematopoiesis in VEXAS syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084069"
                        open
                      >
                        <summary class="article-expander__title">Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet&#x27;s disease harboring GATA2 mutation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet&#x27;s disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37083525"
                        open
                      >
                        <summary class="article-expander__title">Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by TET2, TP53, and CBL mutations</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084382"
                        open
                      >
                        <summary class="article-expander__title">Spectrum of clonal hematopoiesis in VEXAS syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084069"
                        open
                      >
                        <summary class="article-expander__title">Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet&#x27;s disease harboring GATA2 mutation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet&#x27;s disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37083525"
                        open
                      >
                        <summary class="article-expander__title">Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by TET2, TP53, and CBL mutations</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084382"
                        open
                      >
                        <summary class="article-expander__title">Spectrum of clonal hematopoiesis in VEXAS syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230428205526&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084069"
                        open
                      >
                        <summary class="article-expander__title">Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet&#x27;s disease harboring GATA2 mutation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230428205526&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet&#x27;s disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37083525"
                        open
                      >
                        <summary class="article-expander__title">Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by TET2, TP53, and CBL mutations</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230428205526&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084382"
                        open
                      >
                        <summary class="article-expander__title">Spectrum of clonal hematopoiesis in VEXAS syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084069"
                        open
                      >
                        <summary class="article-expander__title">Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet&#x27;s disease harboring GATA2 mutation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet&#x27;s disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37083525"
                        open
                      >
                        <summary class="article-expander__title">Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by TET2, TP53, and CBL mutations</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084382"
                        open
                      >
                        <summary class="article-expander__title">Spectrum of clonal hematopoiesis in VEXAS syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084069"
                        open
                      >
                        <summary class="article-expander__title">Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet&#x27;s disease harboring GATA2 mutation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet&#x27;s disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37083525"
                        open
                      >
                        <summary class="article-expander__title">Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by TET2, TP53, and CBL mutations</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084382"
                        open
                      >
                        <summary class="article-expander__title">Spectrum of clonal hematopoiesis in VEXAS syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084069"
                        open
                      >
                        <summary class="article-expander__title">Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet&#x27;s disease harboring GATA2 mutation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet&#x27;s disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37083525"
                        open
                      >
                        <summary class="article-expander__title">Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by TET2, TP53, and CBL mutations</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084382"
                        open
                      >
                        <summary class="article-expander__title">Spectrum of clonal hematopoiesis in VEXAS syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084069"
                        open
                      >
                        <summary class="article-expander__title">Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet&#x27;s disease harboring GATA2 mutation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet&#x27;s disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37083525"
                        open
                      >
                        <summary class="article-expander__title">Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by TET2, TP53, and CBL mutations</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084382"
                        open
                      >
                        <summary class="article-expander__title">Spectrum of clonal hematopoiesis in VEXAS syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084069"
                        open
                      >
                        <summary class="article-expander__title">Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet&#x27;s disease harboring GATA2 mutation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet&#x27;s disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37083525"
                        open
                      >
                        <summary class="article-expander__title">Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by TET2, TP53, and CBL mutations</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084382"
                        open
                      >
                        <summary class="article-expander__title">Spectrum of clonal hematopoiesis in VEXAS syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084069"
                        open
                      >
                        <summary class="article-expander__title">Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet&#x27;s disease harboring GATA2 mutation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet&#x27;s disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37083525"
                        open
                      >
                        <summary class="article-expander__title">Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by TET2, TP53, and CBL mutations</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084382"
                        open
                      >
                        <summary class="article-expander__title">Spectrum of clonal hematopoiesis in VEXAS syndrome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084382/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>VEXAS is caused by somatic mutations in UBA1 (UBA1mut) and characterized by heterogenous systemic auto-inflammation and progressive hematologic manifestations, meeting criteria for myelodysplastic syndrome (MDS) and plasma cell dyscrasias. The landscape of myeloid-related gene mutations leading to typical clonal hematopoiesis (CH) in these patients is unknown. Retrospectively, we screened 80 VEXAS patients for CH in their peripheral blood (PB) and correlated findings with clinical outcomes in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37084069"
                        open
                      >
                        <summary class="article-expander__title">Successful allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms complicated with secondary pulmonary alveolar proteinosis and Behçet&#x27;s disease harboring GATA2 mutation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37084069/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasms (MDS) are defined by cytopenia and morphologic dysplasia originating from clonal hematopoiesis. They are also frequently complicated with diseases caused by immune dysfunction, such as Behçet&#x27;s disease (BD) and secondary pulmonary alveolar proteinosis (sPAP). MDS with both BD and sPAP is extremely rare, and their prognosis is poor. In addition, haploinsufficiency of the hematopoietic transcription factor gene GATA2 is recognized as a cause of familial MDS and is...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37083525"
                        open
                      >
                        <summary class="article-expander__title">Age-related loss of chromosome Y is associated with levels of sex hormone binding globulin and clonal hematopoiesis defined by TET2, TP53, and CBL mutations</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37083525/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic loss of the Y-chromosome (LOY) in peripheral blood leukocytes is the most common somatic alteration in men and linked to wide range of malignant and nonmalignant conditions. LOY is associated with age, smoking, and constitutional genetics. Here, we aimed to assess the relationships between LOY, serum biomarkers, and clonal hematopoiesis (CH). LOY in U.K. Biobank was strongly associated with levels of sex hormone binding globulin (SHBG), a key regulator of testosterone bioavailability....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-20 datetime="2023-04-20T10:00:00.000Z">2023-04-20</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-20 datetime="2023-04-20T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079859"
                        open
                      >
                        <summary class="article-expander__title">Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079859"
                        open
                      >
                        <summary class="article-expander__title">Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079859"
                        open
                      >
                        <summary class="article-expander__title">Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079859"
                        open
                      >
                        <summary class="article-expander__title">Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079859"
                        open
                      >
                        <summary class="article-expander__title">Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079859"
                        open
                      >
                        <summary class="article-expander__title">Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079859"
                        open
                      >
                        <summary class="article-expander__title">Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079859"
                        open
                      >
                        <summary class="article-expander__title">Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230428205526&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079859"
                        open
                      >
                        <summary class="article-expander__title">Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079859"
                        open
                      >
                        <summary class="article-expander__title">Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079859"
                        open
                      >
                        <summary class="article-expander__title">Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086813"
                        open
                      >
                        <summary class="article-expander__title">Review: MDMX plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor Murine Double Minute X (MDMX) plays crucial roles especially in leukemia initiation. MDMX is broadly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086813"
                        open
                      >
                        <summary class="article-expander__title">Review: MDMX plays a central role in leukemic transformation and may be a promising target for leukemia prevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086813/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a fatal disease resulting from preleukemic hematopoietic conditions including asymptomatic clonal hematopoiesis. The accumulation of genetic changes is one of the causes of leukemic transformation. However, nongenetic factors including the overexpression of specific genes also contribute to preleukemic to leukemic transition. Among them, the p53 inhibitor Murine Double Minute X (MDMX) plays crucial roles especially in leukemia initiation. MDMX is broadly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37081523"
                        open
                      >
                        <summary class="article-expander__title">ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079068"
                        open
                      >
                        <summary class="article-expander__title">Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230507205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37081523"
                        open
                      >
                        <summary class="article-expander__title">ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079068"
                        open
                      >
                        <summary class="article-expander__title">Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37081523"
                        open
                      >
                        <summary class="article-expander__title">ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079068"
                        open
                      >
                        <summary class="article-expander__title">Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37081523"
                        open
                      >
                        <summary class="article-expander__title">ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079068"
                        open
                      >
                        <summary class="article-expander__title">Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37081523"
                        open
                      >
                        <summary class="article-expander__title">ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079068"
                        open
                      >
                        <summary class="article-expander__title">Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37081523"
                        open
                      >
                        <summary class="article-expander__title">ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079068"
                        open
                      >
                        <summary class="article-expander__title">Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37081523"
                        open
                      >
                        <summary class="article-expander__title">ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079068"
                        open
                      >
                        <summary class="article-expander__title">Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37081523"
                        open
                      >
                        <summary class="article-expander__title">ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079068"
                        open
                      >
                        <summary class="article-expander__title">Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37081523"
                        open
                      >
                        <summary class="article-expander__title">ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079068"
                        open
                      >
                        <summary class="article-expander__title">Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37081523"
                        open
                      >
                        <summary class="article-expander__title">ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230428205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079068"
                        open
                      >
                        <summary class="article-expander__title">Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230428205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37081523"
                        open
                      >
                        <summary class="article-expander__title">ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079068"
                        open
                      >
                        <summary class="article-expander__title">Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37081523"
                        open
                      >
                        <summary class="article-expander__title">ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079068"
                        open
                      >
                        <summary class="article-expander__title">Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37081523"
                        open
                      >
                        <summary class="article-expander__title">ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079068"
                        open
                      >
                        <summary class="article-expander__title">Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37081523"
                        open
                      >
                        <summary class="article-expander__title">ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079068"
                        open
                      >
                        <summary class="article-expander__title">Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37081523"
                        open
                      >
                        <summary class="article-expander__title">ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079068"
                        open
                      >
                        <summary class="article-expander__title">Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37081523"
                        open
                      >
                        <summary class="article-expander__title">ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079068"
                        open
                      >
                        <summary class="article-expander__title">Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37081523"
                        open
                      >
                        <summary class="article-expander__title">ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37081523/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: This work demonstrates the power of haplotype phasing to study genomic variation in cfDNA samples and reveals undiscovered intra-tumour heterogeneity with important scientific and clinical implications. Implementation of ACT-Discover could lead to important insights from existing cohorts or underpin future prospective studies seeking to characterise the landscape of tumour evolution through liquid biopsy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079068"
                        open
                      >
                        <summary class="article-expander__title">Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079068"
                        open
                      >
                        <summary class="article-expander__title">Pathological and genomic features of myeloproliferative neoplasms associated with splanchnic vein thrombosis in a single-center cohort</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079068/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Here, we reviewed clinical-morphological data and investigated mutational profiles by NGS in a single-center series of 58 consecutive MPN-SVT patients admitted to our hospital between January 1979 and November 2021. We identified 15.5% of PV, 13.8% of ET, 34.5% of PMF, 8.6% of SMF and 27.6% of MPN-U. Most cases (84.5%) carried JAK2V617F mutation, while seven patients were characterized by other molecular markers, namely MPL in four and CALR mutations in three cases. NGS was performed in 54...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-19 datetime="2023-04-19T10:00:00.000Z">2023-04-19</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-19 datetime="2023-04-19T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230428205526&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230506210046&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230428205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-18 datetime="2023-04-18T10:00:00.000Z">2023-04-18</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-18 datetime="2023-04-18T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37071471"
                        open
                      >
                        <summary class="article-expander__title">Obesity induced inflammation exacerbates clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37071471"
                        open
                      >
                        <summary class="article-expander__title">Obesity induced inflammation exacerbates clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37071471"
                        open
                      >
                        <summary class="article-expander__title">Obesity induced inflammation exacerbates clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230428205526&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37071471"
                        open
                      >
                        <summary class="article-expander__title">Obesity induced inflammation exacerbates clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37071471"
                        open
                      >
                        <summary class="article-expander__title">Obesity induced inflammation exacerbates clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37071471"
                        open
                      >
                        <summary class="article-expander__title">Obesity induced inflammation exacerbates clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37071471"
                        open
                      >
                        <summary class="article-expander__title">Obesity induced inflammation exacerbates clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37071471"
                        open
                      >
                        <summary class="article-expander__title">Obesity induced inflammation exacerbates clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37071471"
                        open
                      >
                        <summary class="article-expander__title">Obesity induced inflammation exacerbates clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37071471"
                        open
                      >
                        <summary class="article-expander__title">Obesity induced inflammation exacerbates clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37071471"
                        open
                      >
                        <summary class="article-expander__title">Obesity induced inflammation exacerbates clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37071471"
                        open
                      >
                        <summary class="article-expander__title">Obesity induced inflammation exacerbates clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37071471"
                        open
                      >
                        <summary class="article-expander__title">Obesity induced inflammation exacerbates clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37071471/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Characterized by the accumulation of somatic mutations in blood cell lineages, clonal hematopoiesis (CH) of indeterminate potential (CHIP) is frequent in ageing, involves expansion of mutated hematopoietic stem and progenitor cells (HSC/Ps) that leads to an increased risk of hematologic malignancy. However, risk factors that contribute to CHIP-associated CH are poorly understood. Obesity induces a pro-inflammatory state and fatty bone marrow (FBM), which may influence CHIP-associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072406"
                        open
                      >
                        <summary class="article-expander__title">Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230505205328&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072406"
                        open
                      >
                        <summary class="article-expander__title">Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072390"
                        open
                      >
                        <summary class="article-expander__title">Bladder cancer organoids as a functional system to model different disease stages and therapy response</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;13
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072406"
                        open
                      >
                        <summary class="article-expander__title">Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072390"
                        open
                      >
                        <summary class="article-expander__title">Bladder cancer organoids as a functional system to model different disease stages and therapy response</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;13
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072406"
                        open
                      >
                        <summary class="article-expander__title">Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072390"
                        open
                      >
                        <summary class="article-expander__title">Bladder cancer organoids as a functional system to model different disease stages and therapy response</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;13
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072406"
                        open
                      >
                        <summary class="article-expander__title">Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072390"
                        open
                      >
                        <summary class="article-expander__title">Bladder cancer organoids as a functional system to model different disease stages and therapy response</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072406"
                        open
                      >
                        <summary class="article-expander__title">Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072390"
                        open
                      >
                        <summary class="article-expander__title">Bladder cancer organoids as a functional system to model different disease stages and therapy response</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;13
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072406"
                        open
                      >
                        <summary class="article-expander__title">Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072390"
                        open
                      >
                        <summary class="article-expander__title">Bladder cancer organoids as a functional system to model different disease stages and therapy response</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;13
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072406"
                        open
                      >
                        <summary class="article-expander__title">Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230428205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072390"
                        open
                      >
                        <summary class="article-expander__title">Bladder cancer organoids as a functional system to model different disease stages and therapy response</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230428205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;13
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072406"
                        open
                      >
                        <summary class="article-expander__title">Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072390"
                        open
                      >
                        <summary class="article-expander__title">Bladder cancer organoids as a functional system to model different disease stages and therapy response</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;13
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072406"
                        open
                      >
                        <summary class="article-expander__title">Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072390"
                        open
                      >
                        <summary class="article-expander__title">Bladder cancer organoids as a functional system to model different disease stages and therapy response</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;13
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072406"
                        open
                      >
                        <summary class="article-expander__title">Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072390"
                        open
                      >
                        <summary class="article-expander__title">Bladder cancer organoids as a functional system to model different disease stages and therapy response</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;13
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072406"
                        open
                      >
                        <summary class="article-expander__title">Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072390"
                        open
                      >
                        <summary class="article-expander__title">Bladder cancer organoids as a functional system to model different disease stages and therapy response</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;13
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072406"
                        open
                      >
                        <summary class="article-expander__title">Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072390"
                        open
                      >
                        <summary class="article-expander__title">Bladder cancer organoids as a functional system to model different disease stages and therapy response</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;13
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072406"
                        open
                      >
                        <summary class="article-expander__title">Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072390"
                        open
                      >
                        <summary class="article-expander__title">Bladder cancer organoids as a functional system to model different disease stages and therapy response</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;13
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072406"
                        open
                      >
                        <summary class="article-expander__title">Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072390"
                        open
                      >
                        <summary class="article-expander__title">Bladder cancer organoids as a functional system to model different disease stages and therapy response</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;13
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072406"
                        open
                      >
                        <summary class="article-expander__title">Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072390"
                        open
                      >
                        <summary class="article-expander__title">Bladder cancer organoids as a functional system to model different disease stages and therapy response</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;13
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072406"
                        open
                      >
                        <summary class="article-expander__title">Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072406/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>HER2-positive gastric cancer (GC) makes up 15-20% of all GC incidences, and targeted therapy with trastuzumab is the standard of treatment. However, the mechanisms of resistance to trastuzumab are still not fully understood and presents a significant challenge in clinical practice. In this study, whole exome sequencing (WES) was performed on paired tumor tissues before trastuzumab treatment (at baseline) and at progressive disease (PD) in 23 GC patients. Clinicopathological and molecular...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37072390"
                        open
                      >
                        <summary class="article-expander__title">Bladder cancer organoids as a functional system to model different disease stages and therapy response</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37072390/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Bladder Cancer (BLCa) inter-patient heterogeneity is the primary cause of treatment failure, suggesting that patients could benefit from a more personalized treatment approach. Patient-derived organoids (PDOs) have been successfully used as a functional model for predicting drug response in different cancers. In our study, we establish PDO cultures from different BLCa stages and grades. PDOs preserve the histological and molecular heterogeneity of the parental tumors, including their multiclonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-17 datetime="2023-04-17T10:00:00.000Z">2023-04-17</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-17 datetime="2023-04-17T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37066022"
                        open
                      >
                        <summary class="article-expander__title">Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230504205311&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37066022"
                        open
                      >
                        <summary class="article-expander__title">Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37066022"
                        open
                      >
                        <summary class="article-expander__title">Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37066022"
                        open
                      >
                        <summary class="article-expander__title">Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37066022"
                        open
                      >
                        <summary class="article-expander__title">Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37066022"
                        open
                      >
                        <summary class="article-expander__title">Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37066022"
                        open
                      >
                        <summary class="article-expander__title">Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230428205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37066022"
                        open
                      >
                        <summary class="article-expander__title">Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37066022"
                        open
                      >
                        <summary class="article-expander__title">Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37066022"
                        open
                      >
                        <summary class="article-expander__title">Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37066022"
                        open
                      >
                        <summary class="article-expander__title">Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37066022"
                        open
                      >
                        <summary class="article-expander__title">Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37066022"
                        open
                      >
                        <summary class="article-expander__title">Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37066022"
                        open
                      >
                        <summary class="article-expander__title">Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37066022"
                        open
                      >
                        <summary class="article-expander__title">Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37066022"
                        open
                      >
                        <summary class="article-expander__title">Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37066022"
                        open
                      >
                        <summary class="article-expander__title">Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37066022"
                        open
                      >
                        <summary class="article-expander__title">Structurally Complex Osteosarcoma Genomes Exhibit Limited Heterogeneity within Individual Tumors and across Evolutionary Time</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37066022/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Osteosarcoma is an aggressive malignancy characterized by high genomic complexity. Identification of few recurrent mutations in protein coding genes suggests that somatic copy-number aberrations (SCNA) are the genetic drivers of disease. Models around genomic instability conflict-it is unclear whether osteosarcomas result from pervasive ongoing clonal evolution with continuous optimization of the fitness landscape or an early catastrophic event followed by stable maintenance of an abnormal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-15 datetime="2023-04-15T10:00:00.000Z">2023-04-15</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-15 datetime="2023-04-15T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37061644"
                        open
                      >
                        <summary class="article-expander__title">Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37061644"
                        open
                      >
                        <summary class="article-expander__title">Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37061644"
                        open
                      >
                        <summary class="article-expander__title">Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37061644"
                        open
                      >
                        <summary class="article-expander__title">Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37061644"
                        open
                      >
                        <summary class="article-expander__title">Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37061644"
                        open
                      >
                        <summary class="article-expander__title">Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230428205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37061644"
                        open
                      >
                        <summary class="article-expander__title">Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37061644"
                        open
                      >
                        <summary class="article-expander__title">Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37061644"
                        open
                      >
                        <summary class="article-expander__title">Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37061644"
                        open
                      >
                        <summary class="article-expander__title">Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37061644"
                        open
                      >
                        <summary class="article-expander__title">Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37061644"
                        open
                      >
                        <summary class="article-expander__title">Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37061644"
                        open
                      >
                        <summary class="article-expander__title">Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37061644"
                        open
                      >
                        <summary class="article-expander__title">Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37061644"
                        open
                      >
                        <summary class="article-expander__title">Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37061644"
                        open
                      >
                        <summary class="article-expander__title">Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37061644"
                        open
                      >
                        <summary class="article-expander__title">Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37061644"
                        open
                      >
                        <summary class="article-expander__title">Colorectal cancer liver metastasis: genomic evolution and crosstalk with the liver microenvironment</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37061644/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Colorectal cancer (CRC) patients frequently develop liver metastases, which are the major cause of cancer-related mortality. The molecular basis and management of colorectal liver metastases (CRLMs) remain a challenging clinical issue. Recent genomic evidence has demonstrated the liver tropism of CRC and the presence of a stricter evolutionary bottleneck in the liver as a target organ compared to lymph nodes. This bottleneck challenging CRC cells in the liver is organ-specific and requires...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-14 datetime="2023-04-14T10:00:00.000Z">2023-04-14</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-14 datetime="2023-04-14T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37057121"
                        open
                      >
                        <summary class="article-expander__title">Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230503205635&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37057121"
                        open
                      >
                        <summary class="article-expander__title">Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37057121"
                        open
                      >
                        <summary class="article-expander__title">Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37057121"
                        open
                      >
                        <summary class="article-expander__title">Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37057121"
                        open
                      >
                        <summary class="article-expander__title">Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37057121"
                        open
                      >
                        <summary class="article-expander__title">Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230428205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37057121"
                        open
                      >
                        <summary class="article-expander__title">Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37057121"
                        open
                      >
                        <summary class="article-expander__title">Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37057121"
                        open
                      >
                        <summary class="article-expander__title">Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37057121"
                        open
                      >
                        <summary class="article-expander__title">Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37057121"
                        open
                      >
                        <summary class="article-expander__title">Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37057121"
                        open
                      >
                        <summary class="article-expander__title">Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37057121"
                        open
                      >
                        <summary class="article-expander__title">Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37075557"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis: Origins and determinants of evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37075557/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accrual of somatic mutations is a byproduct of aging. When a clone bearing a somatic genetic alteration, conferring comparative competitive advantage, displays sufficient outgrowth to become detectable amongst an otherwise polyclonal background in the hematopoietic system, this is called clonal hematopoiesis (CH). Somatic genetic alterations observed in CH include point mutations in cancer related genes, mosaic chromosomal alterations or a combination of these. Interestingly, clonal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37057121"
                        open
                      >
                        <summary class="article-expander__title">Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37057121"
                        open
                      >
                        <summary class="article-expander__title">Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37057121"
                        open
                      >
                        <summary class="article-expander__title">Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37057121"
                        open
                      >
                        <summary class="article-expander__title">Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37057121"
                        open
                      >
                        <summary class="article-expander__title">Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37057121"
                        open
                      >
                        <summary class="article-expander__title">Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37057121"
                        open
                      >
                        <summary class="article-expander__title">Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37057121/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Due to their advantages, liquid biopsy-based approaches have recently gained immense interest in oncology. Potential applications of this method include early detection, informing precision medicine-based individualized treatment, and real-time monitoring of disease evolution and treatment. The development of next-generation sequencing has vastly extended genetic profiling, thus enabling better identification of druggable alterations. However, the clinical application of liquid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-13 datetime="2023-04-13T10:00:00.000Z">2023-04-13</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-13 datetime="2023-04-13T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052531"
                        open
                      >
                        <summary class="article-expander__title">The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052531"
                        open
                      >
                        <summary class="article-expander__title">The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052531"
                        open
                      >
                        <summary class="article-expander__title">The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230428205526&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052531"
                        open
                      >
                        <summary class="article-expander__title">The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052531"
                        open
                      >
                        <summary class="article-expander__title">The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052531"
                        open
                      >
                        <summary class="article-expander__title">The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052531"
                        open
                      >
                        <summary class="article-expander__title">The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052531"
                        open
                      >
                        <summary class="article-expander__title">The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052531"
                        open
                      >
                        <summary class="article-expander__title">The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052531"
                        open
                      >
                        <summary class="article-expander__title">The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052531"
                        open
                      >
                        <summary class="article-expander__title">The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052531"
                        open
                      >
                        <summary class="article-expander__title">The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052531"
                        open
                      >
                        <summary class="article-expander__title">The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052531"
                        open
                      >
                        <summary class="article-expander__title">The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052531"
                        open
                      >
                        <summary class="article-expander__title">The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052531"
                        open
                      >
                        <summary class="article-expander__title">The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052531"
                        open
                      >
                        <summary class="article-expander__title">The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052531"
                        open
                      >
                        <summary class="article-expander__title">The Role of Inflammation in the Initiation and Progression of Myeloid Neoplasms</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052531/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230413205532&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies are devastating hematologic cancers with limited therapeutic options. Inflammation is emerging as a novel driver of myeloid malignancy, with important implications for tumor composition, immune response, therapeutic options, and patient survival. Here, we discuss the role of inflammation in normal and malignant hematopoiesis, from clonal hematopoiesis to full-blown myeloid leukemia. We discuss how inflammation shapes clonal output from hematopoietic stem cells, how...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052539"
                        open
                      >
                        <summary class="article-expander__title">Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37047167"
                        open
                      >
                        <summary class="article-expander__title">Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230502205757&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the &#x27;atavistic reversal&#x27;, &#x27;cancer attractor&#x27;, &#x27;somatic mutation&#x27;, &#x27;genome chaos&#x27;, and &#x27;tissue organization field&#x27; theories. The &#x27;atavistic reversal&#x27; theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called &#x27;gradual atavism&#x27;, and evidence for the &#x27;serial atavism&#x27; model. We showed the gradual core-to-periphery evolutionary growth of the human...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052539"
                        open
                      >
                        <summary class="article-expander__title">Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37047167"
                        open
                      >
                        <summary class="article-expander__title">Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230501205822&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the &#x27;atavistic reversal&#x27;, &#x27;cancer attractor&#x27;, &#x27;somatic mutation&#x27;, &#x27;genome chaos&#x27;, and &#x27;tissue organization field&#x27; theories. The &#x27;atavistic reversal&#x27; theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called &#x27;gradual atavism&#x27;, and evidence for the &#x27;serial atavism&#x27; model. We showed the gradual core-to-periphery evolutionary growth of the human...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052539"
                        open
                      >
                        <summary class="article-expander__title">Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37047167"
                        open
                      >
                        <summary class="article-expander__title">Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230430210026&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the &#x27;atavistic reversal&#x27;, &#x27;cancer attractor&#x27;, &#x27;somatic mutation&#x27;, &#x27;genome chaos&#x27;, and &#x27;tissue organization field&#x27; theories. The &#x27;atavistic reversal&#x27; theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called &#x27;gradual atavism&#x27;, and evidence for the &#x27;serial atavism&#x27; model. We showed the gradual core-to-periphery evolutionary growth of the human...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052539"
                        open
                      >
                        <summary class="article-expander__title">Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37047167"
                        open
                      >
                        <summary class="article-expander__title">Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230429210234&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the &#x27;atavistic reversal&#x27;, &#x27;cancer attractor&#x27;, &#x27;somatic mutation&#x27;, &#x27;genome chaos&#x27;, and &#x27;tissue organization field&#x27; theories. The &#x27;atavistic reversal&#x27; theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called &#x27;gradual atavism&#x27;, and evidence for the &#x27;serial atavism&#x27; model. We showed the gradual core-to-periphery evolutionary growth of the human...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052539"
                        open
                      >
                        <summary class="article-expander__title">Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230428205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37047167"
                        open
                      >
                        <summary class="article-expander__title">Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230428205525&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the &#x27;atavistic reversal&#x27;, &#x27;cancer attractor&#x27;, &#x27;somatic mutation&#x27;, &#x27;genome chaos&#x27;, and &#x27;tissue organization field&#x27; theories. The &#x27;atavistic reversal&#x27; theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called &#x27;gradual atavism&#x27;, and evidence for the &#x27;serial atavism&#x27; model. We showed the gradual core-to-periphery evolutionary growth of the human...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052539"
                        open
                      >
                        <summary class="article-expander__title">Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37047167"
                        open
                      >
                        <summary class="article-expander__title">Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the &#x27;atavistic reversal&#x27;, &#x27;cancer attractor&#x27;, &#x27;somatic mutation&#x27;, &#x27;genome chaos&#x27;, and &#x27;tissue organization field&#x27; theories. The &#x27;atavistic reversal&#x27; theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called &#x27;gradual atavism&#x27;, and evidence for the &#x27;serial atavism&#x27; model. We showed the gradual core-to-periphery evolutionary growth of the human...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046647"
                        open
                      >
                        <summary class="article-expander__title">Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052539"
                        open
                      >
                        <summary class="article-expander__title">Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37047167"
                        open
                      >
                        <summary class="article-expander__title">Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the &#x27;atavistic reversal&#x27;, &#x27;cancer attractor&#x27;, &#x27;somatic mutation&#x27;, &#x27;genome chaos&#x27;, and &#x27;tissue organization field&#x27; theories. The &#x27;atavistic reversal&#x27; theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called &#x27;gradual atavism&#x27;, and evidence for the &#x27;serial atavism&#x27; model. We showed the gradual core-to-periphery evolutionary growth of the human...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046647"
                        open
                      >
                        <summary class="article-expander__title">Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052539"
                        open
                      >
                        <summary class="article-expander__title">Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37047167"
                        open
                      >
                        <summary class="article-expander__title">Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the &#x27;atavistic reversal&#x27;, &#x27;cancer attractor&#x27;, &#x27;somatic mutation&#x27;, &#x27;genome chaos&#x27;, and &#x27;tissue organization field&#x27; theories. The &#x27;atavistic reversal&#x27; theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called &#x27;gradual atavism&#x27;, and evidence for the &#x27;serial atavism&#x27; model. We showed the gradual core-to-periphery evolutionary growth of the human...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046647"
                        open
                      >
                        <summary class="article-expander__title">Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086716"
                        open
                      >
                        <summary class="article-expander__title">Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052539"
                        open
                      >
                        <summary class="article-expander__title">Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37047167"
                        open
                      >
                        <summary class="article-expander__title">Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the &#x27;atavistic reversal&#x27;, &#x27;cancer attractor&#x27;, &#x27;somatic mutation&#x27;, &#x27;genome chaos&#x27;, and &#x27;tissue organization field&#x27; theories. The &#x27;atavistic reversal&#x27; theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called &#x27;gradual atavism&#x27;, and evidence for the &#x27;serial atavism&#x27; model. We showed the gradual core-to-periphery evolutionary growth of the human...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046647"
                        open
                      >
                        <summary class="article-expander__title">Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37086716"
                        open
                      >
                        <summary class="article-expander__title">Early immune pressure initiated by tissue-resident memory T cells sculpts tumor evolution in non-small cell lung cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37086716/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tissue-resident memory T (T(RM)) cells provide immune defense against local infection and can inhibit cancer progression. However, it is unclear to what extent chronic inflammation impacts T(RM) activation and whether T(RM) cells existing in tissues before tumor onset influence cancer evolution in humans. We performed deep profiling of healthy lungs and lung cancers in never-smokers (NSs) and ever-smokers (ESs), finding evidence of enhanced immunosurveillance by cells with a T(RM)-like phenotype...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052539"
                        open
                      >
                        <summary class="article-expander__title">Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37047167"
                        open
                      >
                        <summary class="article-expander__title">Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the &#x27;atavistic reversal&#x27;, &#x27;cancer attractor&#x27;, &#x27;somatic mutation&#x27;, &#x27;genome chaos&#x27;, and &#x27;tissue organization field&#x27; theories. The &#x27;atavistic reversal&#x27; theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called &#x27;gradual atavism&#x27;, and evidence for the &#x27;serial atavism&#x27; model. We showed the gradual core-to-periphery evolutionary growth of the human...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046647"
                        open
                      >
                        <summary class="article-expander__title">Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052539"
                        open
                      >
                        <summary class="article-expander__title">Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37047167"
                        open
                      >
                        <summary class="article-expander__title">Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the &#x27;atavistic reversal&#x27;, &#x27;cancer attractor&#x27;, &#x27;somatic mutation&#x27;, &#x27;genome chaos&#x27;, and &#x27;tissue organization field&#x27; theories. The &#x27;atavistic reversal&#x27; theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called &#x27;gradual atavism&#x27;, and evidence for the &#x27;serial atavism&#x27; model. We showed the gradual core-to-periphery evolutionary growth of the human...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046647"
                        open
                      >
                        <summary class="article-expander__title">Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052539"
                        open
                      >
                        <summary class="article-expander__title">Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37047167"
                        open
                      >
                        <summary class="article-expander__title">Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the &#x27;atavistic reversal&#x27;, &#x27;cancer attractor&#x27;, &#x27;somatic mutation&#x27;, &#x27;genome chaos&#x27;, and &#x27;tissue organization field&#x27; theories. The &#x27;atavistic reversal&#x27; theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called &#x27;gradual atavism&#x27;, and evidence for the &#x27;serial atavism&#x27; model. We showed the gradual core-to-periphery evolutionary growth of the human...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046647"
                        open
                      >
                        <summary class="article-expander__title">Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052539"
                        open
                      >
                        <summary class="article-expander__title">Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37047167"
                        open
                      >
                        <summary class="article-expander__title">Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the &#x27;atavistic reversal&#x27;, &#x27;cancer attractor&#x27;, &#x27;somatic mutation&#x27;, &#x27;genome chaos&#x27;, and &#x27;tissue organization field&#x27; theories. The &#x27;atavistic reversal&#x27; theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called &#x27;gradual atavism&#x27;, and evidence for the &#x27;serial atavism&#x27; model. We showed the gradual core-to-periphery evolutionary growth of the human...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046647"
                        open
                      >
                        <summary class="article-expander__title">Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052539"
                        open
                      >
                        <summary class="article-expander__title">Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37047167"
                        open
                      >
                        <summary class="article-expander__title">Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the &#x27;atavistic reversal&#x27;, &#x27;cancer attractor&#x27;, &#x27;somatic mutation&#x27;, &#x27;genome chaos&#x27;, and &#x27;tissue organization field&#x27; theories. The &#x27;atavistic reversal&#x27; theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called &#x27;gradual atavism&#x27;, and evidence for the &#x27;serial atavism&#x27; model. We showed the gradual core-to-periphery evolutionary growth of the human...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046647"
                        open
                      >
                        <summary class="article-expander__title">Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052539"
                        open
                      >
                        <summary class="article-expander__title">Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37047167"
                        open
                      >
                        <summary class="article-expander__title">Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the &#x27;atavistic reversal&#x27;, &#x27;cancer attractor&#x27;, &#x27;somatic mutation&#x27;, &#x27;genome chaos&#x27;, and &#x27;tissue organization field&#x27; theories. The &#x27;atavistic reversal&#x27; theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called &#x27;gradual atavism&#x27;, and evidence for the &#x27;serial atavism&#x27; model. We showed the gradual core-to-periphery evolutionary growth of the human...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046647"
                        open
                      >
                        <summary class="article-expander__title">Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052539"
                        open
                      >
                        <summary class="article-expander__title">Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37047167"
                        open
                      >
                        <summary class="article-expander__title">Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the &#x27;atavistic reversal&#x27;, &#x27;cancer attractor&#x27;, &#x27;somatic mutation&#x27;, &#x27;genome chaos&#x27;, and &#x27;tissue organization field&#x27; theories. The &#x27;atavistic reversal&#x27; theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called &#x27;gradual atavism&#x27;, and evidence for the &#x27;serial atavism&#x27; model. We showed the gradual core-to-periphery evolutionary growth of the human...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046647"
                        open
                      >
                        <summary class="article-expander__title">Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052539"
                        open
                      >
                        <summary class="article-expander__title">Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37047167"
                        open
                      >
                        <summary class="article-expander__title">Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the &#x27;atavistic reversal&#x27;, &#x27;cancer attractor&#x27;, &#x27;somatic mutation&#x27;, &#x27;genome chaos&#x27;, and &#x27;tissue organization field&#x27; theories. The &#x27;atavistic reversal&#x27; theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called &#x27;gradual atavism&#x27;, and evidence for the &#x27;serial atavism&#x27; model. We showed the gradual core-to-periphery evolutionary growth of the human...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046647"
                        open
                      >
                        <summary class="article-expander__title">Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052539"
                        open
                      >
                        <summary class="article-expander__title">Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37047167"
                        open
                      >
                        <summary class="article-expander__title">Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the &#x27;atavistic reversal&#x27;, &#x27;cancer attractor&#x27;, &#x27;somatic mutation&#x27;, &#x27;genome chaos&#x27;, and &#x27;tissue organization field&#x27; theories. The &#x27;atavistic reversal&#x27; theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called &#x27;gradual atavism&#x27;, and evidence for the &#x27;serial atavism&#x27; model. We showed the gradual core-to-periphery evolutionary growth of the human...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046647"
                        open
                      >
                        <summary class="article-expander__title">Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052539"
                        open
                      >
                        <summary class="article-expander__title">Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37047167"
                        open
                      >
                        <summary class="article-expander__title">Systemic Alterations of Cancer Cells and Their Boost by Polyploidization: Unicellular Attractor (UCA) Model</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37047167/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Using meta-analyses, we introduce a unicellular attractor (UCA) model integrating essential features of the &#x27;atavistic reversal&#x27;, &#x27;cancer attractor&#x27;, &#x27;somatic mutation&#x27;, &#x27;genome chaos&#x27;, and &#x27;tissue organization field&#x27; theories. The &#x27;atavistic reversal&#x27; theory is taken as a keystone. We propose a possible mechanism of this reversal, its refinement called &#x27;gradual atavism&#x27;, and evidence for the &#x27;serial atavism&#x27; model. We showed the gradual core-to-periphery evolutionary growth of the human...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046647"
                        open
                      >
                        <summary class="article-expander__title">Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37052539"
                        open
                      >
                        <summary class="article-expander__title">Progression and transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma and B-cell prolymphocytic leukemia: Report from the 2021 SH/EAHP Workshop</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37052539/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230413205530&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: The workshop highlighted complexity of progression and transformation in CLL/SLL and B-PLL, as well as diagnostic caveats accompanying heterogeneous presentations of RT and other manifestations of disease progression. Molecular genetic studies are pivotal for diagnosis and determination of clonal relationship, and to predict response to treatment and identify resistance to targeted therapy.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046647"
                        open
                      >
                        <summary class="article-expander__title">Mathematical Model of Clonal Evolution Proposes a Personalised Multi-Modal Therapy for High-Risk Neuroblastoma</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230413205530&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma is the most common extra-cranial solid tumour in children. Despite multi-modal therapy, over half of the high-risk patients will succumb. One contributing factor is the one-size-fits-all nature of multi-modal therapy. For example, during the first step (induction chemotherapy), the standard regimen (rapid COJEC) administers fixed doses of chemotherapeutic agents in eight two-week cycles. Perhaps because of differences in resistance, this standard regimen results in highly...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-12 datetime="2023-04-12T10:00:00.000Z">2023-04-12</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-12 datetime="2023-04-12T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046084"
                        open
                      >
                        <summary class="article-expander__title">Clonal haematopoiesis and risk of chronic liver disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046084/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230428205526&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Chronic liver disease is a major public health burden worldwide¹. Although different aetiologies and mechanisms of liver injury exist, progression of chronic liver disease follows a common pathway of liver inflammation, injury and fibrosis². Here we examined the association between clonal haematopoiesis of indeterminate potential (CHIP) and chronic liver disease in 214,563 individuals from 4 independent cohorts with whole-exome sequencing data (Framingham Heart Study, Atherosclerosis Risk in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046083"
                        open
                      >
                        <summary class="article-expander__title">Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046083/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230428205526&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mutations in a diverse set of driver genes increase the fitness of haematopoietic stem cells (HSCs), leading to clonal haematopoiesis¹. These lesions are precursors for blood cancers^(2-6), but the basis of their fitness advantage remains largely unknown, partly owing to a paucity of large cohorts in which the clonal expansion rate has been assessed by longitudinal sampling. Here, to circumvent this limitation, we developed a method to infer the expansion rate from data from a single time point....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045808"
                        open
                      >
                        <summary class="article-expander__title">Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230428205526&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;17
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045808"
                        open
                      >
                        <summary class="article-expander__title">Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;17
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042724"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045808"
                        open
                      >
                        <summary class="article-expander__title">Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;17
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042724"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045808"
                        open
                      >
                        <summary class="article-expander__title">Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;17
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042724"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045808"
                        open
                      >
                        <summary class="article-expander__title">Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;17
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042724"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045808"
                        open
                      >
                        <summary class="article-expander__title">Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;17
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042724"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045808"
                        open
                      >
                        <summary class="article-expander__title">Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;17
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042724"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045808"
                        open
                      >
                        <summary class="article-expander__title">Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;17
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042724"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045808"
                        open
                      >
                        <summary class="article-expander__title">Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;17
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042724"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045808"
                        open
                      >
                        <summary class="article-expander__title">Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;17
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042724"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045808"
                        open
                      >
                        <summary class="article-expander__title">Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;17
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042724"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045808"
                        open
                      >
                        <summary class="article-expander__title">Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;17
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042724"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045808"
                        open
                      >
                        <summary class="article-expander__title">Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;17
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042724"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045808"
                        open
                      >
                        <summary class="article-expander__title">Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;17
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042724"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045808"
                        open
                      >
                        <summary class="article-expander__title">Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042724"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045808"
                        open
                      >
                        <summary class="article-expander__title">Inflammatory signals from fatty bone marrow support DNMT3A driven clonal hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045808/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230413205532&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both fatty bone marrow (FBM) and somatic mutations in hematopoietic stem cells (HSCs), also termed clonal hematopoiesis (CH) accumulate with human aging. However it remains unclear whether FBM can modify the evolution of CH. To address this question, we herein present the interaction between CH and FBM in two preclinical male mouse models: after sub-lethal irradiation or after castration. An adipogenesis inhibitor (PPARγ inhibitor) is used in both models as a control. A significant increase in...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042724"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230413205532&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042724"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis in Older Patients with Breast Cancer Receiving Chemotherapy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042724/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230412205511&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our study shows that CH is common, dynamic, and of potential clinical significance in this population. Our results should stimulate larger efforts to understand the biological and clinical importance of CH in solid tumor malignancies.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046096"
                        open
                      >
                        <summary class="article-expander__title">The evolution of lung cancer and impact of subclonal selection in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;32
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046096"
                        open
                      >
                        <summary class="article-expander__title">The evolution of lung cancer and impact of subclonal selection in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;31
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046096"
                        open
                      >
                        <summary class="article-expander__title">The evolution of lung cancer and impact of subclonal selection in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;31
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046096"
                        open
                      >
                        <summary class="article-expander__title">The evolution of lung cancer and impact of subclonal selection in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;31
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046096"
                        open
                      >
                        <summary class="article-expander__title">The evolution of lung cancer and impact of subclonal selection in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;31
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046095"
                        open
                      >
                        <summary class="article-expander__title">The evolution of non-small cell lung cancer metastases in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046095/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Metastatic disease is responsible for the majority of cancer-related deaths¹. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;30
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045996"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary characterization of lung adenocarcinoma morphology in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045996/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;15
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046096"
                        open
                      >
                        <summary class="article-expander__title">The evolution of lung cancer and impact of subclonal selection in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;31
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046095"
                        open
                      >
                        <summary class="article-expander__title">The evolution of non-small cell lung cancer metastases in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046095/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Metastatic disease is responsible for the majority of cancer-related deaths¹. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;30
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045996"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary characterization of lung adenocarcinoma morphology in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045996/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;15
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042990"
                        open
                      >
                        <summary class="article-expander__title">The clonal heterogeneity of colon cancer with liver metastases</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042990/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data reveal the genetic and heterogeneity between primary and metastatic lesions, as well as among multiple metastases and provide genomic evidence for clonal heterogeneity for CCLM.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046096"
                        open
                      >
                        <summary class="article-expander__title">The evolution of lung cancer and impact of subclonal selection in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;32
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046095"
                        open
                      >
                        <summary class="article-expander__title">The evolution of non-small cell lung cancer metastases in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046095/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Metastatic disease is responsible for the majority of cancer-related deaths¹. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;29
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045996"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary characterization of lung adenocarcinoma morphology in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045996/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;16
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042990"
                        open
                      >
                        <summary class="article-expander__title">The clonal heterogeneity of colon cancer with liver metastases</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042990/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data reveal the genetic and heterogeneity between primary and metastatic lesions, as well as among multiple metastases and provide genomic evidence for clonal heterogeneity for CCLM.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046096"
                        open
                      >
                        <summary class="article-expander__title">The evolution of lung cancer and impact of subclonal selection in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;17
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046095"
                        open
                      >
                        <summary class="article-expander__title">The evolution of non-small cell lung cancer metastases in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046095/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Metastatic disease is responsible for the majority of cancer-related deaths¹. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;16
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045996"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary characterization of lung adenocarcinoma morphology in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045996/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;15
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042990"
                        open
                      >
                        <summary class="article-expander__title">The clonal heterogeneity of colon cancer with liver metastases</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042990/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data reveal the genetic and heterogeneity between primary and metastatic lesions, as well as among multiple metastases and provide genomic evidence for clonal heterogeneity for CCLM.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046096"
                        open
                      >
                        <summary class="article-expander__title">The evolution of lung cancer and impact of subclonal selection in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;17
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046095"
                        open
                      >
                        <summary class="article-expander__title">The evolution of non-small cell lung cancer metastases in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046095/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Metastatic disease is responsible for the majority of cancer-related deaths¹. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;14
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045996"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary characterization of lung adenocarcinoma morphology in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045996/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;15
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042990"
                        open
                      >
                        <summary class="article-expander__title">The clonal heterogeneity of colon cancer with liver metastases</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042990/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data reveal the genetic and heterogeneity between primary and metastatic lesions, as well as among multiple metastases and provide genomic evidence for clonal heterogeneity for CCLM.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046096"
                        open
                      >
                        <summary class="article-expander__title">The evolution of lung cancer and impact of subclonal selection in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;17
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046095"
                        open
                      >
                        <summary class="article-expander__title">The evolution of non-small cell lung cancer metastases in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046095/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Metastatic disease is responsible for the majority of cancer-related deaths¹. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;15
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045996"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary characterization of lung adenocarcinoma morphology in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045996/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;15
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042990"
                        open
                      >
                        <summary class="article-expander__title">The clonal heterogeneity of colon cancer with liver metastases</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042990/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data reveal the genetic and heterogeneity between primary and metastatic lesions, as well as among multiple metastases and provide genomic evidence for clonal heterogeneity for CCLM.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046096"
                        open
                      >
                        <summary class="article-expander__title">The evolution of lung cancer and impact of subclonal selection in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;17
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046095"
                        open
                      >
                        <summary class="article-expander__title">The evolution of non-small cell lung cancer metastases in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046095/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Metastatic disease is responsible for the majority of cancer-related deaths¹. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;16
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045996"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary characterization of lung adenocarcinoma morphology in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045996/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;15
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042990"
                        open
                      >
                        <summary class="article-expander__title">The clonal heterogeneity of colon cancer with liver metastases</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042990/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data reveal the genetic and heterogeneity between primary and metastatic lesions, as well as among multiple metastases and provide genomic evidence for clonal heterogeneity for CCLM.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046096"
                        open
                      >
                        <summary class="article-expander__title">The evolution of lung cancer and impact of subclonal selection in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;17
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046095"
                        open
                      >
                        <summary class="article-expander__title">The evolution of non-small cell lung cancer metastases in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046095/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Metastatic disease is responsible for the majority of cancer-related deaths¹. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;15
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045996"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary characterization of lung adenocarcinoma morphology in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045996/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;15
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042990"
                        open
                      >
                        <summary class="article-expander__title">The clonal heterogeneity of colon cancer with liver metastases</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042990/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data reveal the genetic and heterogeneity between primary and metastatic lesions, as well as among multiple metastases and provide genomic evidence for clonal heterogeneity for CCLM.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046096"
                        open
                      >
                        <summary class="article-expander__title">The evolution of lung cancer and impact of subclonal selection in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;17
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046095"
                        open
                      >
                        <summary class="article-expander__title">The evolution of non-small cell lung cancer metastases in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046095/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Metastatic disease is responsible for the majority of cancer-related deaths¹. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;15
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045996"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary characterization of lung adenocarcinoma morphology in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045996/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;15
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042990"
                        open
                      >
                        <summary class="article-expander__title">The clonal heterogeneity of colon cancer with liver metastases</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042990/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data reveal the genetic and heterogeneity between primary and metastatic lesions, as well as among multiple metastases and provide genomic evidence for clonal heterogeneity for CCLM.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046096"
                        open
                      >
                        <summary class="article-expander__title">The evolution of lung cancer and impact of subclonal selection in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;17
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046095"
                        open
                      >
                        <summary class="article-expander__title">The evolution of non-small cell lung cancer metastases in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046095/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Metastatic disease is responsible for the majority of cancer-related deaths¹. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;15
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045996"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary characterization of lung adenocarcinoma morphology in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045996/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;15
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042990"
                        open
                      >
                        <summary class="article-expander__title">The clonal heterogeneity of colon cancer with liver metastases</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042990/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data reveal the genetic and heterogeneity between primary and metastatic lesions, as well as among multiple metastases and provide genomic evidence for clonal heterogeneity for CCLM.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046096"
                        open
                      >
                        <summary class="article-expander__title">The evolution of lung cancer and impact of subclonal selection in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046096/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230413205530&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung cancer is the leading cause of cancer-associated mortality worldwide¹. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell lung cancer prospectively enrolled into the TRACERx study. This project aims to decipher lung cancer evolution and address the primary study endpoint: determining the relationship between intratumour heterogeneity and clinical outcome. In lung adenocarcinoma, mutations in 22 out of 40 common cancer...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;16
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37046095"
                        open
                      >
                        <summary class="article-expander__title">The evolution of non-small cell lung cancer metastases in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37046095/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230413205530&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Metastatic disease is responsible for the majority of cancer-related deaths¹. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;14
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37045996"
                        open
                      >
                        <summary class="article-expander__title">Evolutionary characterization of lung adenocarcinoma morphology in TRACERx</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37045996/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230413205530&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Lung adenocarcinomas (LUADs) display a broad histological spectrum from low-grade lepidic tumors through to mid-grade acinar and papillary and high-grade solid, cribriform and micropapillary tumors. How morphology reflects tumor evolution and disease progression is poorly understood. Whole-exome sequencing data generated from 805 primary tumor regions and 121 paired metastatic samples across 248 LUADs from the TRACERx 421 cohort, together with RNA-sequencing data from 463 primary tumor regions,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;13
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042990"
                        open
                      >
                        <summary class="article-expander__title">The clonal heterogeneity of colon cancer with liver metastases</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042990/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230413205530&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data reveal the genetic and heterogeneity between primary and metastatic lesions, as well as among multiple metastases and provide genomic evidence for clonal heterogeneity for CCLM.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37042990"
                        open
                      >
                        <summary class="article-expander__title">The clonal heterogeneity of colon cancer with liver metastases</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37042990/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230412205510&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: Our data reveal the genetic and heterogeneity between primary and metastatic lesions, as well as among multiple metastases and provide genomic evidence for clonal heterogeneity for CCLM.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-11 datetime="2023-04-11T10:00:00.000Z">2023-04-11</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-11 datetime="2023-04-11T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37039116"
                        open
                      >
                        <summary class="article-expander__title">clevRvis: visualization techniques for clonal evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37039116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: clevRvis represents a novel option for user-friendly analysis of clonal evolution, contributing to gaining new insights into tumor development.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37039116"
                        open
                      >
                        <summary class="article-expander__title">clevRvis: visualization techniques for clonal evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37039116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: clevRvis represents a novel option for user-friendly analysis of clonal evolution, contributing to gaining new insights into tumor development.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37039116"
                        open
                      >
                        <summary class="article-expander__title">clevRvis: visualization techniques for clonal evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37039116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: clevRvis represents a novel option for user-friendly analysis of clonal evolution, contributing to gaining new insights into tumor development.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37039116"
                        open
                      >
                        <summary class="article-expander__title">clevRvis: visualization techniques for clonal evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37039116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: clevRvis represents a novel option for user-friendly analysis of clonal evolution, contributing to gaining new insights into tumor development.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37039116"
                        open
                      >
                        <summary class="article-expander__title">clevRvis: visualization techniques for clonal evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37039116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: clevRvis represents a novel option for user-friendly analysis of clonal evolution, contributing to gaining new insights into tumor development.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37039116"
                        open
                      >
                        <summary class="article-expander__title">clevRvis: visualization techniques for clonal evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37039116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: clevRvis represents a novel option for user-friendly analysis of clonal evolution, contributing to gaining new insights into tumor development.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37039116"
                        open
                      >
                        <summary class="article-expander__title">clevRvis: visualization techniques for clonal evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37039116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: clevRvis represents a novel option for user-friendly analysis of clonal evolution, contributing to gaining new insights into tumor development.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37039116"
                        open
                      >
                        <summary class="article-expander__title">clevRvis: visualization techniques for clonal evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37039116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230413205530&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: clevRvis represents a novel option for user-friendly analysis of clonal evolution, contributing to gaining new insights into tumor development.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37039116"
                        open
                      >
                        <summary class="article-expander__title">clevRvis: visualization techniques for clonal evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37039116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230412205510&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: clevRvis represents a novel option for user-friendly analysis of clonal evolution, contributing to gaining new insights into tumor development.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37039116"
                        open
                      >
                        <summary class="article-expander__title">clevRvis: visualization techniques for clonal evolution</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37039116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: clevRvis represents a novel option for user-friendly analysis of clonal evolution, contributing to gaining new insights into tumor development.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-10 datetime="2023-04-10T10:00:00.000Z">2023-04-10</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-10 datetime="2023-04-10T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37090647"
                        open
                      >
                        <summary class="article-expander__title">Modeling single cell DNA replication dynamics and aneuploidy in genomically unstable cancers</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37090647/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>DNA replication is a highly coordinated cell cycle process that can become dysregulated in cancer, increasing both proliferation and mutation rates. Single-cell whole genome sequencing holds potential for studying replication dynamics of cancer cells; however, computational methods for identifying S-phase cells and inferring single-cell replication timing profiles remain immature for samples with heterogeneous copy number. Here we report a new method, PERT, which jointly infers replication and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37035178"
                        open
                      >
                        <summary class="article-expander__title">Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37035178/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hereditary cancer syndromes (HCS) account for 5~10% of all cancer diagnosis. Lynch syndrome (LS) is one of the most common HCS, caused by germline mutations in the DNA mismatch repair (MMR) genes. Even with prospective cancer surveillance, LS is associated with up to 50% lifetime risk of colorectal, endometrial, and other cancers. While significant progress has been made in the timely identification of germline pathogenic variant carriers and monitoring and early detection of precancerous...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37035178"
                        open
                      >
                        <summary class="article-expander__title">Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37035178/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hereditary cancer syndromes (HCS) account for 5~10% of all cancer diagnosis. Lynch syndrome (LS) is one of the most common HCS, caused by germline mutations in the DNA mismatch repair (MMR) genes. Even with prospective cancer surveillance, LS is associated with up to 50% lifetime risk of colorectal, endometrial, and other cancers. While significant progress has been made in the timely identification of germline pathogenic variant carriers and monitoring and early detection of precancerous...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37035178"
                        open
                      >
                        <summary class="article-expander__title">Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37035178/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hereditary cancer syndromes (HCS) account for 5~10% of all cancer diagnosis. Lynch syndrome (LS) is one of the most common HCS, caused by germline mutations in the DNA mismatch repair (MMR) genes. Even with prospective cancer surveillance, LS is associated with up to 50% lifetime risk of colorectal, endometrial, and other cancers. While significant progress has been made in the timely identification of germline pathogenic variant carriers and monitoring and early detection of precancerous...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37035178"
                        open
                      >
                        <summary class="article-expander__title">Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37035178/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hereditary cancer syndromes (HCS) account for 5~10% of all cancer diagnosis. Lynch syndrome (LS) is one of the most common HCS, caused by germline mutations in the DNA mismatch repair (MMR) genes. Even with prospective cancer surveillance, LS is associated with up to 50% lifetime risk of colorectal, endometrial, and other cancers. While significant progress has been made in the timely identification of germline pathogenic variant carriers and monitoring and early detection of precancerous...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37035178"
                        open
                      >
                        <summary class="article-expander__title">Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37035178/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hereditary cancer syndromes (HCS) account for 5~10% of all cancer diagnosis. Lynch syndrome (LS) is one of the most common HCS, caused by germline mutations in the DNA mismatch repair (MMR) genes. Even with prospective cancer surveillance, LS is associated with up to 50% lifetime risk of colorectal, endometrial, and other cancers. While significant progress has been made in the timely identification of germline pathogenic variant carriers and monitoring and early detection of precancerous...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37035178"
                        open
                      >
                        <summary class="article-expander__title">Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37035178/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hereditary cancer syndromes (HCS) account for 5~10% of all cancer diagnosis. Lynch syndrome (LS) is one of the most common HCS, caused by germline mutations in the DNA mismatch repair (MMR) genes. Even with prospective cancer surveillance, LS is associated with up to 50% lifetime risk of colorectal, endometrial, and other cancers. While significant progress has been made in the timely identification of germline pathogenic variant carriers and monitoring and early detection of precancerous...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37035178"
                        open
                      >
                        <summary class="article-expander__title">Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37035178/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230413205530&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hereditary cancer syndromes (HCS) account for 5~10% of all cancer diagnosis. Lynch syndrome (LS) is one of the most common HCS, caused by germline mutations in the DNA mismatch repair (MMR) genes. Even with prospective cancer surveillance, LS is associated with up to 50% lifetime risk of colorectal, endometrial, and other cancers. While significant progress has been made in the timely identification of germline pathogenic variant carriers and monitoring and early detection of precancerous...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37035178"
                        open
                      >
                        <summary class="article-expander__title">Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37035178/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230412205510&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hereditary cancer syndromes (HCS) account for 5~10% of all cancer diagnosis. Lynch syndrome (LS) is one of the most common HCS, caused by germline mutations in the DNA mismatch repair (MMR) genes. Even with prospective cancer surveillance, LS is associated with up to 50% lifetime risk of colorectal, endometrial, and other cancers. While significant progress has been made in the timely identification of germline pathogenic variant carriers and monitoring and early detection of precancerous...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37035178"
                        open
                      >
                        <summary class="article-expander__title">Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37035178/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hereditary cancer syndromes (HCS) account for 5~10% of all cancer diagnosis. Lynch syndrome (LS) is one of the most common HCS, caused by germline mutations in the DNA mismatch repair (MMR) genes. Even with prospective cancer surveillance, LS is associated with up to 50% lifetime risk of colorectal, endometrial, and other cancers. While significant progress has been made in the timely identification of germline pathogenic variant carriers and monitoring and early detection of precancerous...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37035178"
                        open
                      >
                        <summary class="article-expander__title">Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37035178/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hereditary cancer syndromes (HCS) account for 5~10% of all cancer diagnosis. Lynch syndrome (LS) is one of the most common HCS, caused by germline mutations in the DNA mismatch repair (MMR) genes. Even with prospective cancer surveillance, LS is associated with up to 50% lifetime risk of colorectal, endometrial, and other cancers. While significant progress has been made in the timely identification of germline pathogenic variant carriers and monitoring and early detection of precancerous...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-09 datetime="2023-04-09T10:00:00.000Z">2023-04-09</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-09 datetime="2023-04-09T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37032134"
                        open
                      >
                        <summary class="article-expander__title">A new form of familial platelet disorder caused by germline mutations in RUNX1 in a pedigree</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37032134/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Objective: To investigate the clinical and biological characteristics of familial platelet disorder (FPD) with germline Runt-related transcription factor (RUNX) 1 mutations. Methods: Patients diagnosed with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with RUNX1 mutations from February 2016 to December 2021 in Wuhan No.1 Hospital underwent pedigree analysis and were screened for gene mutations (somatic and germline). Patients diagnosed with FPD with germline RUNX1 mutations...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37032134"
                        open
                      >
                        <summary class="article-expander__title">A new form of familial platelet disorder caused by germline mutations in RUNX1 in a pedigree</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37032134/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Objective: To investigate the clinical and biological characteristics of familial platelet disorder (FPD) with germline Runt-related transcription factor (RUNX) 1 mutations. Methods: Patients diagnosed with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with RUNX1 mutations from February 2016 to December 2021 in Wuhan No.1 Hospital underwent pedigree analysis and were screened for gene mutations (somatic and germline). Patients diagnosed with FPD with germline RUNX1 mutations...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37032134"
                        open
                      >
                        <summary class="article-expander__title">A new form of familial platelet disorder caused by germline mutations in RUNX1 in a pedigree</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37032134/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Objective: To investigate the clinical and biological characteristics of familial platelet disorder (FPD) with germline Runt-related transcription factor (RUNX) 1 mutations. Methods: Patients diagnosed with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with RUNX1 mutations from February 2016 to December 2021 in Wuhan No.1 Hospital underwent pedigree analysis and were screened for gene mutations (somatic and germline). Patients diagnosed with FPD with germline RUNX1 mutations...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37032134"
                        open
                      >
                        <summary class="article-expander__title">A new form of familial platelet disorder caused by germline mutations in RUNX1 in a pedigree</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37032134/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Objective: To investigate the clinical and biological characteristics of familial platelet disorder (FPD) with germline Runt-related transcription factor (RUNX) 1 mutations. Methods: Patients diagnosed with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with RUNX1 mutations from February 2016 to December 2021 in Wuhan No.1 Hospital underwent pedigree analysis and were screened for gene mutations (somatic and germline). Patients diagnosed with FPD with germline RUNX1 mutations...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37032134"
                        open
                      >
                        <summary class="article-expander__title">A new form of familial platelet disorder caused by germline mutations in RUNX1 in a pedigree</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37032134/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Objective: To investigate the clinical and biological characteristics of familial platelet disorder (FPD) with germline Runt-related transcription factor (RUNX) 1 mutations. Methods: Patients diagnosed with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with RUNX1 mutations from February 2016 to December 2021 in Wuhan No.1 Hospital underwent pedigree analysis and were screened for gene mutations (somatic and germline). Patients diagnosed with FPD with germline RUNX1 mutations...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37032134"
                        open
                      >
                        <summary class="article-expander__title">A new form of familial platelet disorder caused by germline mutations in RUNX1 in a pedigree</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37032134/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Objective: To investigate the clinical and biological characteristics of familial platelet disorder (FPD) with germline Runt-related transcription factor (RUNX) 1 mutations. Methods: Patients diagnosed with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with RUNX1 mutations from February 2016 to December 2021 in Wuhan No.1 Hospital underwent pedigree analysis and were screened for gene mutations (somatic and germline). Patients diagnosed with FPD with germline RUNX1 mutations...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37032134"
                        open
                      >
                        <summary class="article-expander__title">A new form of familial platelet disorder caused by germline mutations in RUNX1 in a pedigree</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37032134/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230413205530&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Objective: To investigate the clinical and biological characteristics of familial platelet disorder (FPD) with germline Runt-related transcription factor (RUNX) 1 mutations. Methods: Patients diagnosed with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with RUNX1 mutations from February 2016 to December 2021 in Wuhan No.1 Hospital underwent pedigree analysis and were screened for gene mutations (somatic and germline). Patients diagnosed with FPD with germline RUNX1 mutations...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37032134"
                        open
                      >
                        <summary class="article-expander__title">A new form of familial platelet disorder caused by germline mutations in RUNX1 in a pedigree</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37032134/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230412205510&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Objective: To investigate the clinical and biological characteristics of familial platelet disorder (FPD) with germline Runt-related transcription factor (RUNX) 1 mutations. Methods: Patients diagnosed with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with RUNX1 mutations from February 2016 to December 2021 in Wuhan No.1 Hospital underwent pedigree analysis and were screened for gene mutations (somatic and germline). Patients diagnosed with FPD with germline RUNX1 mutations...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37032134"
                        open
                      >
                        <summary class="article-expander__title">A new form of familial platelet disorder caused by germline mutations in RUNX1 in a pedigree</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37032134/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Objective: To investigate the clinical and biological characteristics of familial platelet disorder (FPD) with germline Runt-related transcription factor (RUNX) 1 mutations. Methods: Patients diagnosed with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with RUNX1 mutations from February 2016 to December 2021 in Wuhan No.1 Hospital underwent pedigree analysis and were screened for gene mutations (somatic and germline). Patients diagnosed with FPD with germline RUNX1 mutations...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37032134"
                        open
                      >
                        <summary class="article-expander__title">A new form of familial platelet disorder caused by germline mutations in RUNX1 in a pedigree</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37032134/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Objective: To investigate the clinical and biological characteristics of familial platelet disorder (FPD) with germline Runt-related transcription factor (RUNX) 1 mutations. Methods: Patients diagnosed with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with RUNX1 mutations from February 2016 to December 2021 in Wuhan No.1 Hospital underwent pedigree analysis and were screened for gene mutations (somatic and germline). Patients diagnosed with FPD with germline RUNX1 mutations...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-08 datetime="2023-04-08T10:00:00.000Z">2023-04-08</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-08 datetime="2023-04-08T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37031307"
                        open
                      >
                        <summary class="article-expander__title">High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37031307/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Aberrant DNA methylation at CpG dinucleotides is a cancer hallmark that is associated with the emergence of resistance to anti cancer treatment, though molecular mechanisms and biological significance remain elusive. Genome scale methylation maps by currently used methods are based on chemical modification of DNA and are best suited for analyses of methylation at CpG rich regions (CpG islands). We report the first high coverage whole-genome map in cancer using the long read nanopore technology,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37031307"
                        open
                      >
                        <summary class="article-expander__title">High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37031307/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Aberrant DNA methylation at CpG dinucleotides is a cancer hallmark that is associated with the emergence of resistance to anti cancer treatment, though molecular mechanisms and biological significance remain elusive. Genome scale methylation maps by currently used methods are based on chemical modification of DNA and are best suited for analyses of methylation at CpG rich regions (CpG islands). We report the first high coverage whole-genome map in cancer using the long read nanopore technology,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37031307"
                        open
                      >
                        <summary class="article-expander__title">High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37031307/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Aberrant DNA methylation at CpG dinucleotides is a cancer hallmark that is associated with the emergence of resistance to anti cancer treatment, though molecular mechanisms and biological significance remain elusive. Genome scale methylation maps by currently used methods are based on chemical modification of DNA and are best suited for analyses of methylation at CpG rich regions (CpG islands). We report the first high coverage whole-genome map in cancer using the long read nanopore technology,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37031307"
                        open
                      >
                        <summary class="article-expander__title">High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37031307/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Aberrant DNA methylation at CpG dinucleotides is a cancer hallmark that is associated with the emergence of resistance to anti cancer treatment, though molecular mechanisms and biological significance remain elusive. Genome scale methylation maps by currently used methods are based on chemical modification of DNA and are best suited for analyses of methylation at CpG rich regions (CpG islands). We report the first high coverage whole-genome map in cancer using the long read nanopore technology,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37031307"
                        open
                      >
                        <summary class="article-expander__title">High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37031307/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Aberrant DNA methylation at CpG dinucleotides is a cancer hallmark that is associated with the emergence of resistance to anti cancer treatment, though molecular mechanisms and biological significance remain elusive. Genome scale methylation maps by currently used methods are based on chemical modification of DNA and are best suited for analyses of methylation at CpG rich regions (CpG islands). We report the first high coverage whole-genome map in cancer using the long read nanopore technology,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37031307"
                        open
                      >
                        <summary class="article-expander__title">High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37031307/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230413205530&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Aberrant DNA methylation at CpG dinucleotides is a cancer hallmark that is associated with the emergence of resistance to anti cancer treatment, though molecular mechanisms and biological significance remain elusive. Genome scale methylation maps by currently used methods are based on chemical modification of DNA and are best suited for analyses of methylation at CpG rich regions (CpG islands). We report the first high coverage whole-genome map in cancer using the long read nanopore technology,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37031307"
                        open
                      >
                        <summary class="article-expander__title">High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37031307/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230412205510&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Aberrant DNA methylation at CpG dinucleotides is a cancer hallmark that is associated with the emergence of resistance to anti cancer treatment, though molecular mechanisms and biological significance remain elusive. Genome scale methylation maps by currently used methods are based on chemical modification of DNA and are best suited for analyses of methylation at CpG rich regions (CpG islands). We report the first high coverage whole-genome map in cancer using the long read nanopore technology,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37031307"
                        open
                      >
                        <summary class="article-expander__title">High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37031307/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Aberrant DNA methylation at CpG dinucleotides is a cancer hallmark that is associated with the emergence of resistance to anti cancer treatment, though molecular mechanisms and biological significance remain elusive. Genome scale methylation maps by currently used methods are based on chemical modification of DNA and are best suited for analyses of methylation at CpG rich regions (CpG islands). We report the first high coverage whole-genome map in cancer using the long read nanopore technology,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-07 datetime="2023-04-07T10:00:00.000Z">2023-04-07</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-07 datetime="2023-04-07T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37026511"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37026511/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia, are a group of clonal hematopoietic stem cell (HSC) diseases. The incidence increases with global population aging. Genome sequencing uncovered mutational profiles in patients with myeloid malignancies and healthy elderly individuals. However, the molecular and cellular basis of disease development remains unclear. Accumulating evidence shows mitochondrial involvement in the pathogenesis of myeloid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37025252"
                        open
                      >
                        <summary class="article-expander__title">A review of research on the intersection between breast cancer and cardiovascular research in the Women&#x27;s Health Initiative (WHI)</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37025252/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both obesity and metabolic syndrome are linked to increased incidence of type 2 diabetes, cardiovascular disease (CVD), and cancers of the breast (post-menopausal), and other obesity-related cancers. Over the past 50 years, the worldwide prevalence of obesity and metabolic syndrome has increased, with a concomitant higher incidence of associated co-morbidities and mortality. The precise mechanism linking metabolic syndrome to increased cancer incidence is incompletely understood, however,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37026511"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37026511/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia, are a group of clonal hematopoietic stem cell (HSC) diseases. The incidence increases with global population aging. Genome sequencing uncovered mutational profiles in patients with myeloid malignancies and healthy elderly individuals. However, the molecular and cellular basis of disease development remains unclear. Accumulating evidence shows mitochondrial involvement in the pathogenesis of myeloid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37025252"
                        open
                      >
                        <summary class="article-expander__title">A review of research on the intersection between breast cancer and cardiovascular research in the Women&#x27;s Health Initiative (WHI)</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37025252/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both obesity and metabolic syndrome are linked to increased incidence of type 2 diabetes, cardiovascular disease (CVD), and cancers of the breast (post-menopausal), and other obesity-related cancers. Over the past 50 years, the worldwide prevalence of obesity and metabolic syndrome has increased, with a concomitant higher incidence of associated co-morbidities and mortality. The precise mechanism linking metabolic syndrome to increased cancer incidence is incompletely understood, however,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37026511"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37026511/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia, are a group of clonal hematopoietic stem cell (HSC) diseases. The incidence increases with global population aging. Genome sequencing uncovered mutational profiles in patients with myeloid malignancies and healthy elderly individuals. However, the molecular and cellular basis of disease development remains unclear. Accumulating evidence shows mitochondrial involvement in the pathogenesis of myeloid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37025252"
                        open
                      >
                        <summary class="article-expander__title">A review of research on the intersection between breast cancer and cardiovascular research in the Women&#x27;s Health Initiative (WHI)</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37025252/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both obesity and metabolic syndrome are linked to increased incidence of type 2 diabetes, cardiovascular disease (CVD), and cancers of the breast (post-menopausal), and other obesity-related cancers. Over the past 50 years, the worldwide prevalence of obesity and metabolic syndrome has increased, with a concomitant higher incidence of associated co-morbidities and mortality. The precise mechanism linking metabolic syndrome to increased cancer incidence is incompletely understood, however,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37026511"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37026511/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia, are a group of clonal hematopoietic stem cell (HSC) diseases. The incidence increases with global population aging. Genome sequencing uncovered mutational profiles in patients with myeloid malignancies and healthy elderly individuals. However, the molecular and cellular basis of disease development remains unclear. Accumulating evidence shows mitochondrial involvement in the pathogenesis of myeloid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37025252"
                        open
                      >
                        <summary class="article-expander__title">A review of research on the intersection between breast cancer and cardiovascular research in the Women&#x27;s Health Initiative (WHI)</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37025252/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both obesity and metabolic syndrome are linked to increased incidence of type 2 diabetes, cardiovascular disease (CVD), and cancers of the breast (post-menopausal), and other obesity-related cancers. Over the past 50 years, the worldwide prevalence of obesity and metabolic syndrome has increased, with a concomitant higher incidence of associated co-morbidities and mortality. The precise mechanism linking metabolic syndrome to increased cancer incidence is incompletely understood, however,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37026511"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37026511/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia, are a group of clonal hematopoietic stem cell (HSC) diseases. The incidence increases with global population aging. Genome sequencing uncovered mutational profiles in patients with myeloid malignancies and healthy elderly individuals. However, the molecular and cellular basis of disease development remains unclear. Accumulating evidence shows mitochondrial involvement in the pathogenesis of myeloid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37025252"
                        open
                      >
                        <summary class="article-expander__title">A review of research on the intersection between breast cancer and cardiovascular research in the Women&#x27;s Health Initiative (WHI)</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37025252/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both obesity and metabolic syndrome are linked to increased incidence of type 2 diabetes, cardiovascular disease (CVD), and cancers of the breast (post-menopausal), and other obesity-related cancers. Over the past 50 years, the worldwide prevalence of obesity and metabolic syndrome has increased, with a concomitant higher incidence of associated co-morbidities and mortality. The precise mechanism linking metabolic syndrome to increased cancer incidence is incompletely understood, however,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37026511"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37026511/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia, are a group of clonal hematopoietic stem cell (HSC) diseases. The incidence increases with global population aging. Genome sequencing uncovered mutational profiles in patients with myeloid malignancies and healthy elderly individuals. However, the molecular and cellular basis of disease development remains unclear. Accumulating evidence shows mitochondrial involvement in the pathogenesis of myeloid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37025252"
                        open
                      >
                        <summary class="article-expander__title">A review of research on the intersection between breast cancer and cardiovascular research in the Women&#x27;s Health Initiative (WHI)</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37025252/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both obesity and metabolic syndrome are linked to increased incidence of type 2 diabetes, cardiovascular disease (CVD), and cancers of the breast (post-menopausal), and other obesity-related cancers. Over the past 50 years, the worldwide prevalence of obesity and metabolic syndrome has increased, with a concomitant higher incidence of associated co-morbidities and mortality. The precise mechanism linking metabolic syndrome to increased cancer incidence is incompletely understood, however,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37026511"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37026511/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia, are a group of clonal hematopoietic stem cell (HSC) diseases. The incidence increases with global population aging. Genome sequencing uncovered mutational profiles in patients with myeloid malignancies and healthy elderly individuals. However, the molecular and cellular basis of disease development remains unclear. Accumulating evidence shows mitochondrial involvement in the pathogenesis of myeloid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37025252"
                        open
                      >
                        <summary class="article-expander__title">A review of research on the intersection between breast cancer and cardiovascular research in the Women&#x27;s Health Initiative (WHI)</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37025252/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both obesity and metabolic syndrome are linked to increased incidence of type 2 diabetes, cardiovascular disease (CVD), and cancers of the breast (post-menopausal), and other obesity-related cancers. Over the past 50 years, the worldwide prevalence of obesity and metabolic syndrome has increased, with a concomitant higher incidence of associated co-morbidities and mortality. The precise mechanism linking metabolic syndrome to increased cancer incidence is incompletely understood, however,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37026511"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37026511/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia, are a group of clonal hematopoietic stem cell (HSC) diseases. The incidence increases with global population aging. Genome sequencing uncovered mutational profiles in patients with myeloid malignancies and healthy elderly individuals. However, the molecular and cellular basis of disease development remains unclear. Accumulating evidence shows mitochondrial involvement in the pathogenesis of myeloid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37025252"
                        open
                      >
                        <summary class="article-expander__title">A review of research on the intersection between breast cancer and cardiovascular research in the Women&#x27;s Health Initiative (WHI)</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37025252/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both obesity and metabolic syndrome are linked to increased incidence of type 2 diabetes, cardiovascular disease (CVD), and cancers of the breast (post-menopausal), and other obesity-related cancers. Over the past 50 years, the worldwide prevalence of obesity and metabolic syndrome has increased, with a concomitant higher incidence of associated co-morbidities and mortality. The precise mechanism linking metabolic syndrome to increased cancer incidence is incompletely understood, however,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37026511"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37026511/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia, are a group of clonal hematopoietic stem cell (HSC) diseases. The incidence increases with global population aging. Genome sequencing uncovered mutational profiles in patients with myeloid malignancies and healthy elderly individuals. However, the molecular and cellular basis of disease development remains unclear. Accumulating evidence shows mitochondrial involvement in the pathogenesis of myeloid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37025252"
                        open
                      >
                        <summary class="article-expander__title">A review of research on the intersection between breast cancer and cardiovascular research in the Women&#x27;s Health Initiative (WHI)</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37025252/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both obesity and metabolic syndrome are linked to increased incidence of type 2 diabetes, cardiovascular disease (CVD), and cancers of the breast (post-menopausal), and other obesity-related cancers. Over the past 50 years, the worldwide prevalence of obesity and metabolic syndrome has increased, with a concomitant higher incidence of associated co-morbidities and mortality. The precise mechanism linking metabolic syndrome to increased cancer incidence is incompletely understood, however,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37026511"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37026511/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia, are a group of clonal hematopoietic stem cell (HSC) diseases. The incidence increases with global population aging. Genome sequencing uncovered mutational profiles in patients with myeloid malignancies and healthy elderly individuals. However, the molecular and cellular basis of disease development remains unclear. Accumulating evidence shows mitochondrial involvement in the pathogenesis of myeloid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37025252"
                        open
                      >
                        <summary class="article-expander__title">A review of research on the intersection between breast cancer and cardiovascular research in the Women&#x27;s Health Initiative (WHI)</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37025252/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both obesity and metabolic syndrome are linked to increased incidence of type 2 diabetes, cardiovascular disease (CVD), and cancers of the breast (post-menopausal), and other obesity-related cancers. Over the past 50 years, the worldwide prevalence of obesity and metabolic syndrome has increased, with a concomitant higher incidence of associated co-morbidities and mortality. The precise mechanism linking metabolic syndrome to increased cancer incidence is incompletely understood, however,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37026511"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37026511/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia, are a group of clonal hematopoietic stem cell (HSC) diseases. The incidence increases with global population aging. Genome sequencing uncovered mutational profiles in patients with myeloid malignancies and healthy elderly individuals. However, the molecular and cellular basis of disease development remains unclear. Accumulating evidence shows mitochondrial involvement in the pathogenesis of myeloid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37025252"
                        open
                      >
                        <summary class="article-expander__title">A review of research on the intersection between breast cancer and cardiovascular research in the Women&#x27;s Health Initiative (WHI)</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37025252/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both obesity and metabolic syndrome are linked to increased incidence of type 2 diabetes, cardiovascular disease (CVD), and cancers of the breast (post-menopausal), and other obesity-related cancers. Over the past 50 years, the worldwide prevalence of obesity and metabolic syndrome has increased, with a concomitant higher incidence of associated co-morbidities and mortality. The precise mechanism linking metabolic syndrome to increased cancer incidence is incompletely understood, however,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37026511"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37026511/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia, are a group of clonal hematopoietic stem cell (HSC) diseases. The incidence increases with global population aging. Genome sequencing uncovered mutational profiles in patients with myeloid malignancies and healthy elderly individuals. However, the molecular and cellular basis of disease development remains unclear. Accumulating evidence shows mitochondrial involvement in the pathogenesis of myeloid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37025252"
                        open
                      >
                        <summary class="article-expander__title">A review of research on the intersection between breast cancer and cardiovascular research in the Women&#x27;s Health Initiative (WHI)</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37025252/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both obesity and metabolic syndrome are linked to increased incidence of type 2 diabetes, cardiovascular disease (CVD), and cancers of the breast (post-menopausal), and other obesity-related cancers. Over the past 50 years, the worldwide prevalence of obesity and metabolic syndrome has increased, with a concomitant higher incidence of associated co-morbidities and mortality. The precise mechanism linking metabolic syndrome to increased cancer incidence is incompletely understood, however,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37026511"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37026511/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia, are a group of clonal hematopoietic stem cell (HSC) diseases. The incidence increases with global population aging. Genome sequencing uncovered mutational profiles in patients with myeloid malignancies and healthy elderly individuals. However, the molecular and cellular basis of disease development remains unclear. Accumulating evidence shows mitochondrial involvement in the pathogenesis of myeloid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37025252"
                        open
                      >
                        <summary class="article-expander__title">A review of research on the intersection between breast cancer and cardiovascular research in the Women&#x27;s Health Initiative (WHI)</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37025252/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both obesity and metabolic syndrome are linked to increased incidence of type 2 diabetes, cardiovascular disease (CVD), and cancers of the breast (post-menopausal), and other obesity-related cancers. Over the past 50 years, the worldwide prevalence of obesity and metabolic syndrome has increased, with a concomitant higher incidence of associated co-morbidities and mortality. The precise mechanism linking metabolic syndrome to increased cancer incidence is incompletely understood, however,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37026511"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37026511/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia, are a group of clonal hematopoietic stem cell (HSC) diseases. The incidence increases with global population aging. Genome sequencing uncovered mutational profiles in patients with myeloid malignancies and healthy elderly individuals. However, the molecular and cellular basis of disease development remains unclear. Accumulating evidence shows mitochondrial involvement in the pathogenesis of myeloid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37025252"
                        open
                      >
                        <summary class="article-expander__title">A review of research on the intersection between breast cancer and cardiovascular research in the Women&#x27;s Health Initiative (WHI)</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37025252/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both obesity and metabolic syndrome are linked to increased incidence of type 2 diabetes, cardiovascular disease (CVD), and cancers of the breast (post-menopausal), and other obesity-related cancers. Over the past 50 years, the worldwide prevalence of obesity and metabolic syndrome has increased, with a concomitant higher incidence of associated co-morbidities and mortality. The precise mechanism linking metabolic syndrome to increased cancer incidence is incompletely understood, however,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37026511"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37026511/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230413205532&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia, are a group of clonal hematopoietic stem cell (HSC) diseases. The incidence increases with global population aging. Genome sequencing uncovered mutational profiles in patients with myeloid malignancies and healthy elderly individuals. However, the molecular and cellular basis of disease development remains unclear. Accumulating evidence shows mitochondrial involvement in the pathogenesis of myeloid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37025252"
                        open
                      >
                        <summary class="article-expander__title">A review of research on the intersection between breast cancer and cardiovascular research in the Women&#x27;s Health Initiative (WHI)</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37025252/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230413205532&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both obesity and metabolic syndrome are linked to increased incidence of type 2 diabetes, cardiovascular disease (CVD), and cancers of the breast (post-menopausal), and other obesity-related cancers. Over the past 50 years, the worldwide prevalence of obesity and metabolic syndrome has increased, with a concomitant higher incidence of associated co-morbidities and mortality. The precise mechanism linking metabolic syndrome to increased cancer incidence is incompletely understood, however,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37026511"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37026511/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230412205511&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia, are a group of clonal hematopoietic stem cell (HSC) diseases. The incidence increases with global population aging. Genome sequencing uncovered mutational profiles in patients with myeloid malignancies and healthy elderly individuals. However, the molecular and cellular basis of disease development remains unclear. Accumulating evidence shows mitochondrial involvement in the pathogenesis of myeloid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37025252"
                        open
                      >
                        <summary class="article-expander__title">A review of research on the intersection between breast cancer and cardiovascular research in the Women&#x27;s Health Initiative (WHI)</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37025252/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230412205511&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both obesity and metabolic syndrome are linked to increased incidence of type 2 diabetes, cardiovascular disease (CVD), and cancers of the breast (post-menopausal), and other obesity-related cancers. Over the past 50 years, the worldwide prevalence of obesity and metabolic syndrome has increased, with a concomitant higher incidence of associated co-morbidities and mortality. The precise mechanism linking metabolic syndrome to increased cancer incidence is incompletely understood, however,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37026511"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37026511/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia, are a group of clonal hematopoietic stem cell (HSC) diseases. The incidence increases with global population aging. Genome sequencing uncovered mutational profiles in patients with myeloid malignancies and healthy elderly individuals. However, the molecular and cellular basis of disease development remains unclear. Accumulating evidence shows mitochondrial involvement in the pathogenesis of myeloid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37025252"
                        open
                      >
                        <summary class="article-expander__title">A review of research on the intersection between breast cancer and cardiovascular research in the Women&#x27;s Health Initiative (WHI)</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37025252/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both obesity and metabolic syndrome are linked to increased incidence of type 2 diabetes, cardiovascular disease (CVD), and cancers of the breast (post-menopausal), and other obesity-related cancers. Over the past 50 years, the worldwide prevalence of obesity and metabolic syndrome has increased, with a concomitant higher incidence of associated co-morbidities and mortality. The precise mechanism linking metabolic syndrome to increased cancer incidence is incompletely understood, however,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37026511"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37026511/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia, are a group of clonal hematopoietic stem cell (HSC) diseases. The incidence increases with global population aging. Genome sequencing uncovered mutational profiles in patients with myeloid malignancies and healthy elderly individuals. However, the molecular and cellular basis of disease development remains unclear. Accumulating evidence shows mitochondrial involvement in the pathogenesis of myeloid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37025252"
                        open
                      >
                        <summary class="article-expander__title">A review of research on the intersection between breast cancer and cardiovascular research in the Women&#x27;s Health Initiative (WHI)</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37025252/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both obesity and metabolic syndrome are linked to increased incidence of type 2 diabetes, cardiovascular disease (CVD), and cancers of the breast (post-menopausal), and other obesity-related cancers. Over the past 50 years, the worldwide prevalence of obesity and metabolic syndrome has increased, with a concomitant higher incidence of associated co-morbidities and mortality. The precise mechanism linking metabolic syndrome to increased cancer incidence is incompletely understood, however,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37026511"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37026511/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia, are a group of clonal hematopoietic stem cell (HSC) diseases. The incidence increases with global population aging. Genome sequencing uncovered mutational profiles in patients with myeloid malignancies and healthy elderly individuals. However, the molecular and cellular basis of disease development remains unclear. Accumulating evidence shows mitochondrial involvement in the pathogenesis of myeloid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37025252"
                        open
                      >
                        <summary class="article-expander__title">A review of research on the intersection between breast cancer and cardiovascular research in the Women&#x27;s Health Initiative (WHI)</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37025252/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both obesity and metabolic syndrome are linked to increased incidence of type 2 diabetes, cardiovascular disease (CVD), and cancers of the breast (post-menopausal), and other obesity-related cancers. Over the past 50 years, the worldwide prevalence of obesity and metabolic syndrome has increased, with a concomitant higher incidence of associated co-morbidities and mortality. The precise mechanism linking metabolic syndrome to increased cancer incidence is incompletely understood, however,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37026511"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37026511/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia, are a group of clonal hematopoietic stem cell (HSC) diseases. The incidence increases with global population aging. Genome sequencing uncovered mutational profiles in patients with myeloid malignancies and healthy elderly individuals. However, the molecular and cellular basis of disease development remains unclear. Accumulating evidence shows mitochondrial involvement in the pathogenesis of myeloid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37025252"
                        open
                      >
                        <summary class="article-expander__title">A review of research on the intersection between breast cancer and cardiovascular research in the Women&#x27;s Health Initiative (WHI)</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37025252/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both obesity and metabolic syndrome are linked to increased incidence of type 2 diabetes, cardiovascular disease (CVD), and cancers of the breast (post-menopausal), and other obesity-related cancers. Over the past 50 years, the worldwide prevalence of obesity and metabolic syndrome has increased, with a concomitant higher incidence of associated co-morbidities and mortality. The precise mechanism linking metabolic syndrome to increased cancer incidence is incompletely understood, however,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37026511"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial dynamics as a pathobiological mediator of clonal myeloid disorders</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37026511/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloid malignancies, including myelodysplastic syndromes and acute myeloid leukemia, are a group of clonal hematopoietic stem cell (HSC) diseases. The incidence increases with global population aging. Genome sequencing uncovered mutational profiles in patients with myeloid malignancies and healthy elderly individuals. However, the molecular and cellular basis of disease development remains unclear. Accumulating evidence shows mitochondrial involvement in the pathogenesis of myeloid...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37025252"
                        open
                      >
                        <summary class="article-expander__title">A review of research on the intersection between breast cancer and cardiovascular research in the Women&#x27;s Health Initiative (WHI)</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37025252/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Both obesity and metabolic syndrome are linked to increased incidence of type 2 diabetes, cardiovascular disease (CVD), and cancers of the breast (post-menopausal), and other obesity-related cancers. Over the past 50 years, the worldwide prevalence of obesity and metabolic syndrome has increased, with a concomitant higher incidence of associated co-morbidities and mortality. The precise mechanism linking metabolic syndrome to increased cancer incidence is incompletely understood, however,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-06 datetime="2023-04-06T10:00:00.000Z">2023-04-06</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-06 datetime="2023-04-06T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37024061"
                        open
                      >
                        <summary class="article-expander__title">The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37024061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230427205816&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid hematopoietic cells, which is characterized by the aberrant clonal proliferation of immature myeloblasts and compromised hematopoiesis. The leukemic cell population is strongly heterogeneous. Leukemic stem cells (LSCs) are an important leukemic cell subset with stemness characteristics and self-renewal ability, which contribute to the development of refractory or relapsed AML. It is now acknowledged that LSCs develop from...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37024061"
                        open
                      >
                        <summary class="article-expander__title">The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37024061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid hematopoietic cells, which is characterized by the aberrant clonal proliferation of immature myeloblasts and compromised hematopoiesis. The leukemic cell population is strongly heterogeneous. Leukemic stem cells (LSCs) are an important leukemic cell subset with stemness characteristics and self-renewal ability, which contribute to the development of refractory or relapsed AML. It is now acknowledged that LSCs develop from...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37024061"
                        open
                      >
                        <summary class="article-expander__title">The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37024061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid hematopoietic cells, which is characterized by the aberrant clonal proliferation of immature myeloblasts and compromised hematopoiesis. The leukemic cell population is strongly heterogeneous. Leukemic stem cells (LSCs) are an important leukemic cell subset with stemness characteristics and self-renewal ability, which contribute to the development of refractory or relapsed AML. It is now acknowledged that LSCs develop from...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37024061"
                        open
                      >
                        <summary class="article-expander__title">The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37024061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid hematopoietic cells, which is characterized by the aberrant clonal proliferation of immature myeloblasts and compromised hematopoiesis. The leukemic cell population is strongly heterogeneous. Leukemic stem cells (LSCs) are an important leukemic cell subset with stemness characteristics and self-renewal ability, which contribute to the development of refractory or relapsed AML. It is now acknowledged that LSCs develop from...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37024061"
                        open
                      >
                        <summary class="article-expander__title">The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37024061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid hematopoietic cells, which is characterized by the aberrant clonal proliferation of immature myeloblasts and compromised hematopoiesis. The leukemic cell population is strongly heterogeneous. Leukemic stem cells (LSCs) are an important leukemic cell subset with stemness characteristics and self-renewal ability, which contribute to the development of refractory or relapsed AML. It is now acknowledged that LSCs develop from...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37024061"
                        open
                      >
                        <summary class="article-expander__title">The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37024061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid hematopoietic cells, which is characterized by the aberrant clonal proliferation of immature myeloblasts and compromised hematopoiesis. The leukemic cell population is strongly heterogeneous. Leukemic stem cells (LSCs) are an important leukemic cell subset with stemness characteristics and self-renewal ability, which contribute to the development of refractory or relapsed AML. It is now acknowledged that LSCs develop from...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37024061"
                        open
                      >
                        <summary class="article-expander__title">The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37024061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid hematopoietic cells, which is characterized by the aberrant clonal proliferation of immature myeloblasts and compromised hematopoiesis. The leukemic cell population is strongly heterogeneous. Leukemic stem cells (LSCs) are an important leukemic cell subset with stemness characteristics and self-renewal ability, which contribute to the development of refractory or relapsed AML. It is now acknowledged that LSCs develop from...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37024061"
                        open
                      >
                        <summary class="article-expander__title">The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37024061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid hematopoietic cells, which is characterized by the aberrant clonal proliferation of immature myeloblasts and compromised hematopoiesis. The leukemic cell population is strongly heterogeneous. Leukemic stem cells (LSCs) are an important leukemic cell subset with stemness characteristics and self-renewal ability, which contribute to the development of refractory or relapsed AML. It is now acknowledged that LSCs develop from...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37024061"
                        open
                      >
                        <summary class="article-expander__title">The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37024061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid hematopoietic cells, which is characterized by the aberrant clonal proliferation of immature myeloblasts and compromised hematopoiesis. The leukemic cell population is strongly heterogeneous. Leukemic stem cells (LSCs) are an important leukemic cell subset with stemness characteristics and self-renewal ability, which contribute to the development of refractory or relapsed AML. It is now acknowledged that LSCs develop from...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37024061"
                        open
                      >
                        <summary class="article-expander__title">The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37024061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid hematopoietic cells, which is characterized by the aberrant clonal proliferation of immature myeloblasts and compromised hematopoiesis. The leukemic cell population is strongly heterogeneous. Leukemic stem cells (LSCs) are an important leukemic cell subset with stemness characteristics and self-renewal ability, which contribute to the development of refractory or relapsed AML. It is now acknowledged that LSCs develop from...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37024061"
                        open
                      >
                        <summary class="article-expander__title">The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37024061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid hematopoietic cells, which is characterized by the aberrant clonal proliferation of immature myeloblasts and compromised hematopoiesis. The leukemic cell population is strongly heterogeneous. Leukemic stem cells (LSCs) are an important leukemic cell subset with stemness characteristics and self-renewal ability, which contribute to the development of refractory or relapsed AML. It is now acknowledged that LSCs develop from...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37024061"
                        open
                      >
                        <summary class="article-expander__title">The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37024061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid hematopoietic cells, which is characterized by the aberrant clonal proliferation of immature myeloblasts and compromised hematopoiesis. The leukemic cell population is strongly heterogeneous. Leukemic stem cells (LSCs) are an important leukemic cell subset with stemness characteristics and self-renewal ability, which contribute to the development of refractory or relapsed AML. It is now acknowledged that LSCs develop from...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37024061"
                        open
                      >
                        <summary class="article-expander__title">The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37024061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid hematopoietic cells, which is characterized by the aberrant clonal proliferation of immature myeloblasts and compromised hematopoiesis. The leukemic cell population is strongly heterogeneous. Leukemic stem cells (LSCs) are an important leukemic cell subset with stemness characteristics and self-renewal ability, which contribute to the development of refractory or relapsed AML. It is now acknowledged that LSCs develop from...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37024061"
                        open
                      >
                        <summary class="article-expander__title">The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37024061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid hematopoietic cells, which is characterized by the aberrant clonal proliferation of immature myeloblasts and compromised hematopoiesis. The leukemic cell population is strongly heterogeneous. Leukemic stem cells (LSCs) are an important leukemic cell subset with stemness characteristics and self-renewal ability, which contribute to the development of refractory or relapsed AML. It is now acknowledged that LSCs develop from...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37024061"
                        open
                      >
                        <summary class="article-expander__title">The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37024061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230413205532&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid hematopoietic cells, which is characterized by the aberrant clonal proliferation of immature myeloblasts and compromised hematopoiesis. The leukemic cell population is strongly heterogeneous. Leukemic stem cells (LSCs) are an important leukemic cell subset with stemness characteristics and self-renewal ability, which contribute to the development of refractory or relapsed AML. It is now acknowledged that LSCs develop from...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37024061"
                        open
                      >
                        <summary class="article-expander__title">The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37024061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230412205511&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid hematopoietic cells, which is characterized by the aberrant clonal proliferation of immature myeloblasts and compromised hematopoiesis. The leukemic cell population is strongly heterogeneous. Leukemic stem cells (LSCs) are an important leukemic cell subset with stemness characteristics and self-renewal ability, which contribute to the development of refractory or relapsed AML. It is now acknowledged that LSCs develop from...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37024061"
                        open
                      >
                        <summary class="article-expander__title">The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37024061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid hematopoietic cells, which is characterized by the aberrant clonal proliferation of immature myeloblasts and compromised hematopoiesis. The leukemic cell population is strongly heterogeneous. Leukemic stem cells (LSCs) are an important leukemic cell subset with stemness characteristics and self-renewal ability, which contribute to the development of refractory or relapsed AML. It is now acknowledged that LSCs develop from...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37024061"
                        open
                      >
                        <summary class="article-expander__title">The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37024061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid hematopoietic cells, which is characterized by the aberrant clonal proliferation of immature myeloblasts and compromised hematopoiesis. The leukemic cell population is strongly heterogeneous. Leukemic stem cells (LSCs) are an important leukemic cell subset with stemness characteristics and self-renewal ability, which contribute to the development of refractory or relapsed AML. It is now acknowledged that LSCs develop from...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37024061"
                        open
                      >
                        <summary class="article-expander__title">The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37024061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid hematopoietic cells, which is characterized by the aberrant clonal proliferation of immature myeloblasts and compromised hematopoiesis. The leukemic cell population is strongly heterogeneous. Leukemic stem cells (LSCs) are an important leukemic cell subset with stemness characteristics and self-renewal ability, which contribute to the development of refractory or relapsed AML. It is now acknowledged that LSCs develop from...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37024061"
                        open
                      >
                        <summary class="article-expander__title">The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37024061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid hematopoietic cells, which is characterized by the aberrant clonal proliferation of immature myeloblasts and compromised hematopoiesis. The leukemic cell population is strongly heterogeneous. Leukemic stem cells (LSCs) are an important leukemic cell subset with stemness characteristics and self-renewal ability, which contribute to the development of refractory or relapsed AML. It is now acknowledged that LSCs develop from...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37024061"
                        open
                      >
                        <summary class="article-expander__title">The role of exosomes in the stemness maintenance and progression of acute myeloid leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37024061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is an aggressive malignancy of myeloid hematopoietic cells, which is characterized by the aberrant clonal proliferation of immature myeloblasts and compromised hematopoiesis. The leukemic cell population is strongly heterogeneous. Leukemic stem cells (LSCs) are an important leukemic cell subset with stemness characteristics and self-renewal ability, which contribute to the development of refractory or relapsed AML. It is now acknowledged that LSCs develop from...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37023969"
                        open
                      >
                        <summary class="article-expander__title">Clonal interactions in cancer: Integrating quantitative models with experimental and clinical data</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37023969/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tumors consist of different genotypically distinct subpopulations-or subclones-of cells. These subclones can influence neighboring clones in a process called &quot;clonal interaction.&quot; Conventionally, research on driver mutations in cancer has focused on their cell-autonomous effects that lead to an increase in fitness of the cells containing the driver. Recently, with the advent of improved experimental and computational technologies for investigating tumor heterogeneity and clonal dynamics, new...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37023969"
                        open
                      >
                        <summary class="article-expander__title">Clonal interactions in cancer: Integrating quantitative models with experimental and clinical data</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37023969/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tumors consist of different genotypically distinct subpopulations-or subclones-of cells. These subclones can influence neighboring clones in a process called &quot;clonal interaction.&quot; Conventionally, research on driver mutations in cancer has focused on their cell-autonomous effects that lead to an increase in fitness of the cells containing the driver. Recently, with the advent of improved experimental and computational technologies for investigating tumor heterogeneity and clonal dynamics, new...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37023969"
                        open
                      >
                        <summary class="article-expander__title">Clonal interactions in cancer: Integrating quantitative models with experimental and clinical data</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37023969/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tumors consist of different genotypically distinct subpopulations-or subclones-of cells. These subclones can influence neighboring clones in a process called &quot;clonal interaction.&quot; Conventionally, research on driver mutations in cancer has focused on their cell-autonomous effects that lead to an increase in fitness of the cells containing the driver. Recently, with the advent of improved experimental and computational technologies for investigating tumor heterogeneity and clonal dynamics, new...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37023969"
                        open
                      >
                        <summary class="article-expander__title">Clonal interactions in cancer: Integrating quantitative models with experimental and clinical data</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37023969/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tumors consist of different genotypically distinct subpopulations-or subclones-of cells. These subclones can influence neighboring clones in a process called &quot;clonal interaction.&quot; Conventionally, research on driver mutations in cancer has focused on their cell-autonomous effects that lead to an increase in fitness of the cells containing the driver. Recently, with the advent of improved experimental and computational technologies for investigating tumor heterogeneity and clonal dynamics, new...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37023969"
                        open
                      >
                        <summary class="article-expander__title">Clonal interactions in cancer: Integrating quantitative models with experimental and clinical data</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37023969/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tumors consist of different genotypically distinct subpopulations-or subclones-of cells. These subclones can influence neighboring clones in a process called &quot;clonal interaction.&quot; Conventionally, research on driver mutations in cancer has focused on their cell-autonomous effects that lead to an increase in fitness of the cells containing the driver. Recently, with the advent of improved experimental and computational technologies for investigating tumor heterogeneity and clonal dynamics, new...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37023969"
                        open
                      >
                        <summary class="article-expander__title">Clonal interactions in cancer: integrating quantitative models with experimental and clinical data</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37023969/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230413205530&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tumors consist of different genotypically distinct subpopulations-or subclones-of cells. These subclones can influence neighboring clones in a process called &quot;clonal interaction.&quot; Conventionally, research on driver mutations in cancer has focused on their cell-autonomous effects that lead to an increase in fitness of the cells containing the driver. Recently, with the advent of improved experimental and computational technologies for investigating tumor heterogeneity and clonal dynamics, new...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37023969"
                        open
                      >
                        <summary class="article-expander__title">Clonal interactions in cancer: integrating quantitative models with experimental and clinical data</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37023969/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230412205510&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tumors consist of different genotypically distinct subpopulations-or subclones-of cells. These subclones can influence neighboring clones in a process called &quot;clonal interaction.&quot; Conventionally, research on driver mutations in cancer has focused on their cell-autonomous effects that lead to an increase in fitness of the cells containing the driver. Recently, with the advent of improved experimental and computational technologies for investigating tumor heterogeneity and clonal dynamics, new...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37023969"
                        open
                      >
                        <summary class="article-expander__title">Clonal interactions in cancer: integrating quantitative models with experimental and clinical data</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37023969/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tumors consist of different genotypically distinct subpopulations-or subclones-of cells. These subclones can influence neighboring clones in a process called &quot;clonal interaction.&quot; Conventionally, research on driver mutations in cancer has focused on their cell-autonomous effects that lead to an increase in fitness of the cells containing the driver. Recently, with the advent of improved experimental and computational technologies for investigating tumor heterogeneity and clonal dynamics, new...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37023969"
                        open
                      >
                        <summary class="article-expander__title">Clonal interactions in cancer: integrating quantitative models with experimental and clinical data</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37023969/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tumors consist of different genotypically distinct subpopulations-or subclones-of cells. These subclones can influence neighboring clones in a process called &quot;clonal interaction.&quot; Conventionally, research on driver mutations in cancer has focused on their cell-autonomous effects that lead to an increase in fitness of the cells containing the driver. Recently, with the advent of improved experimental and computational technologies for investigating tumor heterogeneity and clonal dynamics, new...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37023969"
                        open
                      >
                        <summary class="article-expander__title">Clonal interactions in cancer: integrating quantitative models with experimental and clinical data</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37023969/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tumors consist of different genotypically distinct subpopulations-or subclones-of cells. These subclones can influence neighboring clones in a process called &quot;clonal interaction.&quot; Conventionally, research on driver mutations in cancer has focused on their cell-autonomous effects that lead to an increase in fitness of the cells containing the driver. Recently, with the advent of improved experimental and computational technologies for investigating tumor heterogeneity and clonal dynamics, new...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37023969"
                        open
                      >
                        <summary class="article-expander__title">Clonal interactions in cancer: integrating quantitative models with experimental and clinical data</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37023969/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tumors consist of different genotypically distinct subpopulations-or subclones-of cells. These subclones can influence neighboring clones in a process called &quot;clonal interaction.&quot; Conventionally, research on driver mutations in cancer has focused on their cell-autonomous effects that lead to an increase in fitness of the cells containing the driver. Recently, with the advent of improved experimental and computational technologies for investigating tumor heterogeneity and clonal dynamics, new...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37023969"
                        open
                      >
                        <summary class="article-expander__title">Clonal interactions in cancer: integrating quantitative models with experimental and clinical data</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37023969/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Tumors consist of different genotypically distinct subpopulations-or subclones-of cells. These subclones can influence neighboring clones in a process called &quot;clonal interaction.&quot; Conventionally, research on driver mutations in cancer has focused on their cell-autonomous effects that lead to an increase in fitness of the cells containing the driver. Recently, with the advent of improved experimental and computational technologies for investigating tumor heterogeneity and clonal dynamics, new...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-05 datetime="2023-04-05T10:00:00.000Z">2023-04-05</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-05 datetime="2023-04-05T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37018661"
                        open
                      >
                        <summary class="article-expander__title">Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37018661/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230426205911&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The ability to isolate and characterize different HSPC (hematopoietic stem/progenitor cell) populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis and regeneration, as well as in age-related conditions such as clonal hematopoiesis and leukemogenesis. Significant progress has been made in the past few decades in determining the composition of the cell types that exist in this system, but the most significant advances have come from mouse studies....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37018661"
                        open
                      >
                        <summary class="article-expander__title">Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37018661/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230425205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The ability to isolate and characterize different HSPC (hematopoietic stem/progenitor cell) populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis and regeneration, as well as in age-related conditions such as clonal hematopoiesis and leukemogenesis. Significant progress has been made in the past few decades in determining the composition of the cell types that exist in this system, but the most significant advances have come from mouse studies....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37018661"
                        open
                      >
                        <summary class="article-expander__title">Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37018661/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The ability to isolate and characterize different HSPC (hematopoietic stem/progenitor cell) populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis and regeneration, as well as in age-related conditions such as clonal hematopoiesis and leukemogenesis. Significant progress has been made in the past few decades in determining the composition of the cell types that exist in this system, but the most significant advances have come from mouse studies....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37018661"
                        open
                      >
                        <summary class="article-expander__title">Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37018661/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The ability to isolate and characterize different HSPC (hematopoietic stem/progenitor cell) populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis and regeneration, as well as in age-related conditions such as clonal hematopoiesis and leukemogenesis. Significant progress has been made in the past few decades in determining the composition of the cell types that exist in this system, but the most significant advances have come from mouse studies....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37018661"
                        open
                      >
                        <summary class="article-expander__title">Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37018661/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The ability to isolate and characterize different HSPC (hematopoietic stem/progenitor cell) populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis and regeneration, as well as in age-related conditions such as clonal hematopoiesis and leukemogenesis. Significant progress has been made in the past few decades in determining the composition of the cell types that exist in this system, but the most significant advances have come from mouse studies....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37018661"
                        open
                      >
                        <summary class="article-expander__title">Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37018661/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The ability to isolate and characterize different HSPC (hematopoietic stem/progenitor cell) populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis and regeneration, as well as in age-related conditions such as clonal hematopoiesis and leukemogenesis. Significant progress has been made in the past few decades in determining the composition of the cell types that exist in this system, but the most significant advances have come from mouse studies....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37018661"
                        open
                      >
                        <summary class="article-expander__title">Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37018661/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The ability to isolate and characterize different HSPC (hematopoietic stem/progenitor cell) populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis and regeneration, as well as in age-related conditions such as clonal hematopoiesis and leukemogenesis. Significant progress has been made in the past few decades in determining the composition of the cell types that exist in this system, but the most significant advances have come from mouse studies....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37018661"
                        open
                      >
                        <summary class="article-expander__title">Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37018661/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The ability to isolate and characterize different HSPC (hematopoietic stem/progenitor cell) populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis and regeneration, as well as in age-related conditions such as clonal hematopoiesis and leukemogenesis. Significant progress has been made in the past few decades in determining the composition of the cell types that exist in this system, but the most significant advances have come from mouse studies....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37018661"
                        open
                      >
                        <summary class="article-expander__title">Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37018661/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The ability to isolate and characterize different HSPC (hematopoietic stem/progenitor cell) populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis and regeneration, as well as in age-related conditions such as clonal hematopoiesis and leukemogenesis. Significant progress has been made in the past few decades in determining the composition of the cell types that exist in this system, but the most significant advances have come from mouse studies....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37018661"
                        open
                      >
                        <summary class="article-expander__title">Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37018661/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The ability to isolate and characterize different HSPC (hematopoietic stem/progenitor cell) populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis and regeneration, as well as in age-related conditions such as clonal hematopoiesis and leukemogenesis. Significant progress has been made in the past few decades in determining the composition of the cell types that exist in this system, but the most significant advances have come from mouse studies....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37018661"
                        open
                      >
                        <summary class="article-expander__title">Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37018661/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The ability to isolate and characterize different HSPC (hematopoietic stem/progenitor cell) populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis and regeneration, as well as in age-related conditions such as clonal hematopoiesis and leukemogenesis. Significant progress has been made in the past few decades in determining the composition of the cell types that exist in this system, but the most significant advances have come from mouse studies....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37018661"
                        open
                      >
                        <summary class="article-expander__title">Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37018661/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The ability to isolate and characterize different HSPC (hematopoietic stem/progenitor cell) populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis and regeneration, as well as in age-related conditions such as clonal hematopoiesis and leukemogenesis. Significant progress has been made in the past few decades in determining the composition of the cell types that exist in this system, but the most significant advances have come from mouse studies....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37018661"
                        open
                      >
                        <summary class="article-expander__title">Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37018661/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The ability to isolate and characterize different HSPC (hematopoietic stem/progenitor cell) populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis and regeneration, as well as in age-related conditions such as clonal hematopoiesis and leukemogenesis. Significant progress has been made in the past few decades in determining the composition of the cell types that exist in this system, but the most significant advances have come from mouse studies....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37018661"
                        open
                      >
                        <summary class="article-expander__title">Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37018661/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230413205532&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The ability to isolate and characterize different HSPC (hematopoietic stem/progenitor cell) populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis and regeneration, as well as in age-related conditions such as clonal hematopoiesis and leukemogenesis. Significant progress has been made in the past few decades in determining the composition of the cell types that exist in this system, but the most significant advances have come from mouse studies....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37018661"
                        open
                      >
                        <summary class="article-expander__title">Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37018661/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230412205511&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The ability to isolate and characterize different HSPC (hematopoietic stem/progenitor cell) populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis and regeneration, as well as in age-related conditions such as clonal hematopoiesis and leukemogenesis. Significant progress has been made in the past few decades in determining the composition of the cell types that exist in this system, but the most significant advances have come from mouse studies....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37018661"
                        open
                      >
                        <summary class="article-expander__title">Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37018661/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The ability to isolate and characterize different HSPC (hematopoietic stem/progenitor cell) populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis and regeneration, as well as in age-related conditions such as clonal hematopoiesis and leukemogenesis. Significant progress has been made in the past few decades in determining the composition of the cell types that exist in this system, but the most significant advances have come from mouse studies....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37018661"
                        open
                      >
                        <summary class="article-expander__title">Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37018661/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The ability to isolate and characterize different HSPC (hematopoietic stem/progenitor cell) populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis and regeneration, as well as in age-related conditions such as clonal hematopoiesis and leukemogenesis. Significant progress has been made in the past few decades in determining the composition of the cell types that exist in this system, but the most significant advances have come from mouse studies....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37018661"
                        open
                      >
                        <summary class="article-expander__title">Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37018661/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The ability to isolate and characterize different HSPC (hematopoietic stem/progenitor cell) populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis and regeneration, as well as in age-related conditions such as clonal hematopoiesis and leukemogenesis. Significant progress has been made in the past few decades in determining the composition of the cell types that exist in this system, but the most significant advances have come from mouse studies....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37018661"
                        open
                      >
                        <summary class="article-expander__title">Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37018661/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The ability to isolate and characterize different HSPC (hematopoietic stem/progenitor cell) populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis and regeneration, as well as in age-related conditions such as clonal hematopoiesis and leukemogenesis. Significant progress has been made in the past few decades in determining the composition of the cell types that exist in this system, but the most significant advances have come from mouse studies....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37018661"
                        open
                      >
                        <summary class="article-expander__title">Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37018661/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The ability to isolate and characterize different HSPC (hematopoietic stem/progenitor cell) populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis and regeneration, as well as in age-related conditions such as clonal hematopoiesis and leukemogenesis. Significant progress has been made in the past few decades in determining the composition of the cell types that exist in this system, but the most significant advances have come from mouse studies....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37018661"
                        open
                      >
                        <summary class="article-expander__title">Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37018661/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The ability to isolate and characterize different HSPC (hematopoietic stem/progenitor cell) populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis and regeneration, as well as in age-related conditions such as clonal hematopoiesis and leukemogenesis. Significant progress has been made in the past few decades in determining the composition of the cell types that exist in this system, but the most significant advances have come from mouse studies....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37018661"
                        open
                      >
                        <summary class="article-expander__title">Human CD34+ hematopoietic stem cell hierarchy: how far are we with its delineation at the most primitive level?</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37018661/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The ability to isolate and characterize different HSPC (hematopoietic stem/progenitor cell) populations opens avenues to understand how hematopoiesis is regulated during development, homeostasis and regeneration, as well as in age-related conditions such as clonal hematopoiesis and leukemogenesis. Significant progress has been made in the past few decades in determining the composition of the cell types that exist in this system, but the most significant advances have come from mouse studies....</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-04 datetime="2023-04-04T10:00:00.000Z">2023-04-04</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-04 datetime="2023-04-04T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37016431"
                        open
                      >
                        <summary class="article-expander__title">NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37016431/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In spite of cell-context-dependent changes mediated by EK, there appears to be a shared transcriptional program dependent on compartment shifts which could explain phenotypic differences across EK cell lines. This core program is an attractive target for therapeutic intervention.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37016431"
                        open
                      >
                        <summary class="article-expander__title">NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37016431/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In spite of cell-context-dependent changes mediated by EK, there appears to be a shared transcriptional program dependent on compartment shifts which could explain phenotypic differences across EK cell lines. This core program is an attractive target for therapeutic intervention.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37016431"
                        open
                      >
                        <summary class="article-expander__title">NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37016431/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In spite of cell-context-dependent changes mediated by EK, there appears to be a shared transcriptional program dependent on compartment shifts which could explain phenotypic differences across EK cell lines. This core program is an attractive target for therapeutic intervention.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37016431"
                        open
                      >
                        <summary class="article-expander__title">NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37016431/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230413205530&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In spite of cell-context-dependent changes mediated by EK, there appears to be a shared transcriptional program dependent on compartment shifts which could explain phenotypic differences across EK cell lines. This core program is an attractive target for therapeutic intervention.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37016431"
                        open
                      >
                        <summary class="article-expander__title">NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37016431/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230412205510&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In spite of cell-context-dependent changes mediated by EK, there appears to be a shared transcriptional program dependent on compartment shifts which could explain phenotypic differences across EK cell lines. This core program is an attractive target for therapeutic intervention.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37016431"
                        open
                      >
                        <summary class="article-expander__title">NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37016431/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In spite of cell-context-dependent changes mediated by EK, there appears to be a shared transcriptional program dependent on compartment shifts which could explain phenotypic differences across EK cell lines. This core program is an attractive target for therapeutic intervention.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37016431"
                        open
                      >
                        <summary class="article-expander__title">NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37016431/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In spite of cell-context-dependent changes mediated by EK, there appears to be a shared transcriptional program dependent on compartment shifts which could explain phenotypic differences across EK cell lines. This core program is an attractive target for therapeutic intervention.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37016431"
                        open
                      >
                        <summary class="article-expander__title">NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37016431/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In spite of cell-context-dependent changes mediated by EK, there appears to be a shared transcriptional program dependent on compartment shifts which could explain phenotypic differences across EK cell lines. This core program is an attractive target for therapeutic intervention.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37016431"
                        open
                      >
                        <summary class="article-expander__title">NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37016431/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In spite of cell-context-dependent changes mediated by EK, there appears to be a shared transcriptional program dependent on compartment shifts which could explain phenotypic differences across EK cell lines. This core program is an attractive target for therapeutic intervention.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37016431"
                        open
                      >
                        <summary class="article-expander__title">NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37016431/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In spite of cell-context-dependent changes mediated by EK, there appears to be a shared transcriptional program dependent on compartment shifts which could explain phenotypic differences across EK cell lines. This core program is an attractive target for therapeutic intervention.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;12
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37016431"
                        open
                      >
                        <summary class="article-expander__title">NSD2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37016431/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In spite of cell-context-dependent changes mediated by EK, there appears to be a shared transcriptional program dependent on compartment shifts which could explain phenotypic differences across EK cell lines. This core program is an attractive target for therapeutic intervention.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-03 datetime="2023-04-03T10:00:00.000Z">2023-04-03</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-03 datetime="2023-04-03T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37007111"
                        open
                      >
                        <summary class="article-expander__title">SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37007111/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by peripheral blood cytopenia and an increased risk of transformation to acute myeloid leukemia (AML). Approximately half of the patients with MDS have somatic mutations in the spliceosome gene. Splicing Factor 3B Subunit 1A (SF3B1), the most frequently occurring splicing factor mutation in MDS is significantly associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37007111"
                        open
                      >
                        <summary class="article-expander__title">SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37007111/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by peripheral blood cytopenia and an increased risk of transformation to acute myeloid leukemia (AML). Approximately half of the patients with MDS have somatic mutations in the spliceosome gene. Splicing Factor 3B Subunit 1A (SF3B1), the most frequently occurring splicing factor mutation in MDS is significantly associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37007111"
                        open
                      >
                        <summary class="article-expander__title">SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37007111/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by peripheral blood cytopenia and an increased risk of transformation to acute myeloid leukemia (AML). Approximately half of the patients with MDS have somatic mutations in the spliceosome gene. Splicing Factor 3B Subunit 1A (SF3B1), the most frequently occurring splicing factor mutation in MDS is significantly associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37007111"
                        open
                      >
                        <summary class="article-expander__title">SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37007111/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by peripheral blood cytopenia and an increased risk of transformation to acute myeloid leukemia (AML). Approximately half of the patients with MDS have somatic mutations in the spliceosome gene. Splicing Factor 3B Subunit 1A (SF3B1), the most frequently occurring splicing factor mutation in MDS is significantly associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37007111"
                        open
                      >
                        <summary class="article-expander__title">SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37007111/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by peripheral blood cytopenia and an increased risk of transformation to acute myeloid leukemia (AML). Approximately half of the patients with MDS have somatic mutations in the spliceosome gene. Splicing Factor 3B Subunit 1A (SF3B1), the most frequently occurring splicing factor mutation in MDS is significantly associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37007111"
                        open
                      >
                        <summary class="article-expander__title">SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37007111/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by peripheral blood cytopenia and an increased risk of transformation to acute myeloid leukemia (AML). Approximately half of the patients with MDS have somatic mutations in the spliceosome gene. Splicing Factor 3B Subunit 1A (SF3B1), the most frequently occurring splicing factor mutation in MDS is significantly associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37007111"
                        open
                      >
                        <summary class="article-expander__title">SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37007111/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by peripheral blood cytopenia and an increased risk of transformation to acute myeloid leukemia (AML). Approximately half of the patients with MDS have somatic mutations in the spliceosome gene. Splicing Factor 3B Subunit 1A (SF3B1), the most frequently occurring splicing factor mutation in MDS is significantly associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37007111"
                        open
                      >
                        <summary class="article-expander__title">SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37007111/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by peripheral blood cytopenia and an increased risk of transformation to acute myeloid leukemia (AML). Approximately half of the patients with MDS have somatic mutations in the spliceosome gene. Splicing Factor 3B Subunit 1A (SF3B1), the most frequently occurring splicing factor mutation in MDS is significantly associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37007111"
                        open
                      >
                        <summary class="article-expander__title">SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37007111/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by peripheral blood cytopenia and an increased risk of transformation to acute myeloid leukemia (AML). Approximately half of the patients with MDS have somatic mutations in the spliceosome gene. Splicing Factor 3B Subunit 1A (SF3B1), the most frequently occurring splicing factor mutation in MDS is significantly associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230413205532&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37007111"
                        open
                      >
                        <summary class="article-expander__title">SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37007111/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230413205532&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by peripheral blood cytopenia and an increased risk of transformation to acute myeloid leukemia (AML). Approximately half of the patients with MDS have somatic mutations in the spliceosome gene. Splicing Factor 3B Subunit 1A (SF3B1), the most frequently occurring splicing factor mutation in MDS is significantly associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230412205511&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37007111"
                        open
                      >
                        <summary class="article-expander__title">SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37007111/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230412205511&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by peripheral blood cytopenia and an increased risk of transformation to acute myeloid leukemia (AML). Approximately half of the patients with MDS have somatic mutations in the spliceosome gene. Splicing Factor 3B Subunit 1A (SF3B1), the most frequently occurring splicing factor mutation in MDS is significantly associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37007111"
                        open
                      >
                        <summary class="article-expander__title">SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37007111/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by peripheral blood cytopenia and an increased risk of transformation to acute myeloid leukemia (AML). Approximately half of the patients with MDS have somatic mutations in the spliceosome gene. Splicing Factor 3B Subunit 1A (SF3B1), the most frequently occurring splicing factor mutation in MDS is significantly associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37007111"
                        open
                      >
                        <summary class="article-expander__title">SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37007111/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by peripheral blood cytopenia and an increased risk of transformation to acute myeloid leukemia (AML). Approximately half of the patients with MDS have somatic mutations in the spliceosome gene. Splicing Factor 3B Subunit 1A (SF3B1), the most frequently occurring splicing factor mutation in MDS is significantly associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37007111"
                        open
                      >
                        <summary class="article-expander__title">SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37007111/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by peripheral blood cytopenia and an increased risk of transformation to acute myeloid leukemia (AML). Approximately half of the patients with MDS have somatic mutations in the spliceosome gene. Splicing Factor 3B Subunit 1A (SF3B1), the most frequently occurring splicing factor mutation in MDS is significantly associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37007111"
                        open
                      >
                        <summary class="article-expander__title">SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37007111/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by peripheral blood cytopenia and an increased risk of transformation to acute myeloid leukemia (AML). Approximately half of the patients with MDS have somatic mutations in the spliceosome gene. Splicing Factor 3B Subunit 1A (SF3B1), the most frequently occurring splicing factor mutation in MDS is significantly associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37007111"
                        open
                      >
                        <summary class="article-expander__title">SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37007111/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by peripheral blood cytopenia and an increased risk of transformation to acute myeloid leukemia (AML). Approximately half of the patients with MDS have somatic mutations in the spliceosome gene. Splicing Factor 3B Subunit 1A (SF3B1), the most frequently occurring splicing factor mutation in MDS is significantly associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37007111"
                        open
                      >
                        <summary class="article-expander__title">SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37007111/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by peripheral blood cytopenia and an increased risk of transformation to acute myeloid leukemia (AML). Approximately half of the patients with MDS have somatic mutations in the spliceosome gene. Splicing Factor 3B Subunit 1A (SF3B1), the most frequently occurring splicing factor mutation in MDS is significantly associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37007111"
                        open
                      >
                        <summary class="article-expander__title">SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37007111/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by peripheral blood cytopenia and an increased risk of transformation to acute myeloid leukemia (AML). Approximately half of the patients with MDS have somatic mutations in the spliceosome gene. Splicing Factor 3B Subunit 1A (SF3B1), the most frequently occurring splicing factor mutation in MDS is significantly associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37007111"
                        open
                      >
                        <summary class="article-expander__title">SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37007111/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by peripheral blood cytopenia and an increased risk of transformation to acute myeloid leukemia (AML). Approximately half of the patients with MDS have somatic mutations in the spliceosome gene. Splicing Factor 3B Subunit 1A (SF3B1), the most frequently occurring splicing factor mutation in MDS is significantly associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37007111"
                        open
                      >
                        <summary class="article-expander__title">SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37007111/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic syndromes (MDS) are clonal hematologic malignancies characterized by ineffective hematopoiesis and dysplasia of the myeloid cell lineage and are characterized by peripheral blood cytopenia and an increased risk of transformation to acute myeloid leukemia (AML). Approximately half of the patients with MDS have somatic mutations in the spliceosome gene. Splicing Factor 3B Subunit 1A (SF3B1), the most frequently occurring splicing factor mutation in MDS is significantly associated...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37012292"
                        open
                      >
                        <summary class="article-expander__title">The structure of the hematopoietic system can explain chronic myeloid leukemia progression</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37012292/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Almost all cancer types share the hallmarks of cancer and a similar tumor formation: fueled by stochastic mutations in somatic cells. In case of chronic myeloid leukemia (CML), this evolutionary process can be tracked from an asymptomatic long-lasting chronic phase to a final rapidly evolving blast phase. Somatic evolution in CML occurs in the context of healthy blood production, a hierarchical process of cell division; initiated by stem cells that self-renew and differentiate to produce mature...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37012292"
                        open
                      >
                        <summary class="article-expander__title">The structure of the hematopoietic system can explain chronic myeloid leukemia progression</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37012292/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Almost all cancer types share the hallmarks of cancer and a similar tumor formation: fueled by stochastic mutations in somatic cells. In case of chronic myeloid leukemia (CML), this evolutionary process can be tracked from an asymptomatic long-lasting chronic phase to a final rapidly evolving blast phase. Somatic evolution in CML occurs in the context of healthy blood production, a hierarchical process of cell division; initiated by stem cells that self-renew and differentiate to produce mature...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37012292"
                        open
                      >
                        <summary class="article-expander__title">The structure of the hematopoietic system can explain chronic myeloid leukemia progression</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37012292/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230413205530&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Almost all cancer types share the hallmarks of cancer and a similar tumor formation: fueled by stochastic mutations in somatic cells. In case of chronic myeloid leukemia (CML), this evolutionary process can be tracked from an asymptomatic long-lasting chronic phase to a final rapidly evolving blast phase. Somatic evolution in CML occurs in the context of healthy blood production, a hierarchical process of cell division; initiated by stem cells that self-renew and differentiate to produce mature...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230413205530&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009703"
                        open
                      >
                        <summary class="article-expander__title">HPV Integration Can Drive the Formation of Virus-Host Extrachromosomal DNA in Tumors</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009703/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230413205530&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Human papillomavirus (HPV)-positive cancer cells contain virus and host DNA and exhibit marked genome instability. In this issue of Cancer Discovery, Akagi and colleagues characterize the remarkably complex landscape of virus-host DNA molecules in HPV-positive cells, providing evidence for diverse integrated and extrachromosomal virus-host hybrid DNAs with the potential to drive clonal evolution. See related article by Akagi et al., p. 910 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37012292"
                        open
                      >
                        <summary class="article-expander__title">The structure of the hematopoietic system can explain chronic myeloid leukemia progression</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37012292/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230412205510&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Almost all cancer types share the hallmarks of cancer and a similar tumor formation: fueled by stochastic mutations in somatic cells. In case of chronic myeloid leukemia (CML), this evolutionary process can be tracked from an asymptomatic long-lasting chronic phase to a final rapidly evolving blast phase. Somatic evolution in CML occurs in the context of healthy blood production, a hierarchical process of cell division; initiated by stem cells that self-renew and differentiate to produce mature...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230412205510&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009703"
                        open
                      >
                        <summary class="article-expander__title">HPV Integration Can Drive the Formation of Virus-Host Extrachromosomal DNA in Tumors</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009703/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230412205510&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Human papillomavirus (HPV)-positive cancer cells contain virus and host DNA and exhibit marked genome instability. In this issue of Cancer Discovery, Akagi and colleagues characterize the remarkably complex landscape of virus-host DNA molecules in HPV-positive cells, providing evidence for diverse integrated and extrachromosomal virus-host hybrid DNAs with the potential to drive clonal evolution. See related article by Akagi et al., p. 910 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37008163"
                        open
                      >
                        <summary class="article-expander__title">The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37008163/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230412205510&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neutropenia, as an isolated blood cell deficiency, is a feature of a wide spectrum of acquired or congenital, benign or premalignant disorders with a predisposition to develop myelodysplastic neoplasms/acute myeloid leukemia that may arise at any age. In recent years, advances in diagnostic methodologies, particularly in the field of genomics, have revealed novel genes and mechanisms responsible for etiology and disease evolution and opened new perspectives for tailored treatment. Despite the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37012292"
                        open
                      >
                        <summary class="article-expander__title">The structure of the hematopoietic system can explain chronic myeloid leukemia progression</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37012292/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Almost all cancer types share the hallmarks of cancer and a similar tumor formation: fueled by stochastic mutations in somatic cells. In case of chronic myeloid leukemia (CML), this evolutionary process can be tracked from an asymptomatic long-lasting chronic phase to a final rapidly evolving blast phase. Somatic evolution in CML occurs in the context of healthy blood production, a hierarchical process of cell division; initiated by stem cells that self-renew and differentiate to produce mature...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009703"
                        open
                      >
                        <summary class="article-expander__title">HPV Integration Can Drive the Formation of Virus-Host Extrachromosomal DNA in Tumors</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009703/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Human papillomavirus (HPV)-positive cancer cells contain virus and host DNA and exhibit marked genome instability. In this issue of Cancer Discovery, Akagi and colleagues characterize the remarkably complex landscape of virus-host DNA molecules in HPV-positive cells, providing evidence for diverse integrated and extrachromosomal virus-host hybrid DNAs with the potential to drive clonal evolution. See related article by Akagi et al., p. 910 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37008163"
                        open
                      >
                        <summary class="article-expander__title">The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37008163/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neutropenia, as an isolated blood cell deficiency, is a feature of a wide spectrum of acquired or congenital, benign or premalignant disorders with a predisposition to develop myelodysplastic neoplasms/acute myeloid leukemia that may arise at any age. In recent years, advances in diagnostic methodologies, particularly in the field of genomics, have revealed novel genes and mechanisms responsible for etiology and disease evolution and opened new perspectives for tailored treatment. Despite the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37012292"
                        open
                      >
                        <summary class="article-expander__title">The structure of the hematopoietic system can explain chronic myeloid leukemia progression</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37012292/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Almost all cancer types share the hallmarks of cancer and a similar tumor formation: fueled by stochastic mutations in somatic cells. In case of chronic myeloid leukemia (CML), this evolutionary process can be tracked from an asymptomatic long-lasting chronic phase to a final rapidly evolving blast phase. Somatic evolution in CML occurs in the context of healthy blood production, a hierarchical process of cell division; initiated by stem cells that self-renew and differentiate to produce mature...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009703"
                        open
                      >
                        <summary class="article-expander__title">HPV Integration Can Drive the Formation of Virus-Host Extrachromosomal DNA in Tumors</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009703/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Human papillomavirus (HPV)-positive cancer cells contain virus and host DNA and exhibit marked genome instability. In this issue of Cancer Discovery, Akagi and colleagues characterize the remarkably complex landscape of virus-host DNA molecules in HPV-positive cells, providing evidence for diverse integrated and extrachromosomal virus-host hybrid DNAs with the potential to drive clonal evolution. See related article by Akagi et al., p. 910 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37008163"
                        open
                      >
                        <summary class="article-expander__title">The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37008163/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neutropenia, as an isolated blood cell deficiency, is a feature of a wide spectrum of acquired or congenital, benign or premalignant disorders with a predisposition to develop myelodysplastic neoplasms/acute myeloid leukemia that may arise at any age. In recent years, advances in diagnostic methodologies, particularly in the field of genomics, have revealed novel genes and mechanisms responsible for etiology and disease evolution and opened new perspectives for tailored treatment. Despite the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37012292"
                        open
                      >
                        <summary class="article-expander__title">The structure of the hematopoietic system can explain chronic myeloid leukemia progression</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37012292/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Almost all cancer types share the hallmarks of cancer and a similar tumor formation: fueled by stochastic mutations in somatic cells. In case of chronic myeloid leukemia (CML), this evolutionary process can be tracked from an asymptomatic long-lasting chronic phase to a final rapidly evolving blast phase. Somatic evolution in CML occurs in the context of healthy blood production, a hierarchical process of cell division; initiated by stem cells that self-renew and differentiate to produce mature...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009703"
                        open
                      >
                        <summary class="article-expander__title">HPV Integration Can Drive the Formation of Virus-Host Extrachromosomal DNA in Tumors</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009703/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Human papillomavirus (HPV)-positive cancer cells contain virus and host DNA and exhibit marked genome instability. In this issue of Cancer Discovery, Akagi and colleagues characterize the remarkably complex landscape of virus-host DNA molecules in HPV-positive cells, providing evidence for diverse integrated and extrachromosomal virus-host hybrid DNAs with the potential to drive clonal evolution. See related article by Akagi et al., p. 910 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37008163"
                        open
                      >
                        <summary class="article-expander__title">The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37008163/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neutropenia, as an isolated blood cell deficiency, is a feature of a wide spectrum of acquired or congenital, benign or premalignant disorders with a predisposition to develop myelodysplastic neoplasms/acute myeloid leukemia that may arise at any age. In recent years, advances in diagnostic methodologies, particularly in the field of genomics, have revealed novel genes and mechanisms responsible for etiology and disease evolution and opened new perspectives for tailored treatment. Despite the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37012292"
                        open
                      >
                        <summary class="article-expander__title">The structure of the hematopoietic system can explain chronic myeloid leukemia progression</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37012292/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Almost all cancer types share the hallmarks of cancer and a similar tumor formation: fueled by stochastic mutations in somatic cells. In case of chronic myeloid leukemia (CML), this evolutionary process can be tracked from an asymptomatic long-lasting chronic phase to a final rapidly evolving blast phase. Somatic evolution in CML occurs in the context of healthy blood production, a hierarchical process of cell division; initiated by stem cells that self-renew and differentiate to produce mature...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009703"
                        open
                      >
                        <summary class="article-expander__title">HPV Integration Can Drive the Formation of Virus-Host Extrachromosomal DNA in Tumors</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009703/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Human papillomavirus (HPV)-positive cancer cells contain virus and host DNA and exhibit marked genome instability. In this issue of Cancer Discovery, Akagi and colleagues characterize the remarkably complex landscape of virus-host DNA molecules in HPV-positive cells, providing evidence for diverse integrated and extrachromosomal virus-host hybrid DNAs with the potential to drive clonal evolution. See related article by Akagi et al., p. 910 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37008163"
                        open
                      >
                        <summary class="article-expander__title">The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37008163/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neutropenia, as an isolated blood cell deficiency, is a feature of a wide spectrum of acquired or congenital, benign or premalignant disorders with a predisposition to develop myelodysplastic neoplasms/acute myeloid leukemia that may arise at any age. In recent years, advances in diagnostic methodologies, particularly in the field of genomics, have revealed novel genes and mechanisms responsible for etiology and disease evolution and opened new perspectives for tailored treatment. Despite the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37012292"
                        open
                      >
                        <summary class="article-expander__title">The structure of the hematopoietic system can explain chronic myeloid leukemia progression</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37012292/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Almost all cancer types share the hallmarks of cancer and a similar tumor formation: fueled by stochastic mutations in somatic cells. In case of chronic myeloid leukemia (CML), this evolutionary process can be tracked from an asymptomatic long-lasting chronic phase to a final rapidly evolving blast phase. Somatic evolution in CML occurs in the context of healthy blood production, a hierarchical process of cell division; initiated by stem cells that self-renew and differentiate to produce mature...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009703"
                        open
                      >
                        <summary class="article-expander__title">HPV Integration Can Drive the Formation of Virus-Host Extrachromosomal DNA in Tumors</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009703/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Human papillomavirus (HPV)-positive cancer cells contain virus and host DNA and exhibit marked genome instability. In this issue of Cancer Discovery, Akagi and colleagues characterize the remarkably complex landscape of virus-host DNA molecules in HPV-positive cells, providing evidence for diverse integrated and extrachromosomal virus-host hybrid DNAs with the potential to drive clonal evolution. See related article by Akagi et al., p. 910 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37008163"
                        open
                      >
                        <summary class="article-expander__title">The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37008163/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neutropenia, as an isolated blood cell deficiency, is a feature of a wide spectrum of acquired or congenital, benign or premalignant disorders with a predisposition to develop myelodysplastic neoplasms/acute myeloid leukemia that may arise at any age. In recent years, advances in diagnostic methodologies, particularly in the field of genomics, have revealed novel genes and mechanisms responsible for etiology and disease evolution and opened new perspectives for tailored treatment. Despite the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37012292"
                        open
                      >
                        <summary class="article-expander__title">The structure of the hematopoietic system can explain chronic myeloid leukemia progression</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37012292/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Almost all cancer types share the hallmarks of cancer and a similar tumor formation: fueled by stochastic mutations in somatic cells. In case of chronic myeloid leukemia (CML), this evolutionary process can be tracked from an asymptomatic long-lasting chronic phase to a final rapidly evolving blast phase. Somatic evolution in CML occurs in the context of healthy blood production, a hierarchical process of cell division; initiated by stem cells that self-renew and differentiate to produce mature...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009703"
                        open
                      >
                        <summary class="article-expander__title">HPV Integration Can Drive the Formation of Virus-Host Extrachromosomal DNA in Tumors</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009703/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Human papillomavirus (HPV)-positive cancer cells contain virus and host DNA and exhibit marked genome instability. In this issue of Cancer Discovery, Akagi and colleagues characterize the remarkably complex landscape of virus-host DNA molecules in HPV-positive cells, providing evidence for diverse integrated and extrachromosomal virus-host hybrid DNAs with the potential to drive clonal evolution. See related article by Akagi et al., p. 910 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37008163"
                        open
                      >
                        <summary class="article-expander__title">The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37008163/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neutropenia, as an isolated blood cell deficiency, is a feature of a wide spectrum of acquired or congenital, benign or premalignant disorders with a predisposition to develop myelodysplastic neoplasms/acute myeloid leukemia that may arise at any age. In recent years, advances in diagnostic methodologies, particularly in the field of genomics, have revealed novel genes and mechanisms responsible for etiology and disease evolution and opened new perspectives for tailored treatment. Despite the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37012292"
                        open
                      >
                        <summary class="article-expander__title">The structure of the hematopoietic system can explain chronic myeloid leukemia progression</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37012292/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Almost all cancer types share the hallmarks of cancer and a similar tumor formation: fueled by stochastic mutations in somatic cells. In case of chronic myeloid leukemia (CML), this evolutionary process can be tracked from an asymptomatic long-lasting chronic phase to a final rapidly evolving blast phase. Somatic evolution in CML occurs in the context of healthy blood production, a hierarchical process of cell division; initiated by stem cells that self-renew and differentiate to produce mature...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009703"
                        open
                      >
                        <summary class="article-expander__title">HPV Integration Can Drive the Formation of Virus-Host Extrachromosomal DNA in Tumors</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009703/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Human papillomavirus (HPV)-positive cancer cells contain virus and host DNA and exhibit marked genome instability. In this issue of Cancer Discovery, Akagi and colleagues characterize the remarkably complex landscape of virus-host DNA molecules in HPV-positive cells, providing evidence for diverse integrated and extrachromosomal virus-host hybrid DNAs with the potential to drive clonal evolution. See related article by Akagi et al., p. 910 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37008163"
                        open
                      >
                        <summary class="article-expander__title">The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37008163/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neutropenia, as an isolated blood cell deficiency, is a feature of a wide spectrum of acquired or congenital, benign or premalignant disorders with a predisposition to develop myelodysplastic neoplasms/acute myeloid leukemia that may arise at any age. In recent years, advances in diagnostic methodologies, particularly in the field of genomics, have revealed novel genes and mechanisms responsible for etiology and disease evolution and opened new perspectives for tailored treatment. Despite the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37012292"
                        open
                      >
                        <summary class="article-expander__title">The structure of the hematopoietic system can explain chronic myeloid leukemia progression</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37012292/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Almost all cancer types share the hallmarks of cancer and a similar tumor formation: fueled by stochastic mutations in somatic cells. In case of chronic myeloid leukemia (CML), this evolutionary process can be tracked from an asymptomatic long-lasting chronic phase to a final rapidly evolving blast phase. Somatic evolution in CML occurs in the context of healthy blood production, a hierarchical process of cell division; initiated by stem cells that self-renew and differentiate to produce mature...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009705"
                        open
                      >
                        <summary class="article-expander__title">Childhood Cancer Treatment and Clonal Hematopoiesis</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009705/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Hagiwara and colleagues investigated the effects of childhood cancer treatment on the clonal composition of blood. Their findings provide strong evidence that treatment promotes clonal outgrowths (clonal hematopoiesis) in childhood cancer survivors. See related article by Hagiwara et al., p. 844 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009703"
                        open
                      >
                        <summary class="article-expander__title">HPV Integration Can Drive the Formation of Virus-Host Extrachromosomal DNA in Tumors</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009703/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Human papillomavirus (HPV)-positive cancer cells contain virus and host DNA and exhibit marked genome instability. In this issue of Cancer Discovery, Akagi and colleagues characterize the remarkably complex landscape of virus-host DNA molecules in HPV-positive cells, providing evidence for diverse integrated and extrachromosomal virus-host hybrid DNAs with the potential to drive clonal evolution. See related article by Akagi et al., p. 910 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37008163"
                        open
                      >
                        <summary class="article-expander__title">The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37008163/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neutropenia, as an isolated blood cell deficiency, is a feature of a wide spectrum of acquired or congenital, benign or premalignant disorders with a predisposition to develop myelodysplastic neoplasms/acute myeloid leukemia that may arise at any age. In recent years, advances in diagnostic methodologies, particularly in the field of genomics, have revealed novel genes and mechanisms responsible for etiology and disease evolution and opened new perspectives for tailored treatment. Despite the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37009703"
                        open
                      >
                        <summary class="article-expander__title">HPV Integration Can Drive the Formation of Virus-Host Extrachromosomal DNA in Tumors</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37009703/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Human papillomavirus (HPV)-positive cancer cells contain virus and host DNA and exhibit marked genome instability. In this issue of Cancer Discovery, Akagi and colleagues characterize the remarkably complex landscape of virus-host DNA molecules in HPV-positive cells, providing evidence for diverse integrated and extrachromosomal virus-host hybrid DNAs with the potential to drive clonal evolution. See related article by Akagi et al., p. 910 (4).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37008163"
                        open
                      >
                        <summary class="article-expander__title">The European Guidelines on Diagnosis and Management of Neutropenia in Adults and Children: A Consensus Between the European Hematology Association and the EuNet-INNOCHRON COST Action</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37008163/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neutropenia, as an isolated blood cell deficiency, is a feature of a wide spectrum of acquired or congenital, benign or premalignant disorders with a predisposition to develop myelodysplastic neoplasms/acute myeloid leukemia that may arise at any age. In recent years, advances in diagnostic methodologies, particularly in the field of genomics, have revealed novel genes and mechanisms responsible for etiology and disease evolution and opened new perspectives for tailored treatment. Despite the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-04-01 datetime="2023-04-01T10:00:00.000Z">2023-04-01</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-04-01 datetime="2023-04-01T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079859"
                        open
                      >
                        <summary class="article-expander__title">Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230424205743&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079859"
                        open
                      >
                        <summary class="article-expander__title">Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230423205815&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079859"
                        open
                      >
                        <summary class="article-expander__title">Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230422210150&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079859"
                        open
                      >
                        <summary class="article-expander__title">Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230421205657&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37003397"
                        open
                      >
                        <summary class="article-expander__title">Epigenomic machinery regulating pediatric AML: Clonal expansion mechanisms, therapies, and future perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37003397/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a heterogeneous disease with a genetic, epigenetic, and transcriptional etiology mainly presenting somatic and germline abnormalities. AML incidence rises with age but can also occur during childhood. Pediatric AML (pAML) accounts for 15-20% of all pediatric leukemias and differs considerably from adult AML. Next-generation sequencing technologies have enabled the research community to &quot;paint&quot; the genomic and epigenomic landscape in order to identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37079859"
                        open
                      >
                        <summary class="article-expander__title">Persistent Molecular Disease in Adult Patients With AML Evaluated With Whole-Exome and Targeted Error-Corrected DNA Sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37079859/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSION: PMD and clonal hematopoiesis are both common in patients with AML in first remission. These findings demonstrate the importance of baseline testing for accurate interpretation of mutation-based tumor monitoring assays for patients with AML and highlight the need for clinical trials to determine whether these complex mutation patterns correlate with clinical outcomes in AML.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37003397"
                        open
                      >
                        <summary class="article-expander__title">Epigenomic machinery regulating pediatric AML: Clonal expansion mechanisms, therapies, and future perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37003397/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a heterogeneous disease with a genetic, epigenetic, and transcriptional etiology mainly presenting somatic and germline abnormalities. AML incidence rises with age but can also occur during childhood. Pediatric AML (pAML) accounts for 15-20% of all pediatric leukemias and differs considerably from adult AML. Next-generation sequencing technologies have enabled the research community to &quot;paint&quot; the genomic and epigenomic landscape in order to identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37003397"
                        open
                      >
                        <summary class="article-expander__title">Epigenomic machinery regulating pediatric AML: Clonal expansion mechanisms, therapies, and future perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37003397/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a heterogeneous disease with a genetic, epigenetic, and transcriptional etiology mainly presenting somatic and germline abnormalities. AML incidence rises with age but can also occur during childhood. Pediatric AML (pAML) accounts for 15-20% of all pediatric leukemias and differs considerably from adult AML. Next-generation sequencing technologies have enabled the research community to &quot;paint&quot; the genomic and epigenomic landscape in order to identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37003397"
                        open
                      >
                        <summary class="article-expander__title">Epigenomic machinery regulating pediatric AML: Clonal expansion mechanisms, therapies, and future perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37003397/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a heterogeneous disease with a genetic, epigenetic, and transcriptional etiology mainly presenting somatic and germline abnormalities. AML incidence rises with age but can also occur during childhood. Pediatric AML (pAML) accounts for 15-20% of all pediatric leukemias and differs considerably from adult AML. Next-generation sequencing technologies have enabled the research community to &quot;paint&quot; the genomic and epigenomic landscape in order to identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37003397"
                        open
                      >
                        <summary class="article-expander__title">Epigenomic machinery regulating pediatric AML: Clonal expansion mechanisms, therapies, and future perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37003397/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a heterogeneous disease with a genetic, epigenetic, and transcriptional etiology mainly presenting somatic and germline abnormalities. AML incidence rises with age but can also occur during childhood. Pediatric AML (pAML) accounts for 15-20% of all pediatric leukemias and differs considerably from adult AML. Next-generation sequencing technologies have enabled the research community to &quot;paint&quot; the genomic and epigenomic landscape in order to identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37003397"
                        open
                      >
                        <summary class="article-expander__title">Epigenomic machinery regulating pediatric AML: clonal expansion mechanisms, therapies, and future perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37003397/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a heterogeneous disease with a genetic, epigenetic, and transcriptional etiology mainly presenting somatic and germline abnormalities. AML incidence rises with age but can also occur during childhood. Pediatric AML (pAML) accounts for 15-20% of all pediatric leukemias and differs considerably from adult AML. Next-generation sequencing technologies have enabled the research community to &quot;paint&quot; the genomic and epigenomic landscape in order to identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37003397"
                        open
                      >
                        <summary class="article-expander__title">Epigenomic machinery regulating pediatric AML: clonal expansion mechanisms, therapies, and future perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37003397/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a heterogeneous disease with a genetic, epigenetic, and transcriptional etiology mainly presenting somatic and germline abnormalities. AML incidence rises with age but can also occur during childhood. Pediatric AML (pAML) accounts for 15-20% of all pediatric leukemias and differs considerably from adult AML. Next-generation sequencing technologies have enabled the research community to &quot;paint&quot; the genomic and epigenomic landscape in order to identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37003397"
                        open
                      >
                        <summary class="article-expander__title">Epigenomic machinery regulating pediatric AML: clonal expansion mechanisms, therapies, and future perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37003397/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230413205532&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a heterogeneous disease with a genetic, epigenetic, and transcriptional etiology mainly presenting somatic and germline abnormalities. AML incidence rises with age but can also occur during childhood. Pediatric AML (pAML) accounts for 15-20% of all pediatric leukemias and differs considerably from adult AML. Next-generation sequencing technologies have enabled the research community to &quot;paint&quot; the genomic and epigenomic landscape in order to identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37003397"
                        open
                      >
                        <summary class="article-expander__title">Epigenomic machinery regulating pediatric AML: clonal expansion mechanisms, therapies, and future perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37003397/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230412205511&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a heterogeneous disease with a genetic, epigenetic, and transcriptional etiology mainly presenting somatic and germline abnormalities. AML incidence rises with age but can also occur during childhood. Pediatric AML (pAML) accounts for 15-20% of all pediatric leukemias and differs considerably from adult AML. Next-generation sequencing technologies have enabled the research community to &quot;paint&quot; the genomic and epigenomic landscape in order to identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37003397"
                        open
                      >
                        <summary class="article-expander__title">Epigenomic machinery regulating pediatric AML: clonal expansion mechanisms, therapies, and future perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37003397/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a heterogeneous disease with a genetic, epigenetic, and transcriptional etiology mainly presenting somatic and germline abnormalities. AML incidence rises with age but can also occur during childhood. Pediatric AML (pAML) accounts for 15-20% of all pediatric leukemias and differs considerably from adult AML. Next-generation sequencing technologies have enabled the research community to &quot;paint&quot; the genomic and epigenomic landscape in order to identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37003397"
                        open
                      >
                        <summary class="article-expander__title">Epigenomic machinery regulating pediatric AML: clonal expansion mechanisms, therapies, and future perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37003397/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a heterogeneous disease with a genetic, epigenetic, and transcriptional etiology mainly presenting somatic and germline abnormalities. AML incidence rises with age but can also occur during childhood. Pediatric AML (pAML) accounts for 15-20% of all pediatric leukemias and differs considerably from adult AML. Next-generation sequencing technologies have enabled the research community to &quot;paint&quot; the genomic and epigenomic landscape in order to identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37003397"
                        open
                      >
                        <summary class="article-expander__title">Epigenomic machinery regulating pediatric AML: clonal expansion mechanisms, therapies, and future perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37003397/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a heterogeneous disease with a genetic, epigenetic, and transcriptional etiology mainly presenting somatic and germline abnormalities. AML incidence rises with age but can also occur during childhood. Pediatric AML (pAML) accounts for 15-20% of all pediatric leukemias and differs considerably from adult AML. Next-generation sequencing technologies have enabled the research community to &quot;paint&quot; the genomic and epigenomic landscape in order to identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37003397"
                        open
                      >
                        <summary class="article-expander__title">Epigenomic machinery regulating pediatric AML: clonal expansion mechanisms, therapies, and future perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37003397/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a heterogeneous disease with a genetic, epigenetic, and transcriptional etiology mainly presenting somatic and germline abnormalities. AML incidence rises with age but can also occur during childhood. Pediatric AML (pAML) accounts for 15-20% of all pediatric leukemias and differs considerably from adult AML. Next-generation sequencing technologies have enabled the research community to &quot;paint&quot; the genomic and epigenomic landscape in order to identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37003397"
                        open
                      >
                        <summary class="article-expander__title">Epigenomic machinery regulating pediatric AML: clonal expansion mechanisms, therapies, and future perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37003397/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a heterogeneous disease with a genetic, epigenetic, and transcriptional etiology mainly presenting somatic and germline abnormalities. AML incidence rises with age but can also occur during childhood. Pediatric AML (pAML) accounts for 15-20% of all pediatric leukemias and differs considerably from adult AML. Next-generation sequencing technologies have enabled the research community to &quot;paint&quot; the genomic and epigenomic landscape in order to identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37003397"
                        open
                      >
                        <summary class="article-expander__title">Epigenomic machinery regulating pediatric AML: clonal expansion mechanisms, therapies, and future perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37003397/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a heterogeneous disease with a genetic, epigenetic, and transcriptional etiology mainly presenting somatic and germline abnormalities. AML incidence rises with age but can also occur during childhood. Pediatric AML (pAML) accounts for 15-20% of all pediatric leukemias and differs considerably from adult AML. Next-generation sequencing technologies have enabled the research community to &quot;paint&quot; the genomic and epigenomic landscape in order to identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37003397"
                        open
                      >
                        <summary class="article-expander__title">Epigenomic machinery regulating pediatric AML: clonal expansion mechanisms, therapies, and future perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37003397/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a heterogeneous disease with a genetic, epigenetic, and transcriptional etiology mainly presenting somatic and germline abnormalities. AML incidence rises with age but can also occur during childhood. Pediatric AML (pAML) accounts for 15-20% of all pediatric leukemias and differs considerably from adult AML. Next-generation sequencing technologies have enabled the research community to &quot;paint&quot; the genomic and epigenomic landscape in order to identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37003397"
                        open
                      >
                        <summary class="article-expander__title">Epigenomic machinery regulating pediatric AML: clonal expansion mechanisms, therapies, and future perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37003397/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a heterogeneous disease with a genetic, epigenetic, and transcriptional etiology mainly presenting somatic and germline abnormalities. AML incidence rises with age but can also occur during childhood. Pediatric AML (pAML) accounts for 15-20% of all pediatric leukemias and differs considerably from adult AML. Next-generation sequencing technologies have enabled the research community to &quot;paint&quot; the genomic and epigenomic landscape in order to identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37003397"
                        open
                      >
                        <summary class="article-expander__title">Epigenomic machinery regulating pediatric AML: clonal expansion mechanisms, therapies, and future perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37003397/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a heterogeneous disease with a genetic, epigenetic, and transcriptional etiology mainly presenting somatic and germline abnormalities. AML incidence rises with age but can also occur during childhood. Pediatric AML (pAML) accounts for 15-20% of all pediatric leukemias and differs considerably from adult AML. Next-generation sequencing technologies have enabled the research community to &quot;paint&quot; the genomic and epigenomic landscape in order to identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37003397"
                        open
                      >
                        <summary class="article-expander__title">Epigenomic machinery regulating pediatric AML: clonal expansion mechanisms, therapies, and future perspectives</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37003397/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Acute myeloid leukemia (AML) is a heterogeneous disease with a genetic, epigenetic, and transcriptional etiology mainly presenting somatic and germline abnormalities. AML incidence rises with age but can also occur during childhood. Pediatric AML (pAML) accounts for 15-20% of all pediatric leukemias and differs considerably from adult AML. Next-generation sequencing technologies have enabled the research community to &quot;paint&quot; the genomic and epigenomic landscape in order to identify...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-03-31 datetime="2023-03-31T10:00:00.000Z">2023-03-31</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-03-31 datetime="2023-03-31T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37002477"
                        open
                      >
                        <summary class="article-expander__title">Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37002477/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230412205510&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms are characterized by the acquisition at the hematopoietic stem cell level of driver mutations targeting the JAK/STAT pathway. In addition, they also often exhibit additional mutations targeting various pathways such as intracellular signalling, epigenetics, mRNA splicing or transcription. The natural history of myeloproliferative neoplasms is usually marked by a chronic phase of variable duration depending on the disease subtype, which can be followed by an...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37002477"
                        open
                      >
                        <summary class="article-expander__title">Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37002477/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms are characterized by the acquisition at the hematopoietic stem cell level of driver mutations targeting the JAK/STAT pathway. In addition, they also often exhibit additional mutations targeting various pathways such as intracellular signalling, epigenetics, mRNA splicing or transcription. The natural history of myeloproliferative neoplasms is usually marked by a chronic phase of variable duration depending on the disease subtype, which can be followed by an...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37002477"
                        open
                      >
                        <summary class="article-expander__title">Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37002477/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms are characterized by the acquisition at the hematopoietic stem cell level of driver mutations targeting the JAK/STAT pathway. In addition, they also often exhibit additional mutations targeting various pathways such as intracellular signalling, epigenetics, mRNA splicing or transcription. The natural history of myeloproliferative neoplasms is usually marked by a chronic phase of variable duration depending on the disease subtype, which can be followed by an...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37002477"
                        open
                      >
                        <summary class="article-expander__title">Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37002477/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms are characterized by the acquisition at the hematopoietic stem cell level of driver mutations targeting the JAK/STAT pathway. In addition, they also often exhibit additional mutations targeting various pathways such as intracellular signalling, epigenetics, mRNA splicing or transcription. The natural history of myeloproliferative neoplasms is usually marked by a chronic phase of variable duration depending on the disease subtype, which can be followed by an...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37002477"
                        open
                      >
                        <summary class="article-expander__title">Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37002477/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms are characterized by the acquisition at the hematopoietic stem cell level of driver mutations targeting the JAK/STAT pathway. In addition, they also often exhibit additional mutations targeting various pathways such as intracellular signalling, epigenetics, mRNA splicing or transcription. The natural history of myeloproliferative neoplasms is usually marked by a chronic phase of variable duration depending on the disease subtype, which can be followed by an...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37002477"
                        open
                      >
                        <summary class="article-expander__title">Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37002477/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms are characterized by the acquisition at the hematopoietic stem cell level of driver mutations targeting the JAK/STAT pathway. In addition, they also often exhibit additional mutations targeting various pathways such as intracellular signalling, epigenetics, mRNA splicing or transcription. The natural history of myeloproliferative neoplasms is usually marked by a chronic phase of variable duration depending on the disease subtype, which can be followed by an...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37002477"
                        open
                      >
                        <summary class="article-expander__title">Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37002477/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms are characterized by the acquisition at the hematopoietic stem cell level of driver mutations targeting the JAK/STAT pathway. In addition, they also often exhibit additional mutations targeting various pathways such as intracellular signalling, epigenetics, mRNA splicing or transcription. The natural history of myeloproliferative neoplasms is usually marked by a chronic phase of variable duration depending on the disease subtype, which can be followed by an...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37002477"
                        open
                      >
                        <summary class="article-expander__title">Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37002477/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms are characterized by the acquisition at the hematopoietic stem cell level of driver mutations targeting the JAK/STAT pathway. In addition, they also often exhibit additional mutations targeting various pathways such as intracellular signalling, epigenetics, mRNA splicing or transcription. The natural history of myeloproliferative neoplasms is usually marked by a chronic phase of variable duration depending on the disease subtype, which can be followed by an...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37002477"
                        open
                      >
                        <summary class="article-expander__title">Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37002477/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms are characterized by the acquisition at the hematopoietic stem cell level of driver mutations targeting the JAK/STAT pathway. In addition, they also often exhibit additional mutations targeting various pathways such as intracellular signalling, epigenetics, mRNA splicing or transcription. The natural history of myeloproliferative neoplasms is usually marked by a chronic phase of variable duration depending on the disease subtype, which can be followed by an...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37002477"
                        open
                      >
                        <summary class="article-expander__title">Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37002477/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms are characterized by the acquisition at the hematopoietic stem cell level of driver mutations targeting the JAK/STAT pathway. In addition, they also often exhibit additional mutations targeting various pathways such as intracellular signalling, epigenetics, mRNA splicing or transcription. The natural history of myeloproliferative neoplasms is usually marked by a chronic phase of variable duration depending on the disease subtype, which can be followed by an...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37002477"
                        open
                      >
                        <summary class="article-expander__title">Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37002477/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms are characterized by the acquisition at the hematopoietic stem cell level of driver mutations targeting the JAK/STAT pathway. In addition, they also often exhibit additional mutations targeting various pathways such as intracellular signalling, epigenetics, mRNA splicing or transcription. The natural history of myeloproliferative neoplasms is usually marked by a chronic phase of variable duration depending on the disease subtype, which can be followed by an...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:37002477"
                        open
                      >
                        <summary class="article-expander__title">Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/37002477/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms are characterized by the acquisition at the hematopoietic stem cell level of driver mutations targeting the JAK/STAT pathway. In addition, they also often exhibit additional mutations targeting various pathways such as intracellular signalling, epigenetics, mRNA splicing or transcription. The natural history of myeloproliferative neoplasms is usually marked by a chronic phase of variable duration depending on the disease subtype, which can be followed by an...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-03-30 datetime="2023-03-30T10:00:00.000Z">2023-03-30</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-03-30 datetime="2023-03-30T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36994199"
                        open
                      >
                        <summary class="article-expander__title">An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36994199/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230412205510&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The concept of personalized medicine in cancer has emerged rapidly with the advancement of genome sequencing and the identification of clinically relevant variants that contribute to disease prognosis and facilitates targeted therapy options. In this study, we propose to validate a whole exome-based tumor molecular profiling for DNA and RNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993558"
                        open
                      >
                        <summary class="article-expander__title">Analysis of evolutionary dynamics and clonal architecture in prostate cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993558/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230412205510&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The extent to which clinical and genomic characteristics associate with prostate cancer clonal architecture, tumor evolution, and therapeutic response remains unclear. Here, we reconstructed the clonal architecture and evolutionary trajectories of 845 prostate cancer tumors with harmonized clinical and molecular data. We observed that tumors from patients who self-reported as Black had more linear and monoclonal architectures, despite these men having higher rates of biochemical recurrence. This...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993286"
                        open
                      >
                        <summary class="article-expander__title">Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993286/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230412205510&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancer represents a broad spectrum of molecularly and morphologically diverse diseases. Individuals with the same clinical diagnosis can have tumors with drastically different molecular profiles and clinical response to treatment. It remains unclear when these differences arise during disease course and why some tumors are addicted to one oncogenic pathway over another. Somatic genomic aberrations occur within the context of an individual&#x27;s germline genome, which can vary across millions of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36994199"
                        open
                      >
                        <summary class="article-expander__title">An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36994199/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The concept of personalized medicine in cancer has emerged rapidly with the advancement of genome sequencing and the identification of clinically relevant variants that contribute to disease prognosis and facilitates targeted therapy options. In this study, we propose to validate a whole exome-based tumor molecular profiling for DNA and RNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993558"
                        open
                      >
                        <summary class="article-expander__title">Analysis of evolutionary dynamics and clonal architecture in prostate cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993558/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The extent to which clinical and genomic characteristics associate with prostate cancer clonal architecture, tumor evolution, and therapeutic response remains unclear. Here, we reconstructed the clonal architecture and evolutionary trajectories of 845 prostate cancer tumors with harmonized clinical and molecular data. We observed that tumors from patients who self-reported as Black had more linear and monoclonal architectures, despite these men having higher rates of biochemical recurrence. This...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993286"
                        open
                      >
                        <summary class="article-expander__title">Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993286/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancer represents a broad spectrum of molecularly and morphologically diverse diseases. Individuals with the same clinical diagnosis can have tumors with drastically different molecular profiles and clinical response to treatment. It remains unclear when these differences arise during disease course and why some tumors are addicted to one oncogenic pathway over another. Somatic genomic aberrations occur within the context of an individual&#x27;s germline genome, which can vary across millions of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36994199"
                        open
                      >
                        <summary class="article-expander__title">An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36994199/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The concept of personalized medicine in cancer has emerged rapidly with the advancement of genome sequencing and the identification of clinically relevant variants that contribute to disease prognosis and facilitates targeted therapy options. In this study, we propose to validate a whole exome-based tumor molecular profiling for DNA and RNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993558"
                        open
                      >
                        <summary class="article-expander__title">Analysis of evolutionary dynamics and clonal architecture in prostate cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993558/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The extent to which clinical and genomic characteristics associate with prostate cancer clonal architecture, tumor evolution, and therapeutic response remains unclear. Here, we reconstructed the clonal architecture and evolutionary trajectories of 845 prostate cancer tumors with harmonized clinical and molecular data. We observed that tumors from patients who self-reported as Black had more linear and monoclonal architectures, despite these men having higher rates of biochemical recurrence. This...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993286"
                        open
                      >
                        <summary class="article-expander__title">Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993286/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancer represents a broad spectrum of molecularly and morphologically diverse diseases. Individuals with the same clinical diagnosis can have tumors with drastically different molecular profiles and clinical response to treatment. It remains unclear when these differences arise during disease course and why some tumors are addicted to one oncogenic pathway over another. Somatic genomic aberrations occur within the context of an individual&#x27;s germline genome, which can vary across millions of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36994199"
                        open
                      >
                        <summary class="article-expander__title">An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36994199/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The concept of personalized medicine in cancer has emerged rapidly with the advancement of genome sequencing and the identification of clinically relevant variants that contribute to disease prognosis and facilitates targeted therapy options. In this study, we propose to validate a whole exome-based tumor molecular profiling for DNA and RNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993558"
                        open
                      >
                        <summary class="article-expander__title">Analysis of evolutionary dynamics and clonal architecture in prostate cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993558/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The extent to which clinical and genomic characteristics associate with prostate cancer clonal architecture, tumor evolution, and therapeutic response remains unclear. Here, we reconstructed the clonal architecture and evolutionary trajectories of 845 prostate cancer tumors with harmonized clinical and molecular data. We observed that tumors from patients who self-reported as Black had more linear and monoclonal architectures, despite these men having higher rates of biochemical recurrence. This...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993286"
                        open
                      >
                        <summary class="article-expander__title">Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993286/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancer represents a broad spectrum of molecularly and morphologically diverse diseases. Individuals with the same clinical diagnosis can have tumors with drastically different molecular profiles and clinical response to treatment. It remains unclear when these differences arise during disease course and why some tumors are addicted to one oncogenic pathway over another. Somatic genomic aberrations occur within the context of an individual&#x27;s germline genome, which can vary across millions of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36994199"
                        open
                      >
                        <summary class="article-expander__title">An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36994199/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The concept of personalized medicine in cancer has emerged rapidly with the advancement of genome sequencing and the identification of clinically relevant variants that contribute to disease prognosis and facilitates targeted therapy options. In this study, we propose to validate a whole exome-based tumor molecular profiling for DNA and RNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993558"
                        open
                      >
                        <summary class="article-expander__title">Analysis of evolutionary dynamics and clonal architecture in prostate cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993558/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The extent to which clinical and genomic characteristics associate with prostate cancer clonal architecture, tumor evolution, and therapeutic response remains unclear. Here, we reconstructed the clonal architecture and evolutionary trajectories of 845 prostate cancer tumors with harmonized clinical and molecular data. We observed that tumors from patients who self-reported as Black had more linear and monoclonal architectures, despite these men having higher rates of biochemical recurrence. This...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993286"
                        open
                      >
                        <summary class="article-expander__title">Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993286/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancer represents a broad spectrum of molecularly and morphologically diverse diseases. Individuals with the same clinical diagnosis can have tumors with drastically different molecular profiles and clinical response to treatment. It remains unclear when these differences arise during disease course and why some tumors are addicted to one oncogenic pathway over another. Somatic genomic aberrations occur within the context of an individual&#x27;s germline genome, which can vary across millions of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36994199"
                        open
                      >
                        <summary class="article-expander__title">An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36994199/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The concept of personalized medicine in cancer has emerged rapidly with the advancement of genome sequencing and the identification of clinically relevant variants that contribute to disease prognosis and facilitates targeted therapy options. In this study, we propose to validate a whole exome-based tumor molecular profiling for DNA and RNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993558"
                        open
                      >
                        <summary class="article-expander__title">Analysis of evolutionary dynamics and clonal architecture in prostate cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993558/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The extent to which clinical and genomic characteristics associate with prostate cancer clonal architecture, tumor evolution, and therapeutic response remains unclear. Here, we reconstructed the clonal architecture and evolutionary trajectories of 845 prostate cancer tumors with harmonized clinical and molecular data. We observed that tumors from patients who self-reported as Black had more linear and monoclonal architectures, despite these men having higher rates of biochemical recurrence. This...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993286"
                        open
                      >
                        <summary class="article-expander__title">Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993286/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancer represents a broad spectrum of molecularly and morphologically diverse diseases. Individuals with the same clinical diagnosis can have tumors with drastically different molecular profiles and clinical response to treatment. It remains unclear when these differences arise during disease course and why some tumors are addicted to one oncogenic pathway over another. Somatic genomic aberrations occur within the context of an individual&#x27;s germline genome, which can vary across millions of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36994199"
                        open
                      >
                        <summary class="article-expander__title">An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36994199/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The concept of personalized medicine in cancer has emerged rapidly with the advancement of genome sequencing and the identification of clinically relevant variants that contribute to disease prognosis and facilitates targeted therapy options. In this study, we propose to validate a whole exome-based tumor molecular profiling for DNA and RNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993558"
                        open
                      >
                        <summary class="article-expander__title">Analysis of evolutionary dynamics and clonal architecture in prostate cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993558/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The extent to which clinical and genomic characteristics associate with prostate cancer clonal architecture, tumor evolution, and therapeutic response remains unclear. Here, we reconstructed the clonal architecture and evolutionary trajectories of 845 prostate cancer tumors with harmonized clinical and molecular data. We observed that tumors from patients who self-reported as Black had more linear and monoclonal architectures, despite these men having higher rates of biochemical recurrence. This...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993286"
                        open
                      >
                        <summary class="article-expander__title">Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993286/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancer represents a broad spectrum of molecularly and morphologically diverse diseases. Individuals with the same clinical diagnosis can have tumors with drastically different molecular profiles and clinical response to treatment. It remains unclear when these differences arise during disease course and why some tumors are addicted to one oncogenic pathway over another. Somatic genomic aberrations occur within the context of an individual&#x27;s germline genome, which can vary across millions of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36994199"
                        open
                      >
                        <summary class="article-expander__title">An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36994199/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The concept of personalized medicine in cancer has emerged rapidly with the advancement of genome sequencing and the identification of clinically relevant variants that contribute to disease prognosis and facilitates targeted therapy options. In this study, we propose to validate a whole exome-based tumor molecular profiling for DNA and RNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993558"
                        open
                      >
                        <summary class="article-expander__title">Analysis of evolutionary dynamics and clonal architecture in prostate cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993558/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The extent to which clinical and genomic characteristics associate with prostate cancer clonal architecture, tumor evolution, and therapeutic response remains unclear. Here, we reconstructed the clonal architecture and evolutionary trajectories of 845 prostate cancer tumors with harmonized clinical and molecular data. We observed that tumors from patients who self-reported as Black had more linear and monoclonal architectures, despite these men having higher rates of biochemical recurrence. This...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993286"
                        open
                      >
                        <summary class="article-expander__title">Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993286/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancer represents a broad spectrum of molecularly and morphologically diverse diseases. Individuals with the same clinical diagnosis can have tumors with drastically different molecular profiles and clinical response to treatment. It remains unclear when these differences arise during disease course and why some tumors are addicted to one oncogenic pathway over another. Somatic genomic aberrations occur within the context of an individual&#x27;s germline genome, which can vary across millions of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36994199"
                        open
                      >
                        <summary class="article-expander__title">An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36994199/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The concept of personalized medicine in cancer has emerged rapidly with the advancement of genome sequencing and the identification of clinically relevant variants that contribute to disease prognosis and facilitates targeted therapy options. In this study, we propose to validate a whole exome-based tumor molecular profiling for DNA and RNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993558"
                        open
                      >
                        <summary class="article-expander__title">Analysis of evolutionary dynamics and clonal architecture in prostate cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993558/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The extent to which clinical and genomic characteristics associate with prostate cancer clonal architecture, tumor evolution, and therapeutic response remains unclear. Here, we reconstructed the clonal architecture and evolutionary trajectories of 845 prostate cancer tumors with harmonized clinical and molecular data. We observed that tumors from patients who self-reported as Black had more linear and monoclonal architectures, despite these men having higher rates of biochemical recurrence. This...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993286"
                        open
                      >
                        <summary class="article-expander__title">Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993286/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancer represents a broad spectrum of molecularly and morphologically diverse diseases. Individuals with the same clinical diagnosis can have tumors with drastically different molecular profiles and clinical response to treatment. It remains unclear when these differences arise during disease course and why some tumors are addicted to one oncogenic pathway over another. Somatic genomic aberrations occur within the context of an individual&#x27;s germline genome, which can vary across millions of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36994199"
                        open
                      >
                        <summary class="article-expander__title">An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36994199/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The concept of personalized medicine in cancer has emerged rapidly with the advancement of genome sequencing and the identification of clinically relevant variants that contribute to disease prognosis and facilitates targeted therapy options. In this study, we propose to validate a whole exome-based tumor molecular profiling for DNA and RNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993558"
                        open
                      >
                        <summary class="article-expander__title">Analysis of evolutionary dynamics and clonal architecture in prostate cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993558/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The extent to which clinical and genomic characteristics associate with prostate cancer clonal architecture, tumor evolution, and therapeutic response remains unclear. Here, we reconstructed the clonal architecture and evolutionary trajectories of 845 prostate cancer tumors with harmonized clinical and molecular data. We observed that tumors from patients who self-reported as Black had more linear and monoclonal architectures, despite these men having higher rates of biochemical recurrence. This...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993286"
                        open
                      >
                        <summary class="article-expander__title">Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993286/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancer represents a broad spectrum of molecularly and morphologically diverse diseases. Individuals with the same clinical diagnosis can have tumors with drastically different molecular profiles and clinical response to treatment. It remains unclear when these differences arise during disease course and why some tumors are addicted to one oncogenic pathway over another. Somatic genomic aberrations occur within the context of an individual&#x27;s germline genome, which can vary across millions of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36994199"
                        open
                      >
                        <summary class="article-expander__title">An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36994199/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The concept of personalized medicine in cancer has emerged rapidly with the advancement of genome sequencing and the identification of clinically relevant variants that contribute to disease prognosis and facilitates targeted therapy options. In this study, we propose to validate a whole exome-based tumor molecular profiling for DNA and RNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993558"
                        open
                      >
                        <summary class="article-expander__title">Analysis of evolutionary dynamics and clonal architecture in prostate cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993558/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The extent to which clinical and genomic characteristics associate with prostate cancer clonal architecture, tumor evolution, and therapeutic response remains unclear. Here, we reconstructed the clonal architecture and evolutionary trajectories of 845 prostate cancer tumors with harmonized clinical and molecular data. We observed that tumors from patients who self-reported as Black had more linear and monoclonal architectures, despite these men having higher rates of biochemical recurrence. This...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993286"
                        open
                      >
                        <summary class="article-expander__title">Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993286/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancer represents a broad spectrum of molecularly and morphologically diverse diseases. Individuals with the same clinical diagnosis can have tumors with drastically different molecular profiles and clinical response to treatment. It remains unclear when these differences arise during disease course and why some tumors are addicted to one oncogenic pathway over another. Somatic genomic aberrations occur within the context of an individual&#x27;s germline genome, which can vary across millions of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36994199"
                        open
                      >
                        <summary class="article-expander__title">An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36994199/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The concept of personalized medicine in cancer has emerged rapidly with the advancement of genome sequencing and the identification of clinically relevant variants that contribute to disease prognosis and facilitates targeted therapy options. In this study, we propose to validate a whole exome-based tumor molecular profiling for DNA and RNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993558"
                        open
                      >
                        <summary class="article-expander__title">Analysis of evolutionary dynamics and clonal architecture in prostate cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993558/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The extent to which clinical and genomic characteristics associate with prostate cancer clonal architecture, tumor evolution, and therapeutic response remains unclear. Here, we reconstructed the clonal architecture and evolutionary trajectories of 845 prostate cancer tumors with harmonized clinical and molecular data. We observed that tumors from patients who self-reported as Black had more linear and monoclonal architectures, despite these men having higher rates of biochemical recurrence. This...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993286"
                        open
                      >
                        <summary class="article-expander__title">Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993286/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancer represents a broad spectrum of molecularly and morphologically diverse diseases. Individuals with the same clinical diagnosis can have tumors with drastically different molecular profiles and clinical response to treatment. It remains unclear when these differences arise during disease course and why some tumors are addicted to one oncogenic pathway over another. Somatic genomic aberrations occur within the context of an individual&#x27;s germline genome, which can vary across millions of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36994199"
                        open
                      >
                        <summary class="article-expander__title">An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36994199/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The concept of personalized medicine in cancer has emerged rapidly with the advancement of genome sequencing and the identification of clinically relevant variants that contribute to disease prognosis and facilitates targeted therapy options. In this study, we propose to validate a whole exome-based tumor molecular profiling for DNA and RNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993558"
                        open
                      >
                        <summary class="article-expander__title">Analysis of evolutionary dynamics and clonal architecture in prostate cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993558/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The extent to which clinical and genomic characteristics associate with prostate cancer clonal architecture, tumor evolution, and therapeutic response remains unclear. Here, we reconstructed the clonal architecture and evolutionary trajectories of 845 prostate cancer tumors with harmonized clinical and molecular data. We observed that tumors from patients who self-reported as Black had more linear and monoclonal architectures, despite these men having higher rates of biochemical recurrence. This...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993286"
                        open
                      >
                        <summary class="article-expander__title">Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993286/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancer represents a broad spectrum of molecularly and morphologically diverse diseases. Individuals with the same clinical diagnosis can have tumors with drastically different molecular profiles and clinical response to treatment. It remains unclear when these differences arise during disease course and why some tumors are addicted to one oncogenic pathway over another. Somatic genomic aberrations occur within the context of an individual&#x27;s germline genome, which can vary across millions of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36994199"
                        open
                      >
                        <summary class="article-expander__title">An absolute approach to using whole exome DNA and RNA workflow for cancer biomarker testing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36994199/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>INTRODUCTION: The concept of personalized medicine in cancer has emerged rapidly with the advancement of genome sequencing and the identification of clinically relevant variants that contribute to disease prognosis and facilitates targeted therapy options. In this study, we propose to validate a whole exome-based tumor molecular profiling for DNA and RNA from formalin-fixed paraffin-embedded (FFPE) tumor tissue.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993558"
                        open
                      >
                        <summary class="article-expander__title">Analysis of evolutionary dynamics and clonal architecture in prostate cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993558/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The extent to which clinical and genomic characteristics associate with prostate cancer clonal architecture, tumor evolution, and therapeutic response remains unclear. Here, we reconstructed the clonal architecture and evolutionary trajectories of 845 prostate cancer tumors with harmonized clinical and molecular data. We observed that tumors from patients who self-reported as Black had more linear and monoclonal architectures, despite these men having higher rates of biochemical recurrence. This...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36993286"
                        open
                      >
                        <summary class="article-expander__title">Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36993286/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Cancer represents a broad spectrum of molecularly and morphologically diverse diseases. Individuals with the same clinical diagnosis can have tumors with drastically different molecular profiles and clinical response to treatment. It remains unclear when these differences arise during disease course and why some tumors are addicted to one oncogenic pathway over another. Somatic genomic aberrations occur within the context of an individual&#x27;s germline genome, which can vary across millions of...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-03-29 datetime="2023-03-29T10:00:00.000Z">2023-03-29</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-03-29 datetime="2023-03-29T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990546"
                        open
                      >
                        <summary class="article-expander__title">Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990546/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: HSM is frequent in candidates for AVR, is associated with an enrichment of proinflammatory cardiac monocyte-derived macrophages, and predisposes to a higher incidence of POAF. HSM assessment may be useful in the personalized management of patients in the perioperative period. (Post-Operative Myocardial Incident &amp; Atrial Fibrillation [POMI-AF]; NCT03376165).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230420205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990546"
                        open
                      >
                        <summary class="article-expander__title">Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990546/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: HSM is frequent in candidates for AVR, is associated with an enrichment of proinflammatory cardiac monocyte-derived macrophages, and predisposes to a higher incidence of POAF. HSM assessment may be useful in the personalized management of patients in the perioperative period. (Post-Operative Myocardial Incident &amp; Atrial Fibrillation [POMI-AF]; NCT03376165).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36988570"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations and human longevity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36988570/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230419205601&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) are structural alterations associated with aging, cancer, cardiovascular disease, infectious diseases, and mortality. The distribution of mCAs in centenarians and individuals with familial longevity is poorly understood. We used MOsaic CHromosomal Alteration (MoChA) to discover mCAs in 2050 centenarians, offspring, and 248 controls from the New England Centenarian Study (NECS) and in 3642 subjects with familial longevity and 920 spousal controls from the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990546"
                        open
                      >
                        <summary class="article-expander__title">Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990546/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: HSM is frequent in candidates for AVR, is associated with an enrichment of proinflammatory cardiac monocyte-derived macrophages, and predisposes to a higher incidence of POAF. HSM assessment may be useful in the personalized management of patients in the perioperative period. (Post-Operative Myocardial Incident &amp; Atrial Fibrillation [POMI-AF]; NCT03376165).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36988570"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations and human longevity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36988570/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230418205831&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) are structural alterations associated with aging, cancer, cardiovascular disease, infectious diseases, and mortality. The distribution of mCAs in centenarians and individuals with familial longevity is poorly understood. We used MOsaic CHromosomal Alteration (MoChA) to discover mCAs in 2050 centenarians, offspring, and 248 controls from the New England Centenarian Study (NECS) and in 3642 subjects with familial longevity and 920 spousal controls from the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990546"
                        open
                      >
                        <summary class="article-expander__title">Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990546/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: HSM is frequent in candidates for AVR, is associated with an enrichment of proinflammatory cardiac monocyte-derived macrophages, and predisposes to a higher incidence of POAF. HSM assessment may be useful in the personalized management of patients in the perioperative period. (Post-Operative Myocardial Incident &amp; Atrial Fibrillation [POMI-AF]; NCT03376165).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36988570"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations and human longevity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36988570/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) are structural alterations associated with aging, cancer, cardiovascular disease, infectious diseases, and mortality. The distribution of mCAs in centenarians and individuals with familial longevity is poorly understood. We used MOsaic CHromosomal Alteration (MoChA) to discover mCAs in 2050 centenarians, offspring, and 248 controls from the New England Centenarian Study (NECS) and in 3642 subjects with familial longevity and 920 spousal controls from the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36983964"
                        open
                      >
                        <summary class="article-expander__title">Sweet Syndrome Associated with Myelodysplastic Syndrome-A Review of a Multidisciplinary Approach</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36983964/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230417205516&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Sweet syndrome (SS) is a rare disease described as a febrile neutrophilic dermatosis with acute onset, the pathogenesis of which has not yet been elucidated. The syndrome is characterized by the sudden onset of erythematous infiltrated papules or plaques located on the upper body and is associated with fever, leukocytosis and neutrophilia. The lesions show a dense dermal infiltration with mature neutrophils. The condition is responsive to systemic steroids. The central nervous system, bones,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990546"
                        open
                      >
                        <summary class="article-expander__title">Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990546/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: HSM is frequent in candidates for AVR, is associated with an enrichment of proinflammatory cardiac monocyte-derived macrophages, and predisposes to a higher incidence of POAF. HSM assessment may be useful in the personalized management of patients in the perioperative period. (Post-Operative Myocardial Incident &amp; Atrial Fibrillation [POMI-AF]; NCT03376165).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36988570"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations and human longevity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36988570/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) are structural alterations associated with aging, cancer, cardiovascular disease, infectious diseases, and mortality. The distribution of mCAs in centenarians and individuals with familial longevity is poorly understood. We used MOsaic CHromosomal Alteration (MoChA) to discover mCAs in 2050 centenarians, offspring, and 248 controls from the New England Centenarian Study (NECS) and in 3642 subjects with familial longevity and 920 spousal controls from the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36983964"
                        open
                      >
                        <summary class="article-expander__title">Sweet Syndrome Associated with Myelodysplastic Syndrome-A Review of a Multidisciplinary Approach</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36983964/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230416205720&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Sweet syndrome (SS) is a rare disease described as a febrile neutrophilic dermatosis with acute onset, the pathogenesis of which has not yet been elucidated. The syndrome is characterized by the sudden onset of erythematous infiltrated papules or plaques located on the upper body and is associated with fever, leukocytosis and neutrophilia. The lesions show a dense dermal infiltration with mature neutrophils. The condition is responsive to systemic steroids. The central nervous system, bones,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990546"
                        open
                      >
                        <summary class="article-expander__title">Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990546/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: HSM is frequent in candidates for AVR, is associated with an enrichment of proinflammatory cardiac monocyte-derived macrophages, and predisposes to a higher incidence of POAF. HSM assessment may be useful in the personalized management of patients in the perioperative period. (Post-Operative Myocardial Incident &amp; Atrial Fibrillation [POMI-AF]; NCT03376165).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36988570"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations and human longevity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36988570/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) are structural alterations associated with aging, cancer, cardiovascular disease, infectious diseases, and mortality. The distribution of mCAs in centenarians and individuals with familial longevity is poorly understood. We used MOsaic CHromosomal Alteration (MoChA) to discover mCAs in 2050 centenarians, offspring, and 248 controls from the New England Centenarian Study (NECS) and in 3642 subjects with familial longevity and 920 spousal controls from the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36983964"
                        open
                      >
                        <summary class="article-expander__title">Sweet Syndrome Associated with Myelodysplastic Syndrome-A Review of a Multidisciplinary Approach</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36983964/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230415205856&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Sweet syndrome (SS) is a rare disease described as a febrile neutrophilic dermatosis with acute onset, the pathogenesis of which has not yet been elucidated. The syndrome is characterized by the sudden onset of erythematous infiltrated papules or plaques located on the upper body and is associated with fever, leukocytosis and neutrophilia. The lesions show a dense dermal infiltration with mature neutrophils. The condition is responsive to systemic steroids. The central nervous system, bones,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990546"
                        open
                      >
                        <summary class="article-expander__title">Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990546/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: HSM is frequent in candidates for AVR, is associated with an enrichment of proinflammatory cardiac monocyte-derived macrophages, and predisposes to a higher incidence of POAF. HSM assessment may be useful in the personalized management of patients in the perioperative period. (Post-Operative Myocardial Incident &amp; Atrial Fibrillation [POMI-AF]; NCT03376165).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36988570"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations and human longevity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36988570/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) are structural alterations associated with aging, cancer, cardiovascular disease, infectious diseases, and mortality. The distribution of mCAs in centenarians and individuals with familial longevity is poorly understood. We used MOsaic CHromosomal Alteration (MoChA) to discover mCAs in 2050 centenarians, offspring, and 248 controls from the New England Centenarian Study (NECS) and in 3642 subjects with familial longevity and 920 spousal controls from the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36983964"
                        open
                      >
                        <summary class="article-expander__title">Sweet Syndrome Associated with Myelodysplastic Syndrome-A Review of a Multidisciplinary Approach</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36983964/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230414205813&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Sweet syndrome (SS) is a rare disease described as a febrile neutrophilic dermatosis with acute onset, the pathogenesis of which has not yet been elucidated. The syndrome is characterized by the sudden onset of erythematous infiltrated papules or plaques located on the upper body and is associated with fever, leukocytosis and neutrophilia. The lesions show a dense dermal infiltration with mature neutrophils. The condition is responsive to systemic steroids. The central nervous system, bones,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990546"
                        open
                      >
                        <summary class="article-expander__title">Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990546/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230413205532&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: HSM is frequent in candidates for AVR, is associated with an enrichment of proinflammatory cardiac monocyte-derived macrophages, and predisposes to a higher incidence of POAF. HSM assessment may be useful in the personalized management of patients in the perioperative period. (Post-Operative Myocardial Incident &amp; Atrial Fibrillation [POMI-AF]; NCT03376165).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230413205532&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230413205532&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36988570"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations and human longevity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36988570/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230413205532&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) are structural alterations associated with aging, cancer, cardiovascular disease, infectious diseases, and mortality. The distribution of mCAs in centenarians and individuals with familial longevity is poorly understood. We used MOsaic CHromosomal Alteration (MoChA) to discover mCAs in 2050 centenarians, offspring, and 248 controls from the New England Centenarian Study (NECS) and in 3642 subjects with familial longevity and 920 spousal controls from the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36983964"
                        open
                      >
                        <summary class="article-expander__title">Sweet Syndrome Associated with Myelodysplastic Syndrome-A Review of a Multidisciplinary Approach</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36983964/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230413205532&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Sweet syndrome (SS) is a rare disease described as a febrile neutrophilic dermatosis with acute onset, the pathogenesis of which has not yet been elucidated. The syndrome is characterized by the sudden onset of erythematous infiltrated papules or plaques located on the upper body and is associated with fever, leukocytosis and neutrophilia. The lesions show a dense dermal infiltration with mature neutrophils. The condition is responsive to systemic steroids. The central nervous system, bones,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990546"
                        open
                      >
                        <summary class="article-expander__title">Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990546/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230412205511&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: HSM is frequent in candidates for AVR, is associated with an enrichment of proinflammatory cardiac monocyte-derived macrophages, and predisposes to a higher incidence of POAF. HSM assessment may be useful in the personalized management of patients in the perioperative period. (Post-Operative Myocardial Incident &amp; Atrial Fibrillation [POMI-AF]; NCT03376165).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230412205511&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230412205511&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36988570"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations and human longevity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36988570/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230412205511&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) are structural alterations associated with aging, cancer, cardiovascular disease, infectious diseases, and mortality. The distribution of mCAs in centenarians and individuals with familial longevity is poorly understood. We used MOsaic CHromosomal Alteration (MoChA) to discover mCAs in 2050 centenarians, offspring, and 248 controls from the New England Centenarian Study (NECS) and in 3642 subjects with familial longevity and 920 spousal controls from the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36983964"
                        open
                      >
                        <summary class="article-expander__title">Sweet Syndrome Associated with Myelodysplastic Syndrome-A Review of a Multidisciplinary Approach</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36983964/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230412205511&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Sweet syndrome (SS) is a rare disease described as a febrile neutrophilic dermatosis with acute onset, the pathogenesis of which has not yet been elucidated. The syndrome is characterized by the sudden onset of erythematous infiltrated papules or plaques located on the upper body and is associated with fever, leukocytosis and neutrophilia. The lesions show a dense dermal infiltration with mature neutrophils. The condition is responsive to systemic steroids. The central nervous system, bones,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230412205511&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36980287"
                        open
                      >
                        <summary class="article-expander__title">Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36980287/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230412205511&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell-derived disorders characterized by uncontrolled proliferation of differentiated myeloid cells. Two main groups of MPN, BCR::ABL1-positive (Chronic Myeloid Leukemia) and BCR::ABL1-negative (Polycythemia Vera, Essential Thrombocytosis, Primary Myelofibrosis) are distinguished. For many years, cytomorphologic and histologic features were the only proof of MPN and attempted to distinguish the different entities of the subgroup...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990546"
                        open
                      >
                        <summary class="article-expander__title">Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990546/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: HSM is frequent in candidates for AVR, is associated with an enrichment of proinflammatory cardiac monocyte-derived macrophages, and predisposes to a higher incidence of POAF. HSM assessment may be useful in the personalized management of patients in the perioperative period. (Post-Operative Myocardial Incident &amp; Atrial Fibrillation [POMI-AF]; NCT03376165).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36988570"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations and human longevity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36988570/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) are structural alterations associated with aging, cancer, cardiovascular disease, infectious diseases, and mortality. The distribution of mCAs in centenarians and individuals with familial longevity is poorly understood. We used MOsaic CHromosomal Alteration (MoChA) to discover mCAs in 2050 centenarians, offspring, and 248 controls from the New England Centenarian Study (NECS) and in 3642 subjects with familial longevity and 920 spousal controls from the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36983964"
                        open
                      >
                        <summary class="article-expander__title">Sweet Syndrome Associated with Myelodysplastic Syndrome-A Review of a Multidisciplinary Approach</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36983964/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Sweet syndrome (SS) is a rare disease described as a febrile neutrophilic dermatosis with acute onset, the pathogenesis of which has not yet been elucidated. The syndrome is characterized by the sudden onset of erythematous infiltrated papules or plaques located on the upper body and is associated with fever, leukocytosis and neutrophilia. The lesions show a dense dermal infiltration with mature neutrophils. The condition is responsive to systemic steroids. The central nervous system, bones,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36980287"
                        open
                      >
                        <summary class="article-expander__title">Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36980287/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell-derived disorders characterized by uncontrolled proliferation of differentiated myeloid cells. Two main groups of MPN, BCR::ABL1-positive (Chronic Myeloid Leukemia) and BCR::ABL1-negative (Polycythemia Vera, Essential Thrombocytosis, Primary Myelofibrosis) are distinguished. For many years, cytomorphologic and histologic features were the only proof of MPN and attempted to distinguish the different entities of the subgroup...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990546"
                        open
                      >
                        <summary class="article-expander__title">Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990546/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: HSM is frequent in candidates for AVR, is associated with an enrichment of proinflammatory cardiac monocyte-derived macrophages, and predisposes to a higher incidence of POAF. HSM assessment may be useful in the personalized management of patients in the perioperative period. (Post-Operative Myocardial Incident &amp; Atrial Fibrillation [POMI-AF]; NCT03376165).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36988570"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations and human longevity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36988570/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) are structural alterations associated with aging, cancer, cardiovascular disease, infectious diseases, and mortality. The distribution of mCAs in centenarians and individuals with familial longevity is poorly understood. We used MOsaic CHromosomal Alteration (MoChA) to discover mCAs in 2050 centenarians, offspring, and 248 controls from the New England Centenarian Study (NECS) and in 3642 subjects with familial longevity and 920 spousal controls from the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36983964"
                        open
                      >
                        <summary class="article-expander__title">Sweet Syndrome Associated with Myelodysplastic Syndrome-A Review of a Multidisciplinary Approach</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36983964/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Sweet syndrome (SS) is a rare disease described as a febrile neutrophilic dermatosis with acute onset, the pathogenesis of which has not yet been elucidated. The syndrome is characterized by the sudden onset of erythematous infiltrated papules or plaques located on the upper body and is associated with fever, leukocytosis and neutrophilia. The lesions show a dense dermal infiltration with mature neutrophils. The condition is responsive to systemic steroids. The central nervous system, bones,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36980287"
                        open
                      >
                        <summary class="article-expander__title">Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36980287/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell-derived disorders characterized by uncontrolled proliferation of differentiated myeloid cells. Two main groups of MPN, BCR::ABL1-positive (Chronic Myeloid Leukemia) and BCR::ABL1-negative (Polycythemia Vera, Essential Thrombocytosis, Primary Myelofibrosis) are distinguished. For many years, cytomorphologic and histologic features were the only proof of MPN and attempted to distinguish the different entities of the subgroup...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990546"
                        open
                      >
                        <summary class="article-expander__title">Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990546/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: HSM is frequent in candidates for AVR, is associated with an enrichment of proinflammatory cardiac monocyte-derived macrophages, and predisposes to a higher incidence of POAF. HSM assessment may be useful in the personalized management of patients in the perioperative period. (Post-Operative Myocardial Incident &amp; Atrial Fibrillation [POMI-AF]; NCT03376165).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36988570"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations and human longevity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36988570/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) are structural alterations associated with aging, cancer, cardiovascular disease, infectious diseases, and mortality. The distribution of mCAs in centenarians and individuals with familial longevity is poorly understood. We used MOsaic CHromosomal Alteration (MoChA) to discover mCAs in 2050 centenarians, offspring, and 248 controls from the New England Centenarian Study (NECS) and in 3642 subjects with familial longevity and 920 spousal controls from the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36983964"
                        open
                      >
                        <summary class="article-expander__title">Sweet Syndrome Associated with Myelodysplastic Syndrome-A Review of a Multidisciplinary Approach</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36983964/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Sweet syndrome (SS) is a rare disease described as a febrile neutrophilic dermatosis with acute onset, the pathogenesis of which has not yet been elucidated. The syndrome is characterized by the sudden onset of erythematous infiltrated papules or plaques located on the upper body and is associated with fever, leukocytosis and neutrophilia. The lesions show a dense dermal infiltration with mature neutrophils. The condition is responsive to systemic steroids. The central nervous system, bones,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36980287"
                        open
                      >
                        <summary class="article-expander__title">Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36980287/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell-derived disorders characterized by uncontrolled proliferation of differentiated myeloid cells. Two main groups of MPN, BCR::ABL1-positive (Chronic Myeloid Leukemia) and BCR::ABL1-negative (Polycythemia Vera, Essential Thrombocytosis, Primary Myelofibrosis) are distinguished. For many years, cytomorphologic and histologic features were the only proof of MPN and attempted to distinguish the different entities of the subgroup...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990546"
                        open
                      >
                        <summary class="article-expander__title">Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990546/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: HSM is frequent in candidates for AVR, is associated with an enrichment of proinflammatory cardiac monocyte-derived macrophages, and predisposes to a higher incidence of POAF. HSM assessment may be useful in the personalized management of patients in the perioperative period. (Post-Operative Myocardial Incident &amp; Atrial Fibrillation [POMI-AF]; NCT03376165).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36988570"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations and human longevity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36988570/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) are structural alterations associated with aging, cancer, cardiovascular disease, infectious diseases, and mortality. The distribution of mCAs in centenarians and individuals with familial longevity is poorly understood. We used MOsaic CHromosomal Alteration (MoChA) to discover mCAs in 2050 centenarians, offspring, and 248 controls from the New England Centenarian Study (NECS) and in 3642 subjects with familial longevity and 920 spousal controls from the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36983964"
                        open
                      >
                        <summary class="article-expander__title">Sweet Syndrome Associated with Myelodysplastic Syndrome-A Review of a Multidisciplinary Approach</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36983964/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Sweet syndrome (SS) is a rare disease described as a febrile neutrophilic dermatosis with acute onset, the pathogenesis of which has not yet been elucidated. The syndrome is characterized by the sudden onset of erythematous infiltrated papules or plaques located on the upper body and is associated with fever, leukocytosis and neutrophilia. The lesions show a dense dermal infiltration with mature neutrophils. The condition is responsive to systemic steroids. The central nervous system, bones,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36980287"
                        open
                      >
                        <summary class="article-expander__title">Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36980287/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell-derived disorders characterized by uncontrolled proliferation of differentiated myeloid cells. Two main groups of MPN, BCR::ABL1-positive (Chronic Myeloid Leukemia) and BCR::ABL1-negative (Polycythemia Vera, Essential Thrombocytosis, Primary Myelofibrosis) are distinguished. For many years, cytomorphologic and histologic features were the only proof of MPN and attempted to distinguish the different entities of the subgroup...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990546"
                        open
                      >
                        <summary class="article-expander__title">Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990546/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: HSM is frequent in candidates for AVR, is associated with an enrichment of proinflammatory cardiac monocyte-derived macrophages, and predisposes to a higher incidence of POAF. HSM assessment may be useful in the personalized management of patients in the perioperative period. (Post-Operative Myocardial Incident &amp; Atrial Fibrillation [POMI-AF]; NCT03376165).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36988570"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations and human longevity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36988570/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) are structural alterations associated with aging, cancer, cardiovascular disease, infectious diseases, and mortality. The distribution of mCAs in centenarians and individuals with familial longevity is poorly understood. We used MOsaic CHromosomal Alteration (MoChA) to discover mCAs in 2050 centenarians, offspring, and 248 controls from the New England Centenarian Study (NECS) and in 3642 subjects with familial longevity and 920 spousal controls from the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36983964"
                        open
                      >
                        <summary class="article-expander__title">Sweet Syndrome Associated with Myelodysplastic Syndrome-A Review of a Multidisciplinary Approach</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36983964/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Sweet syndrome (SS) is a rare disease described as a febrile neutrophilic dermatosis with acute onset, the pathogenesis of which has not yet been elucidated. The syndrome is characterized by the sudden onset of erythematous infiltrated papules or plaques located on the upper body and is associated with fever, leukocytosis and neutrophilia. The lesions show a dense dermal infiltration with mature neutrophils. The condition is responsive to systemic steroids. The central nervous system, bones,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36980287"
                        open
                      >
                        <summary class="article-expander__title">Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36980287/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell-derived disorders characterized by uncontrolled proliferation of differentiated myeloid cells. Two main groups of MPN, BCR::ABL1-positive (Chronic Myeloid Leukemia) and BCR::ABL1-negative (Polycythemia Vera, Essential Thrombocytosis, Primary Myelofibrosis) are distinguished. For many years, cytomorphologic and histologic features were the only proof of MPN and attempted to distinguish the different entities of the subgroup...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990546"
                        open
                      >
                        <summary class="article-expander__title">Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990546/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: HSM is frequent in candidates for AVR, is associated with an enrichment of proinflammatory cardiac monocyte-derived macrophages, and predisposes to a higher incidence of POAF. HSM assessment may be useful in the personalized management of patients in the perioperative period. (Post-Operative Myocardial Incident &amp; Atrial Fibrillation [POMI-AF]; NCT03376165).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36988570"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations and human longevity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36988570/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) are structural alterations associated with aging, cancer, cardiovascular disease, infectious diseases, and mortality. The distribution of mCAs in centenarians and individuals with familial longevity is poorly understood. We used MOsaic CHromosomal Alteration (MoChA) to discover mCAs in 2050 centenarians, offspring, and 248 controls from the New England Centenarian Study (NECS) and in 3642 subjects with familial longevity and 920 spousal controls from the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36983964"
                        open
                      >
                        <summary class="article-expander__title">Sweet Syndrome Associated with Myelodysplastic Syndrome-A Review of a Multidisciplinary Approach</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36983964/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Sweet syndrome (SS) is a rare disease described as a febrile neutrophilic dermatosis with acute onset, the pathogenesis of which has not yet been elucidated. The syndrome is characterized by the sudden onset of erythematous infiltrated papules or plaques located on the upper body and is associated with fever, leukocytosis and neutrophilia. The lesions show a dense dermal infiltration with mature neutrophils. The condition is responsive to systemic steroids. The central nervous system, bones,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36980287"
                        open
                      >
                        <summary class="article-expander__title">Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36980287/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell-derived disorders characterized by uncontrolled proliferation of differentiated myeloid cells. Two main groups of MPN, BCR::ABL1-positive (Chronic Myeloid Leukemia) and BCR::ABL1-negative (Polycythemia Vera, Essential Thrombocytosis, Primary Myelofibrosis) are distinguished. For many years, cytomorphologic and histologic features were the only proof of MPN and attempted to distinguish the different entities of the subgroup...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990546"
                        open
                      >
                        <summary class="article-expander__title">Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990546/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: HSM is frequent in candidates for AVR, is associated with an enrichment of proinflammatory cardiac monocyte-derived macrophages, and predisposes to a higher incidence of POAF. HSM assessment may be useful in the personalized management of patients in the perioperative period. (Post-Operative Myocardial Incident &amp; Atrial Fibrillation [POMI-AF]; NCT03376165).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36988570"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations and human longevity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36988570/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) are structural alterations associated with aging, cancer, cardiovascular disease, infectious diseases, and mortality. The distribution of mCAs in centenarians and individuals with familial longevity is poorly understood. We used MOsaic CHromosomal Alteration (MoChA) to discover mCAs in 2050 centenarians, offspring, and 248 controls from the New England Centenarian Study (NECS) and in 3642 subjects with familial longevity and 920 spousal controls from the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36983964"
                        open
                      >
                        <summary class="article-expander__title">Sweet Syndrome Associated with Myelodysplastic Syndrome-A Review of a Multidisciplinary Approach</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36983964/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Sweet syndrome (SS) is a rare disease described as a febrile neutrophilic dermatosis with acute onset, the pathogenesis of which has not yet been elucidated. The syndrome is characterized by the sudden onset of erythematous infiltrated papules or plaques located on the upper body and is associated with fever, leukocytosis and neutrophilia. The lesions show a dense dermal infiltration with mature neutrophils. The condition is responsive to systemic steroids. The central nervous system, bones,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36980287"
                        open
                      >
                        <summary class="article-expander__title">Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36980287/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell-derived disorders characterized by uncontrolled proliferation of differentiated myeloid cells. Two main groups of MPN, BCR::ABL1-positive (Chronic Myeloid Leukemia) and BCR::ABL1-negative (Polycythemia Vera, Essential Thrombocytosis, Primary Myelofibrosis) are distinguished. For many years, cytomorphologic and histologic features were the only proof of MPN and attempted to distinguish the different entities of the subgroup...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990546"
                        open
                      >
                        <summary class="article-expander__title">Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990546/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: HSM is frequent in candidates for AVR, is associated with an enrichment of proinflammatory cardiac monocyte-derived macrophages, and predisposes to a higher incidence of POAF. HSM assessment may be useful in the personalized management of patients in the perioperative period. (Post-Operative Myocardial Incident &amp; Atrial Fibrillation [POMI-AF]; NCT03376165).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36988570"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations and human longevity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36988570/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) are structural alterations associated with aging, cancer, cardiovascular disease, infectious diseases, and mortality. The distribution of mCAs in centenarians and individuals with familial longevity is poorly understood. We used MOsaic CHromosomal Alteration (MoChA) to discover mCAs in 2050 centenarians, offspring, and 248 controls from the New England Centenarian Study (NECS) and in 3642 subjects with familial longevity and 920 spousal controls from the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36983964"
                        open
                      >
                        <summary class="article-expander__title">Sweet Syndrome Associated with Myelodysplastic Syndrome-A Review of a Multidisciplinary Approach</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36983964/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Sweet syndrome (SS) is a rare disease described as a febrile neutrophilic dermatosis with acute onset, the pathogenesis of which has not yet been elucidated. The syndrome is characterized by the sudden onset of erythematous infiltrated papules or plaques located on the upper body and is associated with fever, leukocytosis and neutrophilia. The lesions show a dense dermal infiltration with mature neutrophils. The condition is responsive to systemic steroids. The central nervous system, bones,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36980287"
                        open
                      >
                        <summary class="article-expander__title">Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36980287/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell-derived disorders characterized by uncontrolled proliferation of differentiated myeloid cells. Two main groups of MPN, BCR::ABL1-positive (Chronic Myeloid Leukemia) and BCR::ABL1-negative (Polycythemia Vera, Essential Thrombocytosis, Primary Myelofibrosis) are distinguished. For many years, cytomorphologic and histologic features were the only proof of MPN and attempted to distinguish the different entities of the subgroup...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990546"
                        open
                      >
                        <summary class="article-expander__title">Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990546/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: HSM is frequent in candidates for AVR, is associated with an enrichment of proinflammatory cardiac monocyte-derived macrophages, and predisposes to a higher incidence of POAF. HSM assessment may be useful in the personalized management of patients in the perioperative period. (Post-Operative Myocardial Incident &amp; Atrial Fibrillation [POMI-AF]; NCT03376165).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36988570"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations and human longevity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36988570/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) are structural alterations associated with aging, cancer, cardiovascular disease, infectious diseases, and mortality. The distribution of mCAs in centenarians and individuals with familial longevity is poorly understood. We used MOsaic CHromosomal Alteration (MoChA) to discover mCAs in 2050 centenarians, offspring, and 248 controls from the New England Centenarian Study (NECS) and in 3642 subjects with familial longevity and 920 spousal controls from the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36983964"
                        open
                      >
                        <summary class="article-expander__title">Sweet Syndrome Associated with Myelodysplastic Syndrome-A Review of a Multidisciplinary Approach</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36983964/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Sweet syndrome (SS) is a rare disease described as a febrile neutrophilic dermatosis with acute onset, the pathogenesis of which has not yet been elucidated. The syndrome is characterized by the sudden onset of erythematous infiltrated papules or plaques located on the upper body and is associated with fever, leukocytosis and neutrophilia. The lesions show a dense dermal infiltration with mature neutrophils. The condition is responsive to systemic steroids. The central nervous system, bones,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36980287"
                        open
                      >
                        <summary class="article-expander__title">Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36980287/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell-derived disorders characterized by uncontrolled proliferation of differentiated myeloid cells. Two main groups of MPN, BCR::ABL1-positive (Chronic Myeloid Leukemia) and BCR::ABL1-negative (Polycythemia Vera, Essential Thrombocytosis, Primary Myelofibrosis) are distinguished. For many years, cytomorphologic and histologic features were the only proof of MPN and attempted to distinguish the different entities of the subgroup...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990546"
                        open
                      >
                        <summary class="article-expander__title">Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990546/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: HSM is frequent in candidates for AVR, is associated with an enrichment of proinflammatory cardiac monocyte-derived macrophages, and predisposes to a higher incidence of POAF. HSM assessment may be useful in the personalized management of patients in the perioperative period. (Post-Operative Myocardial Incident &amp; Atrial Fibrillation [POMI-AF]; NCT03376165).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36988570"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations and human longevity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36988570/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) are structural alterations associated with aging, cancer, cardiovascular disease, infectious diseases, and mortality. The distribution of mCAs in centenarians and individuals with familial longevity is poorly understood. We used MOsaic CHromosomal Alteration (MoChA) to discover mCAs in 2050 centenarians, offspring, and 248 controls from the New England Centenarian Study (NECS) and in 3642 subjects with familial longevity and 920 spousal controls from the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36983964"
                        open
                      >
                        <summary class="article-expander__title">Sweet Syndrome Associated with Myelodysplastic Syndrome-A Review of a Multidisciplinary Approach</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36983964/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Sweet syndrome (SS) is a rare disease described as a febrile neutrophilic dermatosis with acute onset, the pathogenesis of which has not yet been elucidated. The syndrome is characterized by the sudden onset of erythematous infiltrated papules or plaques located on the upper body and is associated with fever, leukocytosis and neutrophilia. The lesions show a dense dermal infiltration with mature neutrophils. The condition is responsive to systemic steroids. The central nervous system, bones,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36980287"
                        open
                      >
                        <summary class="article-expander__title">Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36980287/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell-derived disorders characterized by uncontrolled proliferation of differentiated myeloid cells. Two main groups of MPN, BCR::ABL1-positive (Chronic Myeloid Leukemia) and BCR::ABL1-negative (Polycythemia Vera, Essential Thrombocytosis, Primary Myelofibrosis) are distinguished. For many years, cytomorphologic and histologic features were the only proof of MPN and attempted to distinguish the different entities of the subgroup...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990546"
                        open
                      >
                        <summary class="article-expander__title">Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990546/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: HSM is frequent in candidates for AVR, is associated with an enrichment of proinflammatory cardiac monocyte-derived macrophages, and predisposes to a higher incidence of POAF. HSM assessment may be useful in the personalized management of patients in the perioperative period. (Post-Operative Myocardial Incident &amp; Atrial Fibrillation [POMI-AF]; NCT03376165).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36988570"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations and human longevity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36988570/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) are structural alterations associated with aging, cancer, cardiovascular disease, infectious diseases, and mortality. The distribution of mCAs in centenarians and individuals with familial longevity is poorly understood. We used MOsaic CHromosomal Alteration (MoChA) to discover mCAs in 2050 centenarians, offspring, and 248 controls from the New England Centenarian Study (NECS) and in 3642 subjects with familial longevity and 920 spousal controls from the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36983964"
                        open
                      >
                        <summary class="article-expander__title">Sweet Syndrome Associated with Myelodysplastic Syndrome-A Review of a Multidisciplinary Approach</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36983964/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Sweet syndrome (SS) is a rare disease described as a febrile neutrophilic dermatosis with acute onset, the pathogenesis of which has not yet been elucidated. The syndrome is characterized by the sudden onset of erythematous infiltrated papules or plaques located on the upper body and is associated with fever, leukocytosis and neutrophilia. The lesions show a dense dermal infiltration with mature neutrophils. The condition is responsive to systemic steroids. The central nervous system, bones,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36980287"
                        open
                      >
                        <summary class="article-expander__title">Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36980287/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell-derived disorders characterized by uncontrolled proliferation of differentiated myeloid cells. Two main groups of MPN, BCR::ABL1-positive (Chronic Myeloid Leukemia) and BCR::ABL1-negative (Polycythemia Vera, Essential Thrombocytosis, Primary Myelofibrosis) are distinguished. For many years, cytomorphologic and histologic features were the only proof of MPN and attempted to distinguish the different entities of the subgroup...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990546"
                        open
                      >
                        <summary class="article-expander__title">Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990546/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: HSM is frequent in candidates for AVR, is associated with an enrichment of proinflammatory cardiac monocyte-derived macrophages, and predisposes to a higher incidence of POAF. HSM assessment may be useful in the personalized management of patients in the perioperative period. (Post-Operative Myocardial Incident &amp; Atrial Fibrillation [POMI-AF]; NCT03376165).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36988570"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations and human longevity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36988570/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) are structural alterations associated with aging, cancer, cardiovascular disease, infectious diseases, and mortality. The distribution of mCAs in centenarians and individuals with familial longevity is poorly understood. We used MOsaic CHromosomal Alteration (MoChA) to discover mCAs in 2050 centenarians, offspring, and 248 controls from the New England Centenarian Study (NECS) and in 3642 subjects with familial longevity and 920 spousal controls from the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36983964"
                        open
                      >
                        <summary class="article-expander__title">Sweet Syndrome Associated with Myelodysplastic Syndrome-A Review of a Multidisciplinary Approach</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36983964/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Sweet syndrome (SS) is a rare disease described as a febrile neutrophilic dermatosis with acute onset, the pathogenesis of which has not yet been elucidated. The syndrome is characterized by the sudden onset of erythematous infiltrated papules or plaques located on the upper body and is associated with fever, leukocytosis and neutrophilia. The lesions show a dense dermal infiltration with mature neutrophils. The condition is responsive to systemic steroids. The central nervous system, bones,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36980287"
                        open
                      >
                        <summary class="article-expander__title">Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36980287/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell-derived disorders characterized by uncontrolled proliferation of differentiated myeloid cells. Two main groups of MPN, BCR::ABL1-positive (Chronic Myeloid Leukemia) and BCR::ABL1-negative (Polycythemia Vera, Essential Thrombocytosis, Primary Myelofibrosis) are distinguished. For many years, cytomorphologic and histologic features were the only proof of MPN and attempted to distinguish the different entities of the subgroup...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990546"
                        open
                      >
                        <summary class="article-expander__title">Hematopoietic Somatic Mosaicism Is Associated With an Increased Risk of Postoperative Atrial Fibrillation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990546/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: HSM is frequent in candidates for AVR, is associated with an enrichment of proinflammatory cardiac monocyte-derived macrophages, and predisposes to a higher incidence of POAF. HSM assessment may be useful in the personalized management of patients in the perioperative period. (Post-Operative Myocardial Incident &amp; Atrial Fibrillation [POMI-AF]; NCT03376165).</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36988570"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations and human longevity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36988570/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) are structural alterations associated with aging, cancer, cardiovascular disease, infectious diseases, and mortality. The distribution of mCAs in centenarians and individuals with familial longevity is poorly understood. We used MOsaic CHromosomal Alteration (MoChA) to discover mCAs in 2050 centenarians, offspring, and 248 controls from the New England Centenarian Study (NECS) and in 3642 subjects with familial longevity and 920 spousal controls from the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36983964"
                        open
                      >
                        <summary class="article-expander__title">Sweet Syndrome Associated with Myelodysplastic Syndrome-A Review of a Multidisciplinary Approach</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36983964/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Sweet syndrome (SS) is a rare disease described as a febrile neutrophilic dermatosis with acute onset, the pathogenesis of which has not yet been elucidated. The syndrome is characterized by the sudden onset of erythematous infiltrated papules or plaques located on the upper body and is associated with fever, leukocytosis and neutrophilia. The lesions show a dense dermal infiltration with mature neutrophils. The condition is responsive to systemic steroids. The central nervous system, bones,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36980287"
                        open
                      >
                        <summary class="article-expander__title">Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36980287/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell-derived disorders characterized by uncontrolled proliferation of differentiated myeloid cells. Two main groups of MPN, BCR::ABL1-positive (Chronic Myeloid Leukemia) and BCR::ABL1-negative (Polycythemia Vera, Essential Thrombocytosis, Primary Myelofibrosis) are distinguished. For many years, cytomorphologic and histologic features were the only proof of MPN and attempted to distinguish the different entities of the subgroup...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230329210032&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36988570"
                        open
                      >
                        <summary class="article-expander__title">Mosaic chromosomal alterations and human longevity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36988570/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230329210032&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Mosaic chromosomal alterations (mCAs) are structural alterations associated with aging, cancer, cardiovascular disease, infectious diseases, and mortality. The distribution of mCAs in centenarians and individuals with familial longevity is poorly understood. We used MOsaic CHromosomal Alteration (MoChA) to discover mCAs in 2050 centenarians, offspring, and 248 controls from the New England Centenarian Study (NECS) and in 3642 subjects with familial longevity and 920 spousal controls from the...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36983964"
                        open
                      >
                        <summary class="article-expander__title">Sweet Syndrome Associated with Myelodysplastic Syndrome-A Review of a Multidisciplinary Approach</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36983964/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230329210032&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Sweet syndrome (SS) is a rare disease described as a febrile neutrophilic dermatosis with acute onset, the pathogenesis of which has not yet been elucidated. The syndrome is characterized by the sudden onset of erythematous infiltrated papules or plaques located on the upper body and is associated with fever, leukocytosis and neutrophilia. The lesions show a dense dermal infiltration with mature neutrophils. The condition is responsive to systemic steroids. The central nervous system, bones,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230329210032&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36980287"
                        open
                      >
                        <summary class="article-expander__title">Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36980287/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230329210032&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell-derived disorders characterized by uncontrolled proliferation of differentiated myeloid cells. Two main groups of MPN, BCR::ABL1-positive (Chronic Myeloid Leukemia) and BCR::ABL1-negative (Polycythemia Vera, Essential Thrombocytosis, Primary Myelofibrosis) are distinguished. For many years, cytomorphologic and histologic features were the only proof of MPN and attempted to distinguish the different entities of the subgroup...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982875"
                        open
                      >
                        <summary class="article-expander__title">Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982875/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed/refractory (R/R) disease, acquired resistance is the leading cause of treatment failure, with somatic BCL2 mutations being the predominant genetic drivers underpinning venetoclax resistance. To assess the correlation between disease progression and the most common BCL2 mutations G101V and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982875"
                        open
                      >
                        <summary class="article-expander__title">Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982875/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed/refractory (R/R) disease, acquired resistance is the leading cause of treatment failure, with somatic BCL2 mutations being the predominant genetic drivers underpinning venetoclax resistance. To assess the correlation between disease progression and the most common BCL2 mutations G101V and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982036"
                        open
                      >
                        <summary class="article-expander__title">Reconstructing Clonal Evolution-A Systematic Evaluation of Current Bioinformatics Approaches</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982036/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accurate reconstruction of clonal evolution, including the identification of newly developing, highly aggressive subclones, is essential for the application of precision medicine in cancer treatment. Reconstruction, aiming for correct variant clustering and clonal evolution tree reconstruction, is commonly performed by tedious manual work. While there is a plethora of tools to automatically generate reconstruction, their reliability, especially reasons for unreliability, are not...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982875"
                        open
                      >
                        <summary class="article-expander__title">Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982875/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed/refractory (R/R) disease, acquired resistance is the leading cause of treatment failure, with somatic BCL2 mutations being the predominant genetic drivers underpinning venetoclax resistance. To assess the correlation between disease progression and the most common BCL2 mutations G101V and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982036"
                        open
                      >
                        <summary class="article-expander__title">Reconstructing Clonal Evolution-A Systematic Evaluation of Current Bioinformatics Approaches</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982036/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accurate reconstruction of clonal evolution, including the identification of newly developing, highly aggressive subclones, is essential for the application of precision medicine in cancer treatment. Reconstruction, aiming for correct variant clustering and clonal evolution tree reconstruction, is commonly performed by tedious manual work. While there is a plethora of tools to automatically generate reconstruction, their reliability, especially reasons for unreliability, are not...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982875"
                        open
                      >
                        <summary class="article-expander__title">Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982875/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed/refractory (R/R) disease, acquired resistance is the leading cause of treatment failure, with somatic BCL2 mutations being the predominant genetic drivers underpinning venetoclax resistance. To assess the correlation between disease progression and the most common BCL2 mutations G101V and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982036"
                        open
                      >
                        <summary class="article-expander__title">Reconstructing Clonal Evolution-A Systematic Evaluation of Current Bioinformatics Approaches</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982036/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accurate reconstruction of clonal evolution, including the identification of newly developing, highly aggressive subclones, is essential for the application of precision medicine in cancer treatment. Reconstruction, aiming for correct variant clustering and clonal evolution tree reconstruction, is commonly performed by tedious manual work. While there is a plethora of tools to automatically generate reconstruction, their reliability, especially reasons for unreliability, are not...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982875"
                        open
                      >
                        <summary class="article-expander__title">Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982875/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed/refractory (R/R) disease, acquired resistance is the leading cause of treatment failure, with somatic BCL2 mutations being the predominant genetic drivers underpinning venetoclax resistance. To assess the correlation between disease progression and the most common BCL2 mutations G101V and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982036"
                        open
                      >
                        <summary class="article-expander__title">Reconstructing Clonal Evolution-A Systematic Evaluation of Current Bioinformatics Approaches</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982036/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accurate reconstruction of clonal evolution, including the identification of newly developing, highly aggressive subclones, is essential for the application of precision medicine in cancer treatment. Reconstruction, aiming for correct variant clustering and clonal evolution tree reconstruction, is commonly performed by tedious manual work. While there is a plethora of tools to automatically generate reconstruction, their reliability, especially reasons for unreliability, are not...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982875"
                        open
                      >
                        <summary class="article-expander__title">Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982875/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed/refractory (R/R) disease, acquired resistance is the leading cause of treatment failure, with somatic BCL2 mutations being the predominant genetic drivers underpinning venetoclax resistance. To assess the correlation between disease progression and the most common BCL2 mutations G101V and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982036"
                        open
                      >
                        <summary class="article-expander__title">Reconstructing Clonal Evolution-A Systematic Evaluation of Current Bioinformatics Approaches</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982036/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accurate reconstruction of clonal evolution, including the identification of newly developing, highly aggressive subclones, is essential for the application of precision medicine in cancer treatment. Reconstruction, aiming for correct variant clustering and clonal evolution tree reconstruction, is commonly performed by tedious manual work. While there is a plethora of tools to automatically generate reconstruction, their reliability, especially reasons for unreliability, are not...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982875"
                        open
                      >
                        <summary class="article-expander__title">Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982875/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed/refractory (R/R) disease, acquired resistance is the leading cause of treatment failure, with somatic BCL2 mutations being the predominant genetic drivers underpinning venetoclax resistance. To assess the correlation between disease progression and the most common BCL2 mutations G101V and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982036"
                        open
                      >
                        <summary class="article-expander__title">Reconstructing Clonal Evolution-A Systematic Evaluation of Current Bioinformatics Approaches</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982036/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accurate reconstruction of clonal evolution, including the identification of newly developing, highly aggressive subclones, is essential for the application of precision medicine in cancer treatment. Reconstruction, aiming for correct variant clustering and clonal evolution tree reconstruction, is commonly performed by tedious manual work. While there is a plethora of tools to automatically generate reconstruction, their reliability, especially reasons for unreliability, are not...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982875"
                        open
                      >
                        <summary class="article-expander__title">Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982875/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed/refractory (R/R) disease, acquired resistance is the leading cause of treatment failure, with somatic BCL2 mutations being the predominant genetic drivers underpinning venetoclax resistance. To assess the correlation between disease progression and the most common BCL2 mutations G101V and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982036"
                        open
                      >
                        <summary class="article-expander__title">Reconstructing Clonal Evolution-A Systematic Evaluation of Current Bioinformatics Approaches</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982036/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accurate reconstruction of clonal evolution, including the identification of newly developing, highly aggressive subclones, is essential for the application of precision medicine in cancer treatment. Reconstruction, aiming for correct variant clustering and clonal evolution tree reconstruction, is commonly performed by tedious manual work. While there is a plethora of tools to automatically generate reconstruction, their reliability, especially reasons for unreliability, are not...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982875"
                        open
                      >
                        <summary class="article-expander__title">Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982875/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed/refractory (R/R) disease, acquired resistance is the leading cause of treatment failure, with somatic BCL2 mutations being the predominant genetic drivers underpinning venetoclax resistance. To assess the correlation between disease progression and the most common BCL2 mutations G101V and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982036"
                        open
                      >
                        <summary class="article-expander__title">Reconstructing Clonal Evolution-A Systematic Evaluation of Current Bioinformatics Approaches</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982036/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accurate reconstruction of clonal evolution, including the identification of newly developing, highly aggressive subclones, is essential for the application of precision medicine in cancer treatment. Reconstruction, aiming for correct variant clustering and clonal evolution tree reconstruction, is commonly performed by tedious manual work. While there is a plethora of tools to automatically generate reconstruction, their reliability, especially reasons for unreliability, are not...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982875"
                        open
                      >
                        <summary class="article-expander__title">Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982875/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed/refractory (R/R) disease, acquired resistance is the leading cause of treatment failure, with somatic BCL2 mutations being the predominant genetic drivers underpinning venetoclax resistance. To assess the correlation between disease progression and the most common BCL2 mutations G101V and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982036"
                        open
                      >
                        <summary class="article-expander__title">Reconstructing Clonal Evolution-A Systematic Evaluation of Current Bioinformatics Approaches</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982036/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accurate reconstruction of clonal evolution, including the identification of newly developing, highly aggressive subclones, is essential for the application of precision medicine in cancer treatment. Reconstruction, aiming for correct variant clustering and clonal evolution tree reconstruction, is commonly performed by tedious manual work. While there is a plethora of tools to automatically generate reconstruction, their reliability, especially reasons for unreliability, are not...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36990116"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis of undetermined potential (CHIP) and clonal cytopenia of unknown significance (CCUS) - Consequences for the clinic</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36990116/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Clonal hematopoiesis of indeterminate potential (CHIP) refers to the outgrowth of blood cells from a hematopoietic stem cell (HSC) clone that acquired one or more somatic mutations, leading to a growth advantage compared to wild type HSCs. In the last years this age-associated phenomenon has been extensively studied, and several cohort studies found association between CH and age-related diseases, esp. leukaemia and cardiovascular disease. For patients with CH present with abnormal blood counts,...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36989374"
                        open
                      >
                        <summary class="article-expander__title">Clonal hematopoiesis detection in patients with cancer using cell-free DNA sequencing</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36989374/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>In the context of cancer, clonal hematopoiesis of indeterminate potential (CHIP) is associated with the development of therapy-related myeloid neoplasms and shorter overall survival. Cell-free DNA (cfDNA) sequencing is becoming widely adopted for genomic screening of patients with cancer but has not been used extensively to determine CHIP status because of a requirement for matched blood and tumor sequencing. We present an accurate classification approach to determine the CH status from cfDNA...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982875"
                        open
                      >
                        <summary class="article-expander__title">Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982875/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed/refractory (R/R) disease, acquired resistance is the leading cause of treatment failure, with somatic BCL2 mutations being the predominant genetic drivers underpinning venetoclax resistance. To assess the correlation between disease progression and the most common BCL2 mutations G101V and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982036"
                        open
                      >
                        <summary class="article-expander__title">Reconstructing Clonal Evolution-A Systematic Evaluation of Current Bioinformatics Approaches</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982036/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accurate reconstruction of clonal evolution, including the identification of newly developing, highly aggressive subclones, is essential for the application of precision medicine in cancer treatment. Reconstruction, aiming for correct variant clustering and clonal evolution tree reconstruction, is commonly performed by tedious manual work. While there is a plethora of tools to automatically generate reconstruction, their reliability, especially reasons for unreliability, are not...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982875"
                        open
                      >
                        <summary class="article-expander__title">Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982875/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed/refractory (R/R) disease, acquired resistance is the leading cause of treatment failure, with somatic BCL2 mutations being the predominant genetic drivers underpinning venetoclax resistance. To assess the correlation between disease progression and the most common BCL2 mutations G101V and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982819"
                        open
                      >
                        <summary class="article-expander__title">The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982819/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Myelodysplastic neoplasm (MDS) represents a heterogeneous group of myeloid disorders that originate from the hematopoietic stem and progenitor cells that lead to the development of clonal hematopoiesis. MDS was characterized by an increased risk of transformation into acute myeloid leukemia (AML). In recent years, with the aid of next-generation sequencing (NGS), an increasing number of molecular aberrations were discovered, such as recurrent mutations in FLT3, NPM1, DNMT3A, TP53, NRAS, and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36982036"
                        open
                      >
                        <summary class="article-expander__title">Reconstructing Clonal Evolution-A Systematic Evaluation of Current Bioinformatics Approaches</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36982036/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>The accurate reconstruction of clonal evolution, including the identification of newly developing, highly aggressive subclones, is essential for the application of precision medicine in cancer treatment. Reconstruction, aiming for correct variant clustering and clonal evolution tree reconstruction, is commonly performed by tedious manual work. While there is a plethora of tools to automatically generate reconstruction, their reliability, especially reasons for unreliability, are not...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;11
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-03-28 datetime="2023-03-28T10:00:00.000Z">2023-03-28</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-03-28 datetime="2023-03-28T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36976266"
                        open
                      >
                        <summary class="article-expander__title">Mosaic Loss of Y Chromosome in White Blood Cells: Its Impact on Men&#x27;s Health</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36976266/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230411205624&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>We present a brief introduction of loss of Y chromosome (LOY) in blood, and describe the known risk factors for this condition. We then overview the associations between LOY and age-related disease traits. Finally, we discuss murine models and potential mechanisms by which LOY contributes to disease.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36976266"
                        open
                      >
                        <summary class="article-expander__title">Mosaic Loss of Y Chromosome in White Blood Cells: Its Impact on Men&#x27;s Health</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36976266/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230410205645&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>We present a brief introduction of loss of Y chromosome (LOY) in blood, and describe the known risk factors for this condition. We then overview the associations between LOY and age-related disease traits. Finally, we discuss murine models and potential mechanisms by which LOY contributes to disease.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36976266"
                        open
                      >
                        <summary class="article-expander__title">Mosaic Loss of Y Chromosome in White Blood Cells: Its Impact on Men&#x27;s Health</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36976266/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230409205609&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>We present a brief introduction of loss of Y chromosome (LOY) in blood, and describe the known risk factors for this condition. We then overview the associations between LOY and age-related disease traits. Finally, we discuss murine models and potential mechanisms by which LOY contributes to disease.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36976266"
                        open
                      >
                        <summary class="article-expander__title">Mosaic Loss of Y Chromosome in White Blood Cells: Its Impact on Men&#x27;s Health</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36976266/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230408205746&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>We present a brief introduction of loss of Y chromosome (LOY) in blood, and describe the known risk factors for this condition. We then overview the associations between LOY and age-related disease traits. Finally, we discuss murine models and potential mechanisms by which LOY contributes to disease.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36976266"
                        open
                      >
                        <summary class="article-expander__title">Mosaic Loss of Y Chromosome in White Blood Cells: Its Impact on Men&#x27;s Health</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36976266/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230407205356&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>We present a brief introduction of loss of Y chromosome (LOY) in blood, and describe the known risk factors for this condition. We then overview the associations between LOY and age-related disease traits. Finally, we discuss murine models and potential mechanisms by which LOY contributes to disease.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36976266"
                        open
                      >
                        <summary class="article-expander__title">Mosaic Loss of Y Chromosome in White Blood Cells: Its Impact on Men&#x27;s Health</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36976266/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>We present a brief introduction of loss of Y chromosome (LOY) in blood, and describe the known risk factors for this condition. We then overview the associations between LOY and age-related disease traits. Finally, we discuss murine models and potential mechanisms by which LOY contributes to disease.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36976266"
                        open
                      >
                        <summary class="article-expander__title">Mosaic Loss of Y Chromosome in White Blood Cells: Its Impact on Men&#x27;s Health</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36976266/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>We present a brief introduction of loss of Y chromosome (LOY) in blood, and describe the known risk factors for this condition. We then overview the associations between LOY and age-related disease traits. Finally, we discuss murine models and potential mechanisms by which LOY contributes to disease.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36976266"
                        open
                      >
                        <summary class="article-expander__title">Mosaic Loss of Y Chromosome in White Blood Cells: Its Impact on Men&#x27;s Health</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36976266/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>We present a brief introduction of loss of Y chromosome (LOY) in blood, and describe the known risk factors for this condition. We then overview the associations between LOY and age-related disease traits. Finally, we discuss murine models and potential mechanisms by which LOY contributes to disease.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36976266"
                        open
                      >
                        <summary class="article-expander__title">Mosaic Loss of Y Chromosome in White Blood Cells: Its Impact on Men&#x27;s Health</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36976266/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>We present a brief introduction of loss of Y chromosome (LOY) in blood, and describe the known risk factors for this condition. We then overview the associations between LOY and age-related disease traits. Finally, we discuss murine models and potential mechanisms by which LOY contributes to disease.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36976266"
                        open
                      >
                        <summary class="article-expander__title">Mosaic Loss of Y Chromosome in White Blood Cells: Its Impact on Men&#x27;s Health</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36976266/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>We present a brief introduction of loss of Y chromosome (LOY) in blood, and describe the known risk factors for this condition. We then overview the associations between LOY and age-related disease traits. Finally, we discuss murine models and potential mechanisms by which LOY contributes to disease.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36976266"
                        open
                      >
                        <summary class="article-expander__title">Mosaic Loss of Y Chromosome in White Blood Cells: Its Impact on Men&#x27;s Health</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36976266/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>We present a brief introduction of loss of Y chromosome (LOY) in blood, and describe the known risk factors for this condition. We then overview the associations between LOY and age-related disease traits. Finally, we discuss murine models and potential mechanisms by which LOY contributes to disease.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36976266"
                        open
                      >
                        <summary class="article-expander__title">Mosaic Loss of Y Chromosome in White Blood Cells: Its Impact on Men&#x27;s Health</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36976266/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>We present a brief introduction of loss of Y chromosome (LOY) in blood, and describe the known risk factors for this condition. We then overview the associations between LOY and age-related disease traits. Finally, we discuss murine models and potential mechanisms by which LOY contributes to disease.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36976266"
                        open
                      >
                        <summary class="article-expander__title">Mosaic Loss of Y Chromosome in White Blood Cells: Its Impact on Men&#x27;s Health</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36976266/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>We present a brief introduction of loss of Y chromosome (LOY) in blood, and describe the known risk factors for this condition. We then overview the associations between LOY and age-related disease traits. Finally, we discuss murine models and potential mechanisms by which LOY contributes to disease.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36976266"
                        open
                      >
                        <summary class="article-expander__title">Mosaic Loss of Y Chromosome in White Blood Cells: Its Impact on Men&#x27;s Health</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36976266/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230329210032&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>We present a brief introduction of loss of Y chromosome (LOY) in blood, and describe the known risk factors for this condition. We then overview the associations between LOY and age-related disease traits. Finally, we discuss murine models and potential mechanisms by which LOY contributes to disease.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36976266"
                        open
                      >
                        <summary class="article-expander__title">Mosaic Loss of Y Chromosome in White Blood Cells: Its Impact on Men&#x27;s Health</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36976266/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230328210444&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>We present a brief introduction of loss of Y chromosome (LOY) in blood, and describe the known risk factors for this condition. We then overview the associations between LOY and age-related disease traits. Finally, we discuss murine models and potential mechanisms by which LOY contributes to disease.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36978147"
                        open
                      >
                        <summary class="article-expander__title">APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36978147/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Apolipoprotein B mRNA-editing enzyme, catalytic polypeptides (APOBECs) are cytosine deaminases involved in innate and adaptive immunity. However, some APOBEC family members can also deaminate host genomes to generate oncogenic mutations. The resulting mutations, primarily signatures 2 and 13, occur in many tumor types and are among the most common mutational signatures in cancer. This review summarizes the current evidence implicating APOBEC3s as major mutators and outlines the exogenous and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36978147"
                        open
                      >
                        <summary class="article-expander__title">APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36978147/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Apolipoprotein B mRNA-editing enzyme, catalytic polypeptides (APOBECs) are cytosine deaminases involved in innate and adaptive immunity. However, some APOBEC family members can also deaminate host genomes to generate oncogenic mutations. The resulting mutations, primarily signatures 2 and 13, occur in many tumor types and are among the most common mutational signatures in cancer. This review summarizes the current evidence implicating APOBEC3s as major mutators and outlines the exogenous and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36978147"
                        open
                      >
                        <summary class="article-expander__title">APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36978147/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Apolipoprotein B mRNA-editing enzyme, catalytic polypeptides (APOBECs) are cytosine deaminases involved in innate and adaptive immunity. However, some APOBEC family members can also deaminate host genomes to generate oncogenic mutations. The resulting mutations, primarily signatures 2 and 13, occur in many tumor types and are among the most common mutational signatures in cancer. This review summarizes the current evidence implicating APOBEC3s as major mutators and outlines the exogenous and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36978147"
                        open
                      >
                        <summary class="article-expander__title">APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36978147/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Apolipoprotein B mRNA-editing enzyme, catalytic polypeptides (APOBECs) are cytosine deaminases involved in innate and adaptive immunity. However, some APOBEC family members can also deaminate host genomes to generate oncogenic mutations. The resulting mutations, primarily signatures 2 and 13, occur in many tumor types and are among the most common mutational signatures in cancer. This review summarizes the current evidence implicating APOBEC3s as major mutators and outlines the exogenous and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36978147"
                        open
                      >
                        <summary class="article-expander__title">APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36978147/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Apolipoprotein B mRNA-editing enzyme, catalytic polypeptides (APOBECs) are cytosine deaminases involved in innate and adaptive immunity. However, some APOBEC family members can also deaminate host genomes to generate oncogenic mutations. The resulting mutations, primarily signatures 2 and 13, occur in many tumor types and are among the most common mutational signatures in cancer. This review summarizes the current evidence implicating APOBEC3s as major mutators and outlines the exogenous and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36978147"
                        open
                      >
                        <summary class="article-expander__title">APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36978147/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Apolipoprotein B mRNA-editing enzyme, catalytic polypeptides (APOBECs) are cytosine deaminases involved in innate and adaptive immunity. However, some APOBEC family members can also deaminate host genomes to generate oncogenic mutations. The resulting mutations, primarily signatures 2 and 13, occur in many tumor types and are among the most common mutational signatures in cancer. This review summarizes the current evidence implicating APOBEC3s as major mutators and outlines the exogenous and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36978147"
                        open
                      >
                        <summary class="article-expander__title">APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36978147/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Apolipoprotein B mRNA-editing enzyme, catalytic polypeptides (APOBECs) are cytosine deaminases involved in innate and adaptive immunity. However, some APOBEC family members can also deaminate host genomes to generate oncogenic mutations. The resulting mutations, primarily signatures 2 and 13, occur in many tumor types and are among the most common mutational signatures in cancer. This review summarizes the current evidence implicating APOBEC3s as major mutators and outlines the exogenous and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36978147"
                        open
                      >
                        <summary class="article-expander__title">APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36978147/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Apolipoprotein B mRNA-editing enzyme, catalytic polypeptides (APOBECs) are cytosine deaminases involved in innate and adaptive immunity. However, some APOBEC family members can also deaminate host genomes to generate oncogenic mutations. The resulting mutations, primarily signatures 2 and 13, occur in many tumor types and are among the most common mutational signatures in cancer. This review summarizes the current evidence implicating APOBEC3s as major mutators and outlines the exogenous and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36978147"
                        open
                      >
                        <summary class="article-expander__title">APOBEC3-mediated mutagenesis in cancer: causes, clinical significance and therapeutic potential</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36978147/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230329210032&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Apolipoprotein B mRNA-editing enzyme, catalytic polypeptides (APOBECs) are cytosine deaminases involved in innate and adaptive immunity. However, some APOBEC family members can also deaminate host genomes to generate oncogenic mutations. The resulting mutations, primarily signatures 2 and 13, occur in many tumor types and are among the most common mutational signatures in cancer. This review summarizes the current evidence implicating APOBEC3s as major mutators and outlines the exogenous and...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-03-27 datetime="2023-03-27T10:00:00.000Z">2023-03-27</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-03-27 datetime="2023-03-27T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36973454"
                        open
                      >
                        <summary class="article-expander__title">Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36973454/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma, the most frequent solid tumor in infants, shows very diverse outcomes from spontaneous regression to fatal disease. When these different tumors originate and how they evolve are not known. Here we quantify the somatic evolution of neuroblastoma by deep whole-genome sequencing, molecular clock analysis and population-genetic modeling in a comprehensive cohort covering all subtypes. We find that tumors across the entire clinical spectrum begin to develop via aberrant mitoses as...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36973454"
                        open
                      >
                        <summary class="article-expander__title">Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36973454/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma, the most frequent solid tumor in infants, shows very diverse outcomes from spontaneous regression to fatal disease. When these different tumors originate and how they evolve are not known. Here we quantify the somatic evolution of neuroblastoma by deep whole-genome sequencing, molecular clock analysis and population-genetic modeling in a comprehensive cohort covering all subtypes. We find that tumors across the entire clinical spectrum begin to develop via aberrant mitoses as...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36973454"
                        open
                      >
                        <summary class="article-expander__title">Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36973454/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma, the most frequent solid tumor in infants, shows very diverse outcomes from spontaneous regression to fatal disease. When these different tumors originate and how they evolve are not known. Here we quantify the somatic evolution of neuroblastoma by deep whole-genome sequencing, molecular clock analysis and population-genetic modeling in a comprehensive cohort covering all subtypes. We find that tumors across the entire clinical spectrum begin to develop via aberrant mitoses as...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36971477"
                        open
                      >
                        <summary class="article-expander__title">Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36971477/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Large B-cell lymphoma of immune privileged sites (LBCL-IP) arise in immune sanctuaries including the testis and central nervous system. After initially reaching complete response, relapses occur in almost 50% of patients, typically at other immune privileged sites. Resolution of the clonal relationships and evolutionary patterns of LBCL-IP is required to understand the unique clinical behavior. We collected a unique set of 33 primary-relapse LBCL-IP sample pairs and performed next-generation...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36973454"
                        open
                      >
                        <summary class="article-expander__title">Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36973454/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma, the most frequent solid tumor in infants, shows very diverse outcomes from spontaneous regression to fatal disease. When these different tumors originate and how they evolve are not known. Here we quantify the somatic evolution of neuroblastoma by deep whole-genome sequencing, molecular clock analysis and population-genetic modeling in a comprehensive cohort covering all subtypes. We find that tumors across the entire clinical spectrum begin to develop via aberrant mitoses as...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36971477"
                        open
                      >
                        <summary class="article-expander__title">Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36971477/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Large B-cell lymphoma of immune privileged sites (LBCL-IP) arise in immune sanctuaries including the testis and central nervous system. After initially reaching complete response, relapses occur in almost 50% of patients, typically at other immune privileged sites. Resolution of the clonal relationships and evolutionary patterns of LBCL-IP is required to understand the unique clinical behavior. We collected a unique set of 33 primary-relapse LBCL-IP sample pairs and performed next-generation...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36973454"
                        open
                      >
                        <summary class="article-expander__title">Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36973454/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma, the most frequent solid tumor in infants, shows very diverse outcomes from spontaneous regression to fatal disease. When these different tumors originate and how they evolve are not known. Here we quantify the somatic evolution of neuroblastoma by deep whole-genome sequencing, molecular clock analysis and population-genetic modeling in a comprehensive cohort covering all subtypes. We find that tumors across the entire clinical spectrum begin to develop via aberrant mitoses as...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36971477"
                        open
                      >
                        <summary class="article-expander__title">Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36971477/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Large B-cell lymphoma of immune privileged sites (LBCL-IP) arise in immune sanctuaries including the testis and central nervous system. After initially reaching complete response, relapses occur in almost 50% of patients, typically at other immune privileged sites. Resolution of the clonal relationships and evolutionary patterns of LBCL-IP is required to understand the unique clinical behavior. We collected a unique set of 33 primary-relapse LBCL-IP sample pairs and performed next-generation...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36973454"
                        open
                      >
                        <summary class="article-expander__title">Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36973454/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma, the most frequent solid tumor in infants, shows very diverse outcomes from spontaneous regression to fatal disease. When these different tumors originate and how they evolve are not known. Here we quantify the somatic evolution of neuroblastoma by deep whole-genome sequencing, molecular clock analysis and population-genetic modeling in a comprehensive cohort covering all subtypes. We find that tumors across the entire clinical spectrum begin to develop via aberrant mitoses as...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36971477"
                        open
                      >
                        <summary class="article-expander__title">Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36971477/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Large B-cell lymphoma of immune privileged sites (LBCL-IP) arise in immune sanctuaries including the testis and central nervous system. After initially reaching complete response, relapses occur in almost 50% of patients, typically at other immune privileged sites. Resolution of the clonal relationships and evolutionary patterns of LBCL-IP is required to understand the unique clinical behavior. We collected a unique set of 33 primary-relapse LBCL-IP sample pairs and performed next-generation...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36973454"
                        open
                      >
                        <summary class="article-expander__title">Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36973454/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma, the most frequent solid tumor in infants, shows very diverse outcomes from spontaneous regression to fatal disease. When these different tumors originate and how they evolve are not known. Here we quantify the somatic evolution of neuroblastoma by deep whole-genome sequencing, molecular clock analysis and population-genetic modeling in a comprehensive cohort covering all subtypes. We find that tumors across the entire clinical spectrum begin to develop via aberrant mitoses as...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36971477"
                        open
                      >
                        <summary class="article-expander__title">Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36971477/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Large B-cell lymphoma of immune privileged sites (LBCL-IP) arise in immune sanctuaries including the testis and central nervous system. After initially reaching complete response, relapses occur in almost 50% of patients, typically at other immune privileged sites. Resolution of the clonal relationships and evolutionary patterns of LBCL-IP is required to understand the unique clinical behavior. We collected a unique set of 33 primary-relapse LBCL-IP sample pairs and performed next-generation...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36973454"
                        open
                      >
                        <summary class="article-expander__title">Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36973454/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230329210032&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma, the most frequent solid tumor in infants, shows very diverse outcomes from spontaneous regression to fatal disease. When these different tumors originate and how they evolve are not known. Here we quantify the somatic evolution of neuroblastoma by deep whole-genome sequencing, molecular clock analysis and population-genetic modeling in a comprehensive cohort covering all subtypes. We find that tumors across the entire clinical spectrum begin to develop via aberrant mitoses as...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36971477"
                        open
                      >
                        <summary class="article-expander__title">Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36971477/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230329210032&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Large B-cell lymphoma of immune privileged sites (LBCL-IP) arise in immune sanctuaries including the testis and central nervous system. After initially reaching complete response, relapses occur in almost 50% of patients, typically at other immune privileged sites. Resolution of the clonal relationships and evolutionary patterns of LBCL-IP is required to understand the unique clinical behavior. We collected a unique set of 33 primary-relapse LBCL-IP sample pairs and performed next-generation...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36973454"
                        open
                      >
                        <summary class="article-expander__title">Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36973454/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230328210444&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Neuroblastoma, the most frequent solid tumor in infants, shows very diverse outcomes from spontaneous regression to fatal disease. When these different tumors originate and how they evolve are not known. Here we quantify the somatic evolution of neuroblastoma by deep whole-genome sequencing, molecular clock analysis and population-genetic modeling in a comprehensive cohort covering all subtypes. We find that tumors across the entire clinical spectrum begin to develop via aberrant mitoses as...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36971477"
                        open
                      >
                        <summary class="article-expander__title">Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36971477/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230328210444&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Large B-cell lymphoma of immune privileged sites (LBCL-IP) arise in immune sanctuaries including the testis and central nervous system. After initially reaching complete response, relapses occur in almost 50% of patients, typically at other immune privileged sites. Resolution of the clonal relationships and evolutionary patterns of LBCL-IP is required to understand the unique clinical behavior. We collected a unique set of 33 primary-relapse LBCL-IP sample pairs and performed next-generation...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36971477"
                        open
                      >
                        <summary class="article-expander__title">Large B-cell lymphomas of immune privileged sites relapse via parallel clonal evolution from a common progenitor B-cell</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36971477/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230327210053&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Large B-cell lymphoma of immune privileged sites (LBCL-IP) arise in immune sanctuaries including the testis and central nervous system. After initially reaching complete response, relapses occur in almost 50% of patients, typically at other immune privileged sites. Resolution of the clonal relationships and evolutionary patterns of LBCL-IP is required to understand the unique clinical behavior. We collected a unique set of 33 primary-relapse LBCL-IP sample pairs and performed next-generation...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-03-25 datetime="2023-03-25T10:00:00.000Z">2023-03-25</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-03-25 datetime="2023-03-25T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36966135"
                        open
                      >
                        <summary class="article-expander__title">Clonal origin and development of high hyperdiploidy in childhood acute lymphoblastic leukaemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36966135/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>High hyperdiploid acute lymphoblastic leukemia (HeH ALL), one of the most common childhood malignancies, is driven by nonrandom aneuploidy (abnormal chromosome numbers) mainly comprising chromosomal gains. In this study, we investigate how aneuploidy in HeH ALL arises. Single cell whole genome sequencing of 2847 cells from nine primary cases and one normal bone marrow reveals that HeH ALL generally display low chromosomal heterogeneity, indicating that they are not characterized by chromosomal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36966135"
                        open
                      >
                        <summary class="article-expander__title">Clonal origin and development of high hyperdiploidy in childhood acute lymphoblastic leukaemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36966135/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>High hyperdiploid acute lymphoblastic leukemia (HeH ALL), one of the most common childhood malignancies, is driven by nonrandom aneuploidy (abnormal chromosome numbers) mainly comprising chromosomal gains. In this study, we investigate how aneuploidy in HeH ALL arises. Single cell whole genome sequencing of 2847 cells from nine primary cases and one normal bone marrow reveals that HeH ALL generally display low chromosomal heterogeneity, indicating that they are not characterized by chromosomal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36966135"
                        open
                      >
                        <summary class="article-expander__title">Clonal origin and development of high hyperdiploidy in childhood acute lymphoblastic leukaemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36966135/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>High hyperdiploid acute lymphoblastic leukemia (HeH ALL), one of the most common childhood malignancies, is driven by nonrandom aneuploidy (abnormal chromosome numbers) mainly comprising chromosomal gains. In this study, we investigate how aneuploidy in HeH ALL arises. Single cell whole genome sequencing of 2847 cells from nine primary cases and one normal bone marrow reveals that HeH ALL generally display low chromosomal heterogeneity, indicating that they are not characterized by chromosomal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36966135"
                        open
                      >
                        <summary class="article-expander__title">Clonal origin and development of high hyperdiploidy in childhood acute lymphoblastic leukaemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36966135/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>High hyperdiploid acute lymphoblastic leukemia (HeH ALL), one of the most common childhood malignancies, is driven by nonrandom aneuploidy (abnormal chromosome numbers) mainly comprising chromosomal gains. In this study, we investigate how aneuploidy in HeH ALL arises. Single cell whole genome sequencing of 2847 cells from nine primary cases and one normal bone marrow reveals that HeH ALL generally display low chromosomal heterogeneity, indicating that they are not characterized by chromosomal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36966135"
                        open
                      >
                        <summary class="article-expander__title">Clonal origin and development of high hyperdiploidy in childhood acute lymphoblastic leukaemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36966135/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>High hyperdiploid acute lymphoblastic leukemia (HeH ALL), one of the most common childhood malignancies, is driven by nonrandom aneuploidy (abnormal chromosome numbers) mainly comprising chromosomal gains. In this study, we investigate how aneuploidy in HeH ALL arises. Single cell whole genome sequencing of 2847 cells from nine primary cases and one normal bone marrow reveals that HeH ALL generally display low chromosomal heterogeneity, indicating that they are not characterized by chromosomal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36966135"
                        open
                      >
                        <summary class="article-expander__title">Clonal origin and development of high hyperdiploidy in childhood acute lymphoblastic leukaemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36966135/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230329210032&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>High hyperdiploid acute lymphoblastic leukemia (HeH ALL), one of the most common childhood malignancies, is driven by nonrandom aneuploidy (abnormal chromosome numbers) mainly comprising chromosomal gains. In this study, we investigate how aneuploidy in HeH ALL arises. Single cell whole genome sequencing of 2847 cells from nine primary cases and one normal bone marrow reveals that HeH ALL generally display low chromosomal heterogeneity, indicating that they are not characterized by chromosomal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;10
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36966135"
                        open
                      >
                        <summary class="article-expander__title">Clonal origin and development of high hyperdiploidy in childhood acute lymphoblastic leukaemia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36966135/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230328210444&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>High hyperdiploid acute lymphoblastic leukemia (HeH ALL), one of the most common childhood malignancies, is driven by nonrandom aneuploidy (abnormal chromosome numbers) mainly comprising chromosomal gains. In this study, we investigate how aneuploidy in HeH ALL arises. Single cell whole genome sequencing of 2847 cells from nine primary cases and one normal bone marrow reveals that HeH ALL generally display low chromosomal heterogeneity, indicating that they are not characterized by chromosomal...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-03-23 datetime="2023-03-23T10:00:00.000Z">2023-03-23</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-03-23 datetime="2023-03-23T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36951061"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36951061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-third of major adverse cardiovascular events in CMD are mediated by CH.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36949957"
                        open
                      >
                        <summary class="article-expander__title">TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36949957/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Somatic mutations in blood indicative of clonal hematopoiesis of indeterminate potential (CHIP) are associated with an increased risk of hematologic malignancy, coronary artery disease, and all-cause mortality. Here we analyze the relation between CHIP status and incident peripheral artery disease (PAD) and atherosclerosis, using whole-exome sequencing and clinical data from the UK Biobank and Mass General Brigham Biobank. CHIP associated with incident PAD and atherosclerotic disease across...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36951061"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36951061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-third of major adverse cardiovascular events in CMD are mediated by CH.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36949957"
                        open
                      >
                        <summary class="article-expander__title">TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36949957/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Somatic mutations in blood indicative of clonal hematopoiesis of indeterminate potential (CHIP) are associated with an increased risk of hematologic malignancy, coronary artery disease, and all-cause mortality. Here we analyze the relation between CHIP status and incident peripheral artery disease (PAD) and atherosclerosis, using whole-exome sequencing and clinical data from the UK Biobank and Mass General Brigham Biobank. CHIP associated with incident PAD and atherosclerotic disease across...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36951061"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36951061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-third of major adverse cardiovascular events in CMD are mediated by CH.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36949957"
                        open
                      >
                        <summary class="article-expander__title">TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36949957/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Somatic mutations in blood indicative of clonal hematopoiesis of indeterminate potential (CHIP) are associated with an increased risk of hematologic malignancy, coronary artery disease, and all-cause mortality. Here we analyze the relation between CHIP status and incident peripheral artery disease (PAD) and atherosclerosis, using whole-exome sequencing and clinical data from the UK Biobank and Mass General Brigham Biobank. CHIP associated with incident PAD and atherosclerotic disease across...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36951061"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36951061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-third of major adverse cardiovascular events in CMD are mediated by CH.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36949957"
                        open
                      >
                        <summary class="article-expander__title">TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36949957/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Somatic mutations in blood indicative of clonal hematopoiesis of indeterminate potential (CHIP) are associated with an increased risk of hematologic malignancy, coronary artery disease, and all-cause mortality. Here we analyze the relation between CHIP status and incident peripheral artery disease (PAD) and atherosclerosis, using whole-exome sequencing and clinical data from the UK Biobank and Mass General Brigham Biobank. CHIP associated with incident PAD and atherosclerotic disease across...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36951061"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36951061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-third of major adverse cardiovascular events in CMD are mediated by CH.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36949957"
                        open
                      >
                        <summary class="article-expander__title">TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36949957/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Somatic mutations in blood indicative of clonal hematopoiesis of indeterminate potential (CHIP) are associated with an increased risk of hematologic malignancy, coronary artery disease, and all-cause mortality. Here we analyze the relation between CHIP status and incident peripheral artery disease (PAD) and atherosclerosis, using whole-exome sequencing and clinical data from the UK Biobank and Mass General Brigham Biobank. CHIP associated with incident PAD and atherosclerotic disease across...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36951061"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36951061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-third of major adverse cardiovascular events in CMD are mediated by CH.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36949957"
                        open
                      >
                        <summary class="article-expander__title">TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36949957/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Somatic mutations in blood indicative of clonal hematopoiesis of indeterminate potential (CHIP) are associated with an increased risk of hematologic malignancy, coronary artery disease, and all-cause mortality. Here we analyze the relation between CHIP status and incident peripheral artery disease (PAD) and atherosclerosis, using whole-exome sequencing and clinical data from the UK Biobank and Mass General Brigham Biobank. CHIP associated with incident PAD and atherosclerotic disease across...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36951061"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36951061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-third of major adverse cardiovascular events in CMD are mediated by CH.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36949957"
                        open
                      >
                        <summary class="article-expander__title">TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36949957/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Somatic mutations in blood indicative of clonal hematopoiesis of indeterminate potential (CHIP) are associated with an increased risk of hematologic malignancy, coronary artery disease, and all-cause mortality. Here we analyze the relation between CHIP status and incident peripheral artery disease (PAD) and atherosclerosis, using whole-exome sequencing and clinical data from the UK Biobank and Mass General Brigham Biobank. CHIP associated with incident PAD and atherosclerotic disease across...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36951061"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36951061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-third of major adverse cardiovascular events in CMD are mediated by CH.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36949957"
                        open
                      >
                        <summary class="article-expander__title">TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36949957/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Somatic mutations in blood indicative of clonal hematopoiesis of indeterminate potential (CHIP) are associated with an increased risk of hematologic malignancy, coronary artery disease, and all-cause mortality. Here we analyze the relation between CHIP status and incident peripheral artery disease (PAD) and atherosclerosis, using whole-exome sequencing and clinical data from the UK Biobank and Mass General Brigham Biobank. CHIP associated with incident PAD and atherosclerotic disease across...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36951061"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36951061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230329210032&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-third of major adverse cardiovascular events in CMD are mediated by CH.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36949957"
                        open
                      >
                        <summary class="article-expander__title">TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36949957/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230329210032&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Somatic mutations in blood indicative of clonal hematopoiesis of indeterminate potential (CHIP) are associated with an increased risk of hematologic malignancy, coronary artery disease, and all-cause mortality. Here we analyze the relation between CHIP status and incident peripheral artery disease (PAD) and atherosclerosis, using whole-exome sequencing and clinical data from the UK Biobank and Mass General Brigham Biobank. CHIP associated with incident PAD and atherosclerotic disease across...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36951061"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36951061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230328210444&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-third of major adverse cardiovascular events in CMD are mediated by CH.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36949957"
                        open
                      >
                        <summary class="article-expander__title">TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36949957/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230328210444&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Somatic mutations in blood indicative of clonal hematopoiesis of indeterminate potential (CHIP) are associated with an increased risk of hematologic malignancy, coronary artery disease, and all-cause mortality. Here we analyze the relation between CHIP status and incident peripheral artery disease (PAD) and atherosclerosis, using whole-exome sequencing and clinical data from the UK Biobank and Mass General Brigham Biobank. CHIP associated with incident PAD and atherosclerotic disease across...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36951061"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36951061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230327210053&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-third of major adverse cardiovascular events in CMD are mediated by CH.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36949957"
                        open
                      >
                        <summary class="article-expander__title">TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36949957/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230327210053&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Somatic mutations in blood indicative of clonal hematopoiesis of indeterminate potential (CHIP) are associated with an increased risk of hematologic malignancy, coronary artery disease, and all-cause mortality. Here we analyze the relation between CHIP status and incident peripheral artery disease (PAD) and atherosclerosis, using whole-exome sequencing and clinical data from the UK Biobank and Mass General Brigham Biobank. CHIP associated with incident PAD and atherosclerotic disease across...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36951061"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36951061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230326205727&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-third of major adverse cardiovascular events in CMD are mediated by CH.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36949957"
                        open
                      >
                        <summary class="article-expander__title">TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36949957/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230326205727&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Somatic mutations in blood indicative of clonal hematopoiesis of indeterminate potential (CHIP) are associated with an increased risk of hematologic malignancy, coronary artery disease, and all-cause mortality. Here we analyze the relation between CHIP status and incident peripheral artery disease (PAD) and atherosclerosis, using whole-exome sequencing and clinical data from the UK Biobank and Mass General Brigham Biobank. CHIP associated with incident PAD and atherosclerotic disease across...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36951061"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36951061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230325210245&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-third of major adverse cardiovascular events in CMD are mediated by CH.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36949957"
                        open
                      >
                        <summary class="article-expander__title">TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36949957/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230325210245&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Somatic mutations in blood indicative of clonal hematopoiesis of indeterminate potential (CHIP) are associated with an increased risk of hematologic malignancy, coronary artery disease, and all-cause mortality. Here we analyze the relation between CHIP status and incident peripheral artery disease (PAD) and atherosclerosis, using whole-exome sequencing and clinical data from the UK Biobank and Mass General Brigham Biobank. CHIP associated with incident PAD and atherosclerotic disease across...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36951061"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36951061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230324205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-third of major adverse cardiovascular events in CMD are mediated by CH.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36949957"
                        open
                      >
                        <summary class="article-expander__title">TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36949957/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230324205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Somatic mutations in blood indicative of clonal hematopoiesis of indeterminate potential (CHIP) are associated with an increased risk of hematologic malignancy, coronary artery disease, and all-cause mortality. Here we analyze the relation between CHIP status and incident peripheral artery disease (PAD) and atherosclerosis, using whole-exome sequencing and clinical data from the UK Biobank and Mass General Brigham Biobank. CHIP associated with incident PAD and atherosclerotic disease across...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;9
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36951061"
                        open
                      >
                        <summary class="article-expander__title">Clonal Hematopoiesis of Indeterminate Potential Is Associated With Coronary Microvascular Dysfunction In Early Nonobstructive Coronary Artery Disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36951061/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230323205759&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>CONCLUSIONS: In humans, we observe patients with CMD are more likely to have CHIP, and nearly one-third of major adverse cardiovascular events in CMD are mediated by CH.</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36949957"
                        open
                      >
                        <summary class="article-expander__title">TP53-mediated clonal hematopoiesis confers increased risk for incident atherosclerotic disease</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36949957/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230323205759&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Somatic mutations in blood indicative of clonal hematopoiesis of indeterminate potential (CHIP) are associated with an increased risk of hematologic malignancy, coronary artery disease, and all-cause mortality. Here we analyze the relation between CHIP status and incident peripheral artery disease (PAD) and atherosclerosis, using whole-exome sequencing and clinical data from the UK Biobank and Mass General Brigham Biobank. CHIP associated with incident PAD and atherosclerotic disease across...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;8
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36958250"
                        open
                      >
                        <summary class="article-expander__title">Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36958250/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Despite a strong rationale for why cancer cells are susceptible to redox-targeting drugs, such drugs often face tumor resistance or dose-limiting toxicity in preclinical and clinical studies. An important reason is the lack of specific biomarkers to better select susceptible cancer entities and stratify patients. Using a large panel of lung cancer cell lines, we identified a set of &quot;antioxidant-capacity&quot; biomarkers (ACB), which were tightly repressed, partly by STAT3 and STAT5A/B in sensitive...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;16
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36958250"
                        open
                      >
                        <summary class="article-expander__title">Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36958250/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Despite a strong rationale for why cancer cells are susceptible to redox-targeting drugs, such drugs often face tumor resistance or dose-limiting toxicity in preclinical and clinical studies. An important reason is the lack of specific biomarkers to better select susceptible cancer entities and stratify patients. Using a large panel of lung cancer cell lines, we identified a set of &quot;antioxidant-capacity&quot; biomarkers (ACB), which were tightly repressed, partly by STAT3 and STAT5A/B in sensitive...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;16
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36958250"
                        open
                      >
                        <summary class="article-expander__title">Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36958250/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Despite a strong rationale for why cancer cells are susceptible to redox-targeting drugs, such drugs often face tumor resistance or dose-limiting toxicity in preclinical and clinical studies. An important reason is the lack of specific biomarkers to better select susceptible cancer entities and stratify patients. Using a large panel of lung cancer cell lines, we identified a set of &quot;antioxidant-capacity&quot; biomarkers (ACB), which were tightly repressed, partly by STAT3 and STAT5A/B in sensitive...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36958250"
                        open
                      >
                        <summary class="article-expander__title">Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36958250/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Despite a strong rationale for why cancer cells are susceptible to redox-targeting drugs, such drugs often face tumor resistance or dose-limiting toxicity in preclinical and clinical studies. An important reason is the lack of specific biomarkers to better select susceptible cancer entities and stratify patients. Using a large panel of lung cancer cell lines, we identified a set of &quot;antioxidant-capacity&quot; biomarkers (ACB), which were tightly repressed, partly by STAT3 and STAT5A/B in sensitive...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36958250"
                        open
                      >
                        <summary class="article-expander__title">Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36958250/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230329210032&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Despite a strong rationale for why cancer cells are susceptible to redox-targeting drugs, such drugs often face tumor resistance or dose-limiting toxicity in preclinical and clinical studies. An important reason is the lack of specific biomarkers to better select susceptible cancer entities and stratify patients. Using a large panel of lung cancer cell lines, we identified a set of &quot;antioxidant-capacity&quot; biomarkers (ACB), which were tightly repressed, partly by STAT3 and STAT5A/B in sensitive...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36958250"
                        open
                      >
                        <summary class="article-expander__title">Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36958250/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230328210444&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Despite a strong rationale for why cancer cells are susceptible to redox-targeting drugs, such drugs often face tumor resistance or dose-limiting toxicity in preclinical and clinical studies. An important reason is the lack of specific biomarkers to better select susceptible cancer entities and stratify patients. Using a large panel of lung cancer cell lines, we identified a set of &quot;antioxidant-capacity&quot; biomarkers (ACB), which were tightly repressed, partly by STAT3 and STAT5A/B in sensitive...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36958250"
                        open
                      >
                        <summary class="article-expander__title">Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36958250/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230327210053&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Despite a strong rationale for why cancer cells are susceptible to redox-targeting drugs, such drugs often face tumor resistance or dose-limiting toxicity in preclinical and clinical studies. An important reason is the lack of specific biomarkers to better select susceptible cancer entities and stratify patients. Using a large panel of lung cancer cell lines, we identified a set of &quot;antioxidant-capacity&quot; biomarkers (ACB), which were tightly repressed, partly by STAT3 and STAT5A/B in sensitive...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36958250"
                        open
                      >
                        <summary class="article-expander__title">Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36958250/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230326205727&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Despite a strong rationale for why cancer cells are susceptible to redox-targeting drugs, such drugs often face tumor resistance or dose-limiting toxicity in preclinical and clinical studies. An important reason is the lack of specific biomarkers to better select susceptible cancer entities and stratify patients. Using a large panel of lung cancer cell lines, we identified a set of &quot;antioxidant-capacity&quot; biomarkers (ACB), which were tightly repressed, partly by STAT3 and STAT5A/B in sensitive...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36958250"
                        open
                      >
                        <summary class="article-expander__title">Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36958250/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230325210245&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Despite a strong rationale for why cancer cells are susceptible to redox-targeting drugs, such drugs often face tumor resistance or dose-limiting toxicity in preclinical and clinical studies. An important reason is the lack of specific biomarkers to better select susceptible cancer entities and stratify patients. Using a large panel of lung cancer cell lines, we identified a set of &quot;antioxidant-capacity&quot; biomarkers (ACB), which were tightly repressed, partly by STAT3 and STAT5A/B in sensitive...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;7
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36958250"
                        open
                      >
                        <summary class="article-expander__title">Low level of antioxidant capacity biomarkers but not target overexpression predicts vulnerability to ROS-inducing drugs</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36958250/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230324205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Despite a strong rationale for why cancer cells are susceptible to redox-targeting drugs, such drugs often face tumor resistance or dose-limiting toxicity in preclinical and clinical studies. An important reason is the lack of specific biomarkers to better select susceptible cancer entities and stratify patients. Using a large panel of lung cancer cell lines, we identified a set of &quot;antioxidant-capacity&quot; biomarkers (ACB), which were tightly repressed, partly by STAT3 and STAT5A/B in sensitive...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2023-03-22 datetime="2023-03-22T10:00:00.000Z">2023-03-22</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2023-03-22 datetime="2023-03-22T10:00:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >Clonal Hematopoiesis</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;ff&#x3D;20230519205525&amp;utm_source&#x3D;axios&amp;fc&#x3D;20220608003622&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_medium&#x3D;rss">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36947811"
                        open
                      >
                        <summary class="article-expander__title">ALWAYS STRESSED BUT NEVER EXHAUSTED: HOW STEM CELLS IN MYELOID NEOPLASMS AVOID EXTINCTION IN INFLAMMATORY CONDITIONS</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36947811/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230406205211&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Chronic or recurrent episodes of acute inflammation cause attrition of normal hematopoietic stem cells (HSCs) that can lead to hematopoietic failure, but they drive progression in myeloid malignancies and their precursor clonal hematopoiesis (CH). Mechanistic parallels exist between hematopoiesis in chronic inflammation and the continuously increased proliferation of myeloid malignancies, particularly myeloproliferative neoplasms (MPNs). The ability to enter dormancy, a state of deep quiescence...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36947811"
                        open
                      >
                        <summary class="article-expander__title">ALWAYS STRESSED BUT NEVER EXHAUSTED: HOW STEM CELLS IN MYELOID NEOPLASMS AVOID EXTINCTION IN INFLAMMATORY CONDITIONS</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36947811/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230405205549&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Chronic or recurrent episodes of acute inflammation cause attrition of normal hematopoietic stem cells (HSCs) that can lead to hematopoietic failure, but they drive progression in myeloid malignancies and their precursor clonal hematopoiesis (CH). Mechanistic parallels exist between hematopoiesis in chronic inflammation and the continuously increased proliferation of myeloid malignancies, particularly myeloproliferative neoplasms (MPNs). The ability to enter dormancy, a state of deep quiescence...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36947811"
                        open
                      >
                        <summary class="article-expander__title">ALWAYS STRESSED BUT NEVER EXHAUSTED: HOW STEM CELLS IN MYELOID NEOPLASMS AVOID EXTINCTION IN INFLAMMATORY CONDITIONS</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36947811/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230404204750&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Chronic or recurrent episodes of acute inflammation cause attrition of normal hematopoietic stem cells (HSCs) that can lead to hematopoietic failure, but they drive progression in myeloid malignancies and their precursor clonal hematopoiesis (CH). Mechanistic parallels exist between hematopoiesis in chronic inflammation and the continuously increased proliferation of myeloid malignancies, particularly myeloproliferative neoplasms (MPNs). The ability to enter dormancy, a state of deep quiescence...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36947811"
                        open
                      >
                        <summary class="article-expander__title">ALWAYS STRESSED BUT NEVER EXHAUSTED: HOW STEM CELLS IN MYELOID NEOPLASMS AVOID EXTINCTION IN INFLAMMATORY CONDITIONS</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36947811/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230403205647&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Chronic or recurrent episodes of acute inflammation cause attrition of normal hematopoietic stem cells (HSCs) that can lead to hematopoietic failure, but they drive progression in myeloid malignancies and their precursor clonal hematopoiesis (CH). Mechanistic parallels exist between hematopoiesis in chronic inflammation and the continuously increased proliferation of myeloid malignancies, particularly myeloproliferative neoplasms (MPNs). The ability to enter dormancy, a state of deep quiescence...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36947811"
                        open
                      >
                        <summary class="article-expander__title">ALWAYS STRESSED BUT NEVER EXHAUSTED: HOW STEM CELLS IN MYELOID NEOPLASMS AVOID EXTINCTION IN INFLAMMATORY CONDITIONS</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36947811/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Chronic or recurrent episodes of acute inflammation cause attrition of normal hematopoietic stem cells (HSCs) that can lead to hematopoietic failure, but they drive progression in myeloid malignancies and their precursor clonal hematopoiesis (CH). Mechanistic parallels exist between hematopoiesis in chronic inflammation and the continuously increased proliferation of myeloid malignancies, particularly myeloproliferative neoplasms (MPNs). The ability to enter dormancy, a state of deep quiescence...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36947811"
                        open
                      >
                        <summary class="article-expander__title">ALWAYS STRESSED BUT NEVER EXHAUSTED: HOW STEM CELLS IN MYELOID NEOPLASMS AVOID EXTINCTION IN INFLAMMATORY CONDITIONS</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36947811/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Chronic or recurrent episodes of acute inflammation cause attrition of normal hematopoietic stem cells (HSCs) that can lead to hematopoietic failure, but they drive progression in myeloid malignancies and their precursor clonal hematopoiesis (CH). Mechanistic parallels exist between hematopoiesis in chronic inflammation and the continuously increased proliferation of myeloid malignancies, particularly myeloproliferative neoplasms (MPNs). The ability to enter dormancy, a state of deep quiescence...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36947811"
                        open
                      >
                        <summary class="article-expander__title">ALWAYS STRESSED BUT NEVER EXHAUSTED: HOW STEM CELLS IN MYELOID NEOPLASMS AVOID EXTINCTION IN INFLAMMATORY CONDITIONS</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36947811/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Chronic or recurrent episodes of acute inflammation cause attrition of normal hematopoietic stem cells (HSCs) that can lead to hematopoietic failure, but they drive progression in myeloid malignancies and their precursor clonal hematopoiesis (CH). Mechanistic parallels exist between hematopoiesis in chronic inflammation and the continuously increased proliferation of myeloid malignancies, particularly myeloproliferative neoplasms (MPNs). The ability to enter dormancy, a state of deep quiescence...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36947811"
                        open
                      >
                        <summary class="article-expander__title">ALWAYS STRESSED BUT NEVER EXHAUSTED: HOW STEM CELLS IN MYELOID NEOPLASMS AVOID EXTINCTION IN INFLAMMATORY CONDITIONS</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36947811/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Chronic or recurrent episodes of acute inflammation cause attrition of normal hematopoietic stem cells (HSCs) that can lead to hematopoietic failure, but they drive progression in myeloid malignancies and their precursor clonal hematopoiesis (CH). Mechanistic parallels exist between hematopoiesis in chronic inflammation and the continuously increased proliferation of myeloid malignancies, particularly myeloproliferative neoplasms (MPNs). The ability to enter dormancy, a state of deep quiescence...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36947811"
                        open
                      >
                        <summary class="article-expander__title">ALWAYS STRESSED BUT NEVER EXHAUSTED: HOW STEM CELLS IN MYELOID NEOPLASMS AVOID EXTINCTION IN INFLAMMATORY CONDITIONS</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36947811/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230329210032&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Chronic or recurrent episodes of acute inflammation cause attrition of normal hematopoietic stem cells (HSCs) that can lead to hematopoietic failure, but they drive progression in myeloid malignancies and their precursor clonal hematopoiesis (CH). Mechanistic parallels exist between hematopoiesis in chronic inflammation and the continuously increased proliferation of myeloid malignancies, particularly myeloproliferative neoplasms (MPNs). The ability to enter dormancy, a state of deep quiescence...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36947811"
                        open
                      >
                        <summary class="article-expander__title">ALWAYS STRESSED BUT NEVER EXHAUSTED: HOW STEM CELLS IN MYELOID NEOPLASMS AVOID EXTINCTION IN INFLAMMATORY CONDITIONS</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36947811/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230328210444&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Chronic or recurrent episodes of acute inflammation cause attrition of normal hematopoietic stem cells (HSCs) that can lead to hematopoietic failure, but they drive progression in myeloid malignancies and their precursor clonal hematopoiesis (CH). Mechanistic parallels exist between hematopoiesis in chronic inflammation and the continuously increased proliferation of myeloid malignancies, particularly myeloproliferative neoplasms (MPNs). The ability to enter dormancy, a state of deep quiescence...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36947811"
                        open
                      >
                        <summary class="article-expander__title">ALWAYS STRESSED BUT NEVER EXHAUSTED: HOW STEM CELLS IN MYELOID NEOPLASMS AVOID EXTINCTION IN INFLAMMATORY CONDITIONS</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36947811/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230327210053&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Chronic or recurrent episodes of acute inflammation cause attrition of normal hematopoietic stem cells (HSCs) that can lead to hematopoietic failure, but they drive progression in myeloid malignancies and their precursor clonal hematopoiesis (CH). Mechanistic parallels exist between hematopoiesis in chronic inflammation and the continuously increased proliferation of myeloid malignancies, particularly myeloproliferative neoplasms (MPNs). The ability to enter dormancy, a state of deep quiescence...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36947811"
                        open
                      >
                        <summary class="article-expander__title">ALWAYS STRESSED BUT NEVER EXHAUSTED: HOW STEM CELLS IN MYELOID NEOPLASMS AVOID EXTINCTION IN INFLAMMATORY CONDITIONS</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36947811/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230326205727&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Chronic or recurrent episodes of acute inflammation cause attrition of normal hematopoietic stem cells (HSCs) that can lead to hematopoietic failure, but they drive progression in myeloid malignancies and their precursor clonal hematopoiesis (CH). Mechanistic parallels exist between hematopoiesis in chronic inflammation and the continuously increased proliferation of myeloid malignancies, particularly myeloproliferative neoplasms (MPNs). The ability to enter dormancy, a state of deep quiescence...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36947811"
                        open
                      >
                        <summary class="article-expander__title">ALWAYS STRESSED BUT NEVER EXHAUSTED: HOW STEM CELLS IN MYELOID NEOPLASMS AVOID EXTINCTION IN INFLAMMATORY CONDITIONS</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36947811/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230325210245&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Chronic or recurrent episodes of acute inflammation cause attrition of normal hematopoietic stem cells (HSCs) that can lead to hematopoietic failure, but they drive progression in myeloid malignancies and their precursor clonal hematopoiesis (CH). Mechanistic parallels exist between hematopoiesis in chronic inflammation and the continuously increased proliferation of myeloid malignancies, particularly myeloproliferative neoplasms (MPNs). The ability to enter dormancy, a state of deep quiescence...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36947811"
                        open
                      >
                        <summary class="article-expander__title">ALWAYS STRESSED BUT NEVER EXHAUSTED: HOW STEM CELLS IN MYELOID NEOPLASMS AVOID EXTINCTION IN INFLAMMATORY CONDITIONS</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36947811/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230324205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Chronic or recurrent episodes of acute inflammation cause attrition of normal hematopoietic stem cells (HSCs) that can lead to hematopoietic failure, but they drive progression in myeloid malignancies and their precursor clonal hematopoiesis (CH). Mechanistic parallels exist between hematopoiesis in chronic inflammation and the continuously increased proliferation of myeloid malignancies, particularly myeloproliferative neoplasms (MPNs). The ability to enter dormancy, a state of deep quiescence...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36947811"
                        open
                      >
                        <summary class="article-expander__title">ALWAYS STRESSED BUT NEVER EXHAUSTED: HOW STEM CELLS IN MYELOID NEOPLASMS AVOID EXTINCTION IN INFLAMMATORY CONDITIONS</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36947811/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230323205759&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Chronic or recurrent episodes of acute inflammation cause attrition of normal hematopoietic stem cells (HSCs) that can lead to hematopoietic failure, but they drive progression in myeloid malignancies and their precursor clonal hematopoiesis (CH). Mechanistic parallels exist between hematopoiesis in chronic inflammation and the continuously increased proliferation of myeloid malignancies, particularly myeloproliferative neoplasms (MPNs). The ability to enter dormancy, a state of deep quiescence...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36947811"
                        open
                      >
                        <summary class="article-expander__title">ALWAYS STRESSED BUT NEVER EXHAUSTED: HOW STEM CELLS IN MYELOID NEOPLASMS AVOID EXTINCTION IN INFLAMMATORY CONDITIONS</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36947811/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc&#x3D;20220608003622&amp;ff&#x3D;20230322205809&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Chronic or recurrent episodes of acute inflammation cause attrition of normal hematopoietic stem cells (HSCs) that can lead to hematopoietic failure, but they drive progression in myeloid malignancies and their precursor clonal hematopoiesis (CH). Mechanistic parallels exist between hematopoiesis in chronic inflammation and the continuously increased proliferation of myeloid malignancies, particularly myeloproliferative neoplasms (MPNs). The ability to enter dormancy, a state of deep quiescence...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;4
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >#cancer#tumor#evolution#somatic</button>
                  <a class="source-heading__link" href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;ff&#x3D;20230519205525&amp;v&#x3D;2.17.9.post6+86293ac&amp;utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36948134"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial transplantation: Effects on chemotherapy in prostate and ovarian cancer cells in vitro and in vivo</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36948134/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230402205550&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Prostate and ovarian cancers affect the male and female reproductive organs and are among the most common cancers in developing countries. Previous studies have demonstrated that cancer cells have a high rate of aerobic glycolysis that is present in nearly all invasive human cancers and persists even under normoxic conditions. Aerobic glycolysis has been correlated with chemotherapeutic resistance and tumor aggressiveness. These data suggest that mitochondrial dysfunction may confer a...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36948134"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial transplantation: Effects on chemotherapy in prostate and ovarian cancer cells in vitro and in vivo</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36948134/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230401210003&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Prostate and ovarian cancers affect the male and female reproductive organs and are among the most common cancers in developing countries. Previous studies have demonstrated that cancer cells have a high rate of aerobic glycolysis that is present in nearly all invasive human cancers and persists even under normoxic conditions. Aerobic glycolysis has been correlated with chemotherapeutic resistance and tumor aggressiveness. These data suggest that mitochondrial dysfunction may confer a...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36948134"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial transplantation: Effects on chemotherapy in prostate and ovarian cancer cells in vitro and in vivo</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36948134/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230331205841&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Prostate and ovarian cancers affect the male and female reproductive organs and are among the most common cancers in developing countries. Previous studies have demonstrated that cancer cells have a high rate of aerobic glycolysis that is present in nearly all invasive human cancers and persists even under normoxic conditions. Aerobic glycolysis has been correlated with chemotherapeutic resistance and tumor aggressiveness. These data suggest that mitochondrial dysfunction may confer a...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36948134"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial transplantation: Effects on chemotherapy in prostate and ovarian cancer cells in vitro and in vivo</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36948134/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230330205959&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Prostate and ovarian cancers affect the male and female reproductive organs and are among the most common cancers in developing countries. Previous studies have demonstrated that cancer cells have a high rate of aerobic glycolysis that is present in nearly all invasive human cancers and persists even under normoxic conditions. Aerobic glycolysis has been correlated with chemotherapeutic resistance and tumor aggressiveness. These data suggest that mitochondrial dysfunction may confer a...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36948134"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial transplantation: Effects on chemotherapy in prostate and ovarian cancer cells in vitro and in vivo</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36948134/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230329210032&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Prostate and ovarian cancers affect the male and female reproductive organs and are among the most common cancers in developing countries. Previous studies have demonstrated that cancer cells have a high rate of aerobic glycolysis that is present in nearly all invasive human cancers and persists even under normoxic conditions. Aerobic glycolysis has been correlated with chemotherapeutic resistance and tumor aggressiveness. These data suggest that mitochondrial dysfunction may confer a...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36948134"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial transplantation: Effects on chemotherapy in prostate and ovarian cancer cells in vitro and in vivo</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36948134/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230328210444&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Prostate and ovarian cancers affect the male and female reproductive organs and are among the most common cancers in developing countries. Previous studies have demonstrated that cancer cells have a high rate of aerobic glycolysis that is present in nearly all invasive human cancers and persists even under normoxic conditions. Aerobic glycolysis has been correlated with chemotherapeutic resistance and tumor aggressiveness. These data suggest that mitochondrial dysfunction may confer a...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36948134"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial transplantation: Effects on chemotherapy in prostate and ovarian cancer cells in vitro and in vivo</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36948134/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230327210053&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Prostate and ovarian cancers affect the male and female reproductive organs and are among the most common cancers in developing countries. Previous studies have demonstrated that cancer cells have a high rate of aerobic glycolysis that is present in nearly all invasive human cancers and persists even under normoxic conditions. Aerobic glycolysis has been correlated with chemotherapeutic resistance and tumor aggressiveness. These data suggest that mitochondrial dysfunction may confer a...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36948134"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial transplantation: Effects on chemotherapy in prostate and ovarian cancer cells in vitro and in vivo</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36948134/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230326205727&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Prostate and ovarian cancers affect the male and female reproductive organs and are among the most common cancers in developing countries. Previous studies have demonstrated that cancer cells have a high rate of aerobic glycolysis that is present in nearly all invasive human cancers and persists even under normoxic conditions. Aerobic glycolysis has been correlated with chemotherapeutic resistance and tumor aggressiveness. These data suggest that mitochondrial dysfunction may confer a...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36948134"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial transplantation: Effects on chemotherapy in prostate and ovarian cancer cells in vitro and in vivo</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36948134/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230325210245&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Prostate and ovarian cancers affect the male and female reproductive organs and are among the most common cancers in developing countries. Previous studies have demonstrated that cancer cells have a high rate of aerobic glycolysis that is present in nearly all invasive human cancers and persists even under normoxic conditions. Aerobic glycolysis has been correlated with chemotherapeutic resistance and tumor aggressiveness. These data suggest that mitochondrial dysfunction may confer a...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36948134"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial transplantation: Effects on chemotherapy in prostate and ovarian cancer cells in vitro and in vivo</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36948134/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230324205646&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Prostate and ovarian cancers affect the male and female reproductive organs and are among the most common cancers in developing countries. Previous studies have demonstrated that cancer cells have a high rate of aerobic glycolysis that is present in nearly all invasive human cancers and persists even under normoxic conditions. Aerobic glycolysis has been correlated with chemotherapeutic resistance and tumor aggressiveness. These data suggest that mitochondrial dysfunction may confer a...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;6
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="pubmed:36948134"
                        open
                      >
                        <summary class="article-expander__title">Mitochondrial transplantation: Effects on chemotherapy in prostate and ovarian cancer cells in vitro and in vivo</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://pubmed.ncbi.nlm.nih.gov/36948134/?utm_source&#x3D;axios&amp;utm_medium&#x3D;rss&amp;utm_campaign&#x3D;pubmed-2&amp;utm_content&#x3D;1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc&#x3D;20220608010801&amp;ff&#x3D;20230323205759&amp;v&#x3D;2.17.9.post6+86293ac">
                          <div class="article-summary-box-inner media-object">
                              <img src="https://cdn.ncbi.nlm.nih.gov/pubmed/persistent/pubmed-meta-image.png" loading="lazy" class="media-object__media article-image" />
                            <span class="media-object__text">
                              <span>Prostate and ovarian cancers affect the male and female reproductive organs and are among the most common cancers in developing countries. Previous studies have demonstrated that cancer cells have a high rate of aerobic glycolysis that is present in nearly all invasive human cancers and persists even under normoxic conditions. Aerobic glycolysis has been correlated with chemotherapeutic resistance and tumor aggressiveness. These data suggest that mitochondrial dysfunction may confer a...</span>
                                &ensp;<span class="article-reading-time">(&hairsp;5
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2022-06-06 datetime="2022-06-06T18:28:04.000Z">2022-06-06</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2022-06-06 datetime="2022-06-06T18:28:04.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >NatureReviewsCancer (@NatureRevCancer) / Twitter</button>
                  <a class="source-heading__link" href="https://twitter.com/NatureRevCancer">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="72a3a11d39c217b1a80cbb551444e6f6"
                        open
                      >
                        <summary class="article-expander__title">@NatureRevCancer: NEW content online! Nodal interferon exposure drives tumour-specific tolerance</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://twitter.com/NatureRevCancer/status/1533878403463405569">
                          <div class="article-summary-box-inner media-object">
                            <span class="media-object__text">
                              <span>NEW content online! Nodal interferon exposure drives tumour-specific tolerance https://t.co/FT4NeBcFTg pic.twitter.com/NRHkVDUsOr
— NatureReviewsCancer (@NatureRevCancer) June 6, 2022</span>
                                &ensp;<span class="article-reading-time">(&hairsp;1
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2022-05-30 datetime="2022-05-30T04:37:42.000Z">2022-05-30</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2022-05-30 datetime="2022-05-30T04:37:42.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >NatureReviewsCancer (@NatureRevCancer) / Twitter</button>
                  <a class="source-heading__link" href="https://twitter.com/NatureRevCancer">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="bb6bc242bcbc356c4a38db850e74d812"
                        open
                      >
                        <summary class="article-expander__title">@VIBConferences: #Cancer #immunotherapy has become a crucial pillar of anticancer therapy. 19 leading researchers at #ImmunoOnco22 will give new insights into the immune response to tumors and tackle unresolved questions.⏰Registration Deadline: Thursday 2 June. Read more</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://twitter.com/VIBConferences/status/1531132720952266752">
                          <div class="article-summary-box-inner media-object">
                            <span class="media-object__text">
                              <span>#Cancer #immunotherapy has become a crucial pillar of anticancer therapy. 19 leading researchers at #ImmunoOnco22 will give new insights into the immune response to tumors and tackle unresolved questions.
⏰Registration Deadline: Thursday 2 June. Read more https://t.co/cc0HC5cj6W pic.twitter.com/u8LFuzBbsV
— VIB Conferences (@VIBConferences) May 30, 2022</span>
                                &ensp;<span class="article-reading-time">(&hairsp;1
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2022-05-27 datetime="2022-05-27T14:45:03.000Z">2022-05-27</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2022-05-27 datetime="2022-05-27T14:45:03.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >NatureReviewsCancer (@NatureRevCancer) / Twitter</button>
                  <a class="source-heading__link" href="https://twitter.com/NatureRevCancer">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="ed6c996dc1a718afb523de6229a53131"
                        open
                      >
                        <summary class="article-expander__title">@NatureRevCancer: NEW content online! Nonsense-mediated RNA decay: an emerging modulator of malignancy</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://twitter.com/NatureRevCancer/status/1530198403686072320">
                          <div class="article-summary-box-inner media-object">
                            <span class="media-object__text">
                              <span>NEW content online! Nonsense-mediated RNA decay: an emerging modulator of malignancy https://t.co/wjuHplkpof pic.twitter.com/1SoKYhRsPO
— NatureReviewsCancer (@NatureRevCancer) May 27, 2022</span>
                                &ensp;<span class="article-reading-time">(&hairsp;1
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="d15a3a4b24853812d7fa21fd56de5815"
                        open
                      >
                        <summary class="article-expander__title">@NatureRevCancer: Our June issue, out NOW! With articles on #therapyresistance, #senescence &amp; targeting CDK4 &amp; CDK6 in #cancer! Plus, a Comment on cancer mRNA vaccines as well as the launch of our new Tools of the Trade articles #NRCToT. So much content 👇🏻💌</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://twitter.com/NatureRevCancer/status/1530174481313972224">
                          <div class="article-summary-box-inner media-object">
                            <span class="media-object__text">
                              <span>Our June issue, out NOW! With articles on #therapyresistance, #senescence &amp; targeting CDK4 &amp; CDK6 in #cancer! Plus, a Comment on cancer mRNA vaccines as well as the launch of our new Tools of the Trade articles #NRCToT. So much content 👇🏻
💌 https://t.co/Fo6XRWV3OZ@natrescancer pic.twitter.com/rbxRPqLV6g
— NatureReviewsCancer (@NatureRevCancer) May 27, 2022</span>
                                &ensp;<span class="article-reading-time">(&hairsp;1
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2022-05-26 datetime="2022-05-26T08:53:50.000Z">2022-05-26</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2022-05-26 datetime="2022-05-26T08:53:50.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >NatureReviewsCancer (@NatureRevCancer) / Twitter</button>
                  <a class="source-heading__link" href="https://twitter.com/NatureRevCancer">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="fe13755a2693ea65459e5e21df097d2a"
                        open
                      >
                        <summary class="article-expander__title">@UlrikeHarjes: This Review by @MarcusDGon @cantleylab is part of the @NatureRevCancer series on #Diet &amp; #SystemicMetabolism in cancer:  do love this topic in general plus I am handling research at @NatureMedicine now.. get in touch if you have something of interest☺️</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://twitter.com/UlrikeHarjes/status/1529747629936193537">
                          <div class="article-summary-box-inner media-object">
                            <span class="media-object__text">
                              <span>This Review by @MarcusDGon @cantleylab is part of the @NatureRevCancer series on #Diet &amp; #SystemicMetabolism in cancer: https://t.co/p3Y2cdNhco
I do love this topic in general plus I am handling research at @NatureMedicine now.. get in touch if you have something of interest☺️ https://t.co/qWH2dTv8j9
— Ulrike Harjes (@UlrikeHarjes) May 26, 2022</span>
                                &ensp;<span class="article-reading-time">(&hairsp;1
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2022-05-25 datetime="2022-05-25T17:35:04.000Z">2022-05-25</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2022-05-25 datetime="2022-05-25T17:35:04.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >NatureReviewsCancer (@NatureRevCancer) / Twitter</button>
                  <a class="source-heading__link" href="https://twitter.com/NatureRevCancer">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="9ba5279424b31b0122a4ae20c18e6d03"
                        open
                      >
                        <summary class="article-expander__title">@NatureRevCancer: NEW content online! Developing dietary interventions as therapy for cancer</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://twitter.com/NatureRevCancer/status/1529516411059437568">
                          <div class="article-summary-box-inner media-object">
                            <span class="media-object__text">
                              <span>NEW content online! Developing dietary interventions as therapy for cancer https://t.co/ijuqctk1wJ pic.twitter.com/KHPpMKnCFa
— NatureReviewsCancer (@NatureRevCancer) May 25, 2022</span>
                                &ensp;<span class="article-reading-time">(&hairsp;1
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2022-05-18 datetime="2022-05-18T14:11:32.000Z">2022-05-18</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2022-05-18 datetime="2022-05-18T14:11:32.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >NatureReviewsCancer (@NatureRevCancer) / Twitter</button>
                  <a class="source-heading__link" href="https://twitter.com/NatureRevCancer">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="611d40f2e6ea2796b028bebda41a86dd"
                        open
                      >
                        <summary class="article-expander__title">@NatureRevCancer: NEW content online! Digging for treasures in the tumour interactome</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://twitter.com/NatureRevCancer/status/1526928478490095616">
                          <div class="article-summary-box-inner media-object">
                            <span class="media-object__text">
                              <span>NEW content online! Digging for treasures in the tumour interactome https://t.co/NhHYAwUgLE
— NatureReviewsCancer (@NatureRevCancer) May 18, 2022</span>
                                &ensp;<span class="article-reading-time">(&hairsp;1
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2022-05-17 datetime="2022-05-17T13:48:21.000Z">2022-05-17</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2022-05-17 datetime="2022-05-17T13:48:21.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >NatureReviewsCancer (@NatureRevCancer) / Twitter</button>
                  <a class="source-heading__link" href="https://twitter.com/NatureRevCancer">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="9590a971b00448cd312078183965b21d"
                        open
                      >
                        <summary class="article-expander__title">@NatureRevCancer: As part of our overall commitment to diversity, equity and inclusion at Springer Nature, we’d like to better understand what DEI means within the global research community. Take the survey here</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://twitter.com/NatureRevCancer/status/1526560254091313156">
                          <div class="article-summary-box-inner media-object">
                            <span class="media-object__text">
                              <span>As part of our overall commitment to diversity, equity and inclusion at Springer Nature, we’d like to better understand what DEI means within the global research community. Take the survey here https://t.co/03yLiUxFTq
— NatureReviewsCancer (@NatureRevCancer) May 17, 2022</span>
                                &ensp;<span class="article-reading-time">(&hairsp;1
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2022-05-12 datetime="2022-05-12T15:25:46.000Z">2022-05-12</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2022-05-12 datetime="2022-05-12T15:25:46.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >NatureReviewsCancer (@NatureRevCancer) / Twitter</button>
                  <a class="source-heading__link" href="https://twitter.com/NatureRevCancer">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="aa38ff4245b93e964773f191844ddc7a"
                        open
                      >
                        <summary class="article-expander__title">@NatureRevCancer: Newsflash! We have a new article type in the journal - Tools of the Trade #NRCToT 🧰 🛠️ where we hope to enable more #ECRs to interact with the editorial team &amp; have a bigger voice in our content. For more info, check out the Editorial 👇🏻</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://twitter.com/NatureRevCancer/status/1524772831904509953">
                          <div class="article-summary-box-inner media-object">
                            <span class="media-object__text">
                              <span>Newsflash! We have a new article type in the journal - Tools of the Trade #NRCToT 🧰 🛠️ where we hope to enable more #ECRs to interact with the editorial team &amp; have a bigger voice in our content. For more info, check out the Editorial 👇🏻 https://t.co/VbyoUJmTRJ
— NatureReviewsCancer (@NatureRevCancer) May 12, 2022</span>
                                &ensp;<span class="article-reading-time">(&hairsp;1
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2022-05-10 datetime="2022-05-10T16:46:03.000Z">2022-05-10</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2022-05-10 datetime="2022-05-10T16:46:03.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >NatureReviewsCancer (@NatureRevCancer) / Twitter</button>
                  <a class="source-heading__link" href="https://twitter.com/NatureRevCancer">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="65aca76b9f794aaa668d84ad32dca4a0"
                        open
                      >
                        <summary class="article-expander__title">@NatureRevCancer: NEW content online! Tools for the next generation</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://twitter.com/NatureRevCancer/status/1524068259712036864">
                          <div class="article-summary-box-inner media-object">
                            <span class="media-object__text">
                              <span>NEW content online! Tools for the next generation https://t.co/lEzTPFYDf5
— NatureReviewsCancer (@NatureRevCancer) May 10, 2022</span>
                                &ensp;<span class="article-reading-time">(&hairsp;1
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="afa9b6784b4ccc7c05ed4efd26ddfb2d"
                        open
                      >
                        <summary class="article-expander__title">@NatureRevCancer: NEW content online! Hunting down rare drug-tolerant cycling cells with Watermelon</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://twitter.com/NatureRevCancer/status/1524022709386190856">
                          <div class="article-summary-box-inner media-object">
                            <span class="media-object__text">
                              <span>NEW content online! Hunting down rare drug-tolerant cycling cells with Watermelon https://t.co/XXT0c9SAYX
— NatureReviewsCancer (@NatureRevCancer) May 10, 2022</span>
                                &ensp;<span class="article-reading-time">(&hairsp;1
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2022-04-29 datetime="2022-04-29T14:40:05.000Z">2022-04-29</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2022-04-29 datetime="2022-04-29T14:40:05.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >NatureReviewsCancer (@NatureRevCancer) / Twitter</button>
                  <a class="source-heading__link" href="https://twitter.com/NatureRevCancer">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="43e2d5ccebc9030f737d656f47ac9d98"
                        open
                      >
                        <summary class="article-expander__title">@VarunVenkatara2: Very happy that our latest Perspective is now online @NatureRevCancer ! We discuss implications of malignant, multicellular networks and potential therapeutic strategies how to disconnect them. Thanks to everyone involved ! #CancerNeuroscience #TumorMicrotubes #neurotwitter</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://twitter.com/VarunVenkatara2/status/1520050291986604033">
                          <div class="article-summary-box-inner media-object">
                            <span class="media-object__text">
                              <span>Very happy that our latest Perspective is now online @NatureRevCancer ! We discuss implications of malignant, multicellular networks and potential therapeutic strategies how to disconnect them. Thanks to everyone involved ! #CancerNeuroscience #TumorMicrotubes #neurotwitter https://t.co/S55cKTGNFd
— Varun Venkataramani (@VarunVenkatara2) April 29, 2022</span>
                                &ensp;<span class="article-reading-time">(&hairsp;1
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="9f6b8644378881f4c2e6b6833c93fc2f"
                        open
                      >
                        <summary class="article-expander__title">@NatureRevCancer: NEW content online! An inhospitable site</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://twitter.com/NatureRevCancer/status/1520020349068316673">
                          <div class="article-summary-box-inner media-object">
                            <span class="media-object__text">
                              <span>NEW content online! An inhospitable site https://t.co/0dvqIKCWxh pic.twitter.com/PtY8J9Fz7r
— NatureReviewsCancer (@NatureRevCancer) April 29, 2022</span>
                                &ensp;<span class="article-reading-time">(&hairsp;1
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="f6d91efcd60dae769e2722585bdfa8df"
                        open
                      >
                        <summary class="article-expander__title">@NatureRevCancer: NEW content online! Disconnecting multicellular networks in brain tumours</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://twitter.com/NatureRevCancer/status/1520020340201598978">
                          <div class="article-summary-box-inner media-object">
                            <span class="media-object__text">
                              <span>NEW content online! Disconnecting multicellular networks in brain tumours https://t.co/LJrzy8bRma pic.twitter.com/CO7BnooP0r
— NatureReviewsCancer (@NatureRevCancer) April 29, 2022</span>
                                &ensp;<span class="article-reading-time">(&hairsp;1
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2022-04-28 datetime="2022-04-28T14:04:34.000Z">2022-04-28</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2022-04-28 datetime="2022-04-28T14:04:34.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >NatureReviewsCancer (@NatureRevCancer) / Twitter</button>
                  <a class="source-heading__link" href="https://twitter.com/NatureRevCancer">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="76e3b436bc8e43ad21366a80c120e395"
                        open
                      >
                        <summary class="article-expander__title">@NatureRevCancer: Our May issue, out NOW! With Reviews on #CRISPR in cancer biology &amp; #therapy, ROS in tumour development &amp; progression, and cancer #proteogenomics, and Comments on esophageal cancer research in Eastern Africa and on Critical Race Theory.💌</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://twitter.com/NatureRevCancer/status/1519678964364623872">
                          <div class="article-summary-box-inner media-object">
                            <span class="media-object__text">
                              <span>Our May issue, out NOW! With Reviews on #CRISPR in cancer biology &amp; #therapy, ROS in tumour development &amp; progression, and cancer #proteogenomics, and Comments on esophageal cancer research in Eastern Africa and on Critical Race Theory.
💌 https://t.co/vQwHFJhpwv@natrescancer pic.twitter.com/6kYgjRYhdT
— NatureReviewsCancer (@NatureRevCancer) April 28, 2022</span>
                                &ensp;<span class="article-reading-time">(&hairsp;1
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="fdf224ea293cdf039086d16e5699a59a"
                        open
                      >
                        <summary class="article-expander__title">@tmurraystewart: Our latest publication on #polyamines is online!@HopkinsMedicine</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://twitter.com/tmurraystewart/status/1519413460978704384">
                          <div class="article-summary-box-inner media-object">
                            <span class="media-object__text">
                              <span>Our latest publication on #polyamines is online!@HopkinsMedicine https://t.co/ehRGgN1w9R
— Tracy Murray Stewart (@tmurraystewart) April 27, 2022</span>
                                &ensp;<span class="article-reading-time">(&hairsp;1
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2022-04-27 datetime="2022-04-27T18:22:03.000Z">2022-04-27</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2022-04-27 datetime="2022-04-27T18:22:03.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >NatureReviewsCancer (@NatureRevCancer) / Twitter</button>
                  <a class="source-heading__link" href="https://twitter.com/NatureRevCancer">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="4f43226ec4dc8e531ff6e64a9c5ab8e6"
                        open
                      >
                        <summary class="article-expander__title">@NatureRevCancer: NEW content online! Polyamines in cancer: integrating organismal metabolism and antitumour immunity</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://twitter.com/NatureRevCancer/status/1519381375874265088">
                          <div class="article-summary-box-inner media-object">
                            <span class="media-object__text">
                              <span>NEW content online! Polyamines in cancer: integrating organismal metabolism and antitumour immunity https://t.co/YCJX1hRQLO pic.twitter.com/zRUCRNXyxH
— NatureReviewsCancer (@NatureRevCancer) April 27, 2022</span>
                                &ensp;<span class="article-reading-time">(&hairsp;1
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="a44ed79b9f76aad377b9272fb392f553"
                        open
                      >
                        <summary class="article-expander__title">@NatureRevCancer: NEW #ResearchHighlight! Lv, Liu, Mo &amp; co demonstrate that in pancreatic #PDAC cells, gasdermin E transports YBX1 to the nucleus, which promotes mucin expression, thereby providing tumour cells with a barrier against digestive enzymes.📯</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://twitter.com/NatureRevCancer/status/1519317944995569664">
                          <div class="article-summary-box-inner media-object">
                            <span class="media-object__text">
                              <span>NEW #ResearchHighlight! Lv, Liu, Mo &amp; co demonstrate that in pancreatic #PDAC cells, gasdermin E transports YBX1 to the nucleus, which promotes mucin expression, thereby providing tumour cells with a barrier against digestive enzymes.
📯 https://t.co/JTUhX0DHQ1@natrescancer pic.twitter.com/2PdCmsDu2p
— NatureReviewsCancer (@NatureRevCancer) April 27, 2022</span>
                                &ensp;<span class="article-reading-time">(&hairsp;1
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2022-04-26 datetime="2022-04-26T14:58:00.000Z">2022-04-26</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2022-04-26 datetime="2022-04-26T14:58:00.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >NatureReviewsCancer (@NatureRevCancer) / Twitter</button>
                  <a class="source-heading__link" href="https://twitter.com/NatureRevCancer">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="06ff7641d8f5fcc0dff91f835ac3bbc1"
                        open
                      >
                        <summary class="article-expander__title">@NatureRevCancer: In the April issue of @NatureRevCancer | Comment, Reimagining cancer research with art, by @CancerSciArtist, Stefani Shoreibah &amp; @tdanino  @natrescancer @Columbia</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://twitter.com/NatureRevCancer/status/1518967636561956865">
                          <div class="article-summary-box-inner media-object">
                            <span class="media-object__text">
                              <span>In the April issue of @NatureRevCancer | Comment, Reimagining cancer research with art, by @CancerSciArtist, Stefani Shoreibah &amp; @tdanino
 https://t.co/GeTVCMJQsp @natrescancer
 @Columbia pic.twitter.com/ZXW6A0Fe0c
— NatureReviewsCancer (@NatureRevCancer) April 26, 2022</span>
                                &ensp;<span class="article-reading-time">(&hairsp;1
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>
      <section class="daily-content js-toggle-accordions-scope">
        <h2 class="daily-heading">
          <button
            class="daily-heading-toggle"
            data-action="toggle-accordions"
            title="Click to toggle the day, Ctrl + click to toggle all."
          >
            <time class="daily-heading-toggle__weekday js-offset-weekday" data-offset-date=2022-04-25 datetime="2022-04-25T12:12:32.000Z">2022-04-25</time>
            <time class="daily-heading-toggle__date js-offset-date" data-offset-date=2022-04-25 datetime="2022-04-25T12:12:32.000Z"></time>
          </button>
        </h2>
        <ul class="sources card">
            <li class="card__section">
              <section class="js-toggle-accordions-scope">
                <h3 class="source-heading">
                  <button
                    class="source-heading__name"
                    data-action="toggle-accordions"
                    title="Click to toggle the source, Ctrl + click to toggle all."
                  >NatureReviewsCancer (@NatureRevCancer) / Twitter</button>
                  <a class="source-heading__link" href="https://twitter.com/NatureRevCancer">Open</a>
                </h3>
                <section class="articles-per-source">
                    <article>
                      <details
                        class="article-expander"
                        data-action="toggle-native-accordion"
                        data-accordion-key="96b2ddff4eb269cf343213c6a1b1ce95"
                        open
                      >
                        <summary class="article-expander__title">@NatureRevCancer: NEW content online! Tracking dormant disseminated tumour cells</summary>
                        <a class="article-summary-link article-summary-box-outer" href="https://twitter.com/NatureRevCancer/status/1518563607440621569">
                          <div class="article-summary-box-inner media-object">
                            <span class="media-object__text">
                              <span>NEW content online! Tracking dormant disseminated tumour cells https://t.co/kSXyWAvCxF
— NatureReviewsCancer (@NatureRevCancer) April 25, 2022</span>
                                &ensp;<span class="article-reading-time">(&hairsp;1
                                  min&hairsp;)</span>
                            </span>
                          </div>
                        </a>
                      </details>
                    </article>
                </section>
              </section>
            </li>
        </ul>
      </section>

    <footer>
      <a class="footer-link" href="https://github.com/MacwanEric/cancer.rss.feed/actions/runs/5029521321">
        <time id="build-timestamp" datetime="2023-05-20T00:55:27.804Z">2023-05-20T00:55:27.804Z</time>
      </a>
      <a class="footer-link" href="https://github.com/osmoscraft/osmosfeed">osmosfeed 1.15.1</a>
    </footer>
    <script src="index.js?v1.14.4"></script>
    <!-- %before-body-end.html% -->
  </body>

</html>